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There is a paucity of data regarding paediatric adherence in resource-limited settings (RLS) 
especially among the very young age groups (<7yrs).  The study investigated the rates of 
adherence, the identification of the adherence measurement, amongst four, which best 
correlates with viral load suppression; as well as correlates of adherence amongst a cohort of 
children younger than 7 years on antiretroviral HIV treatment. 
 




Measures of adherence used: caregiver self-report (CSR), medicine measure/pill count, 
pharmacy refill and clinic attendance.  Child, caregiver, socio-economic and health service 
characteristics were assessed for impact on adherence.  Bivariate and multivariate analyses 
were used to determine agreement between measures and viral load outcome and to determine 




Mean age of children enrolled into the study was 27.08 months with a cohort mean adherence 
rate of 85% and mean viral load suppression o  74% at 6 months.  Biological mothers were 
the majority primary caregivers (85%) and the majority (76%) of caregivers were unemployed 
with 60% receiving some form of social welfare grant.  Results showed that caregiver self-
reported adherence (CSR) was significantly correlated with viral load at 6 months (p=0.004).  
Correlations were found between clinic visits and pharmacy refill (highest values 0.35; 
p=0.000) and between medicine measure and clinic visits (highest value -0.21; p=0.04) but 
none of these measures were significantly correlated with viral load.  Sensitivity and 
specificity analysis for CGSR showed that >95% adherence ensured a good viral load 
outcome.  Four factors were significantly associated with adherence in bivariate analyses.  
These were: access to social welfare grants (OR=2.7; p=0.05); being counselled for initiation 
of ARV treatment by a counsellor vs. a doctor or nurse (OR 3.2, p=0.03); having another 
person in the household other than the index child infected with HIV (OR = 0.34, p=0.05) and 
caregiver depression (OR=0.07, p=0.01).  However, in multivariate analyses certain other 
child, caregiver, socio-economic and health system characteristics as well as the above-




Key findings indicate that adherence rates are relatively high in this cohort and CGSR is valid 
in a resource-poor setting but medicine measure was problematic as a paediatric HAART 
adherence measure. Certain child, caregiver, socio-economic and health system characteristics 
















The idea for this work had its origins during the period of intense „ARV treatment 
activism‟ in South Africa.  It became apparent that government needed to be 
convinced to adopt a national policy of providing ARV treatment in the public sector.  
In our eagerness to demonstrate the numbers in need of treatment, we focussed on the 
adults and children were left out of the specific targets and planning.  Only those 
working directly with the children understood the barriers and challenges facing 
recipients of care and service providers in a context where all systems were geared 
towards adult treatment.  In discussing my ideas with various people, it became 
apparent that there was a need to focus on access to treatment for children as well as 
adherence to treatment among young children since the common response became 
“no-one is investigating that in our setting!”  In developing the protocol I became 
acutely aware of the lack of data regarding adherence to antiretroviral treatment 
among young children in resource-limited settings, especially the age group I finally 
chose (<7 yrs) and thus adherence became my area of focus.  
 
I eagerly sent off my proposals for funding and received glowing reports of my 
protocol but with regrets that the study could not be funded.  This continued until I 
decided that if I did not start somewhere, I would have had to wait till the world 
realized that this was an important area of investigation, by which time it might be too 
late for me to contribute to it.  With the support of colleagues and mentors, I 
registered the protocol for a doctorate degree and began the research in 2004 when the 
National ARV „roll-out‟ programme was in its infancy and less than 4000 children 
were on treatment in the entire country.  In order to support my family and myself I 
had to continue employment in areas which were not always focussed on the present 
research.  This was challenging since I had to do all the work related to this research, 
barring the interviewing.  
 
In retrospect, the lack of funding was perhaps a blessing in disguise since it forced me 
to carry out operational research with no adaptations or extra resources into the 
system in which I was gathering data.  I had no control of whether patients were 











return appointment dates for follow-up were, neither was I notified when these were 
later changed.  Their visit to the clinic took precedence and interviews were 
interrupted at times when their names were being called to see the doctor.  I had no 
control over whether bloods were taken for viral load results or whether these results 
were recorded in the record keeping system once taken.  The only resource I utilized 
was a private room to interview patients in a confidential manner.  This was not easy 
to obtain because the IDC clinic does not have dedicated space like other outpatient 
clinics in the hospital and relies on various clinics to provide consultation rooms on 
the days when these were not occupied.  Space, as in many clinics in South Africa 
was therefore a very scarce resource as well as a source of aggravation at times! 
 
I am relating these constraints not to elicit „sympathy‟ from the reader but to 
demonstrate that most challenges can be overcome with passion, co-operation and 
dedication.  I have witnessed this same passion and dedication in others during the 
early antiretroviral programmes started in this country long before the government 
resources were provided.  I can honestly say that my enthusiasm for contributing to 
this body of knowledge has not waned from commencement of the research to the 
completion of this dissertation.  
 
It is gratifying to see that the world has realized that paediatric antiretroviral treatment 
and adherence is an important focus.  In the last few years, there has been a global call 
to focus on the children and several advances have been made in addressing the issue 
of paediatric ARV treatment.  I am therefore encouraged that the results of the present 
study is available at this time and that it provides direction for policy regarding health 
system intervention to monitor adherence and implement proactive strategies to 
promote adherence within the health service.  The scope of this study can provide 
direction for the focus of future research into identifying barriers in resource-limited 
settings.   
 
The high rate of adherence found amongst the study cohort is contrary to previous 
notions that those living in resource-limited settings would be unable to adhere to the 
strict demands of antiretroviral therapy.  This notion has been refuted by adherence 
studies amongst adults in resource-limited settings and the present study adds to the 











adult counterparts regarding adherent behaviour.  In my opinion, this attainment is an 
indication of the resilience of people living in poverty and overcoming challenges 














AACTG  Adult AIDS Clinical Trials Group 
AIDS   Acquired Immunodeficiency Syndrome 
ART   Antiretroviral Treatment 
ARV    Antiretroviral(s) 
AZT   Zidovudine 
CES-D  Centre for Epidemiologic Studies Depression Scale 
CI   Confidence Interval 
DDI   Didanosine (type of antiretroviral drug) 
D4T   Stavudine (type of antiretroviral drug) 
EFV   Efavirenz (type of antiretroviral drug) 
EMD   Electronic Monitoring Devices 
HIV   Human Immunodeficiency Virus 
HAART   Highly Active Antiretroviral Treatment 
IDC   Infectious Diseases Clinic 
LPV   Lopinavir (type of antiretroviral drug) 
MSF    Medécins sans Frontiéres 
MOSSSS  Medical Outcome Study Social Support Survey 
NVP   Nevirapine (type of antiretroviral drug) 
NRTIs Nucleoside Reverse Transcriptase Inhibitors (class of 
antiretroviral drug) 
NNRTIs Non-nucleoside Reverse Transcriptase Inhibitors (class of 
antiretroviral    drug) 
NSP National strategic Plan, which refers to the HIV & AIDS and 
STI Strategic Plan for South Africa 2007-2011 
PACTG  Paediatric AIDS Clinical Trials Group 
PCR Polymerase Chain Reaction (HIV–DNA test used to diagnose 
HIV in infants) 
PENTA  Paediatric European Network for Treatment of AIDS 
PI   Protease Inhibitors (class of antiretroviral drug) 
PMTCT   Prevention of Mother-to-child-HIV transmission 











STI   Sexually Transmitted Infection 
TB   Tuberculosis 
3TC   Lamivudine (type of antiretroviral drug) 
UNICEF  United Nation‟s Children‟s Fund 
UCT   University of Cape Town 
WHO    World Health Organization 
 
Definition of children: 
All references to children* in this dissertation refer to those aged younger than 14 
years - in line with the National definition used in relation to the ARV programme. 
This is due to the fact that pharmaceutically; children older than 14 years are treated 
using the adult treatment protocol in South Africa. 
 
*It should be noted that this definition differs from the National (SA) definition of 














„Failure to take prescribed medicine for chronic diseases is a massive, world-
wide problem.  Patients fail to receive needed support.‟ 
Headlines of media release of WHO‟s publication of “Adherence to Long-term 




“Significant progress has been made in treating HIV and AIDS since the virus 
was first identified 25 years ago, but along the way children have been 
overlooked.  Children affected by HIV and AIDS have a right to equal access to 
treatment and care; without any significant increases in funding these rights will 
not be met.”   




“Opportunities for guiding exist in every small conversation.  The way you speak 
with people, can improve adherence – you must help people find solutions within 
themselves.  Adherence to life-saving medications is not going to be achieved by 
practitioners policing „bad‟ behaviour.  We are all aware of this.”   
Stephen Rollnick, PATA conference (1
st




“…despite an urgent need for paediatric treatment, alarmingly few drugs are 
available in formulations that are affordable and able to be administered to 
children while the development of new drugs continues to focus mainly on 
adults.”  
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SETTING THE HISTORICAL AND POLICY CONTEXT 
OF HIV AND ANTIRETROVIRAL THERAPY IN SA 
 
1.1 Background  
 
The HIV epidemic is into its third decade since it was first described as AIDS in the 
1980s yet global HIV infection rates continue to increase.  The WHO estimated that in 
2006 approximately 39.5 million people in the world were living with HIV (1% adult 
prevalence) with 4.3 million new infections in 2006 and 2.9 million deaths due to 
AIDS  (UNAIDS 2006).  In 2007 this estimate was down to 33.2 million people 
infected with 2.1 million AIDS deaths.  This reduction in estimate was attributed to 
more accurate data collection and analysis (Joint UN Programme on HIV/AIDS 
2007).   
 
Sub-Saharan Africa continues to bear the overwhelming burden of the disease with a 
5.9% adult prevalence rate.  Globally, HIV infection has increased particularly among 
adult women with 1 million more women over the age of 15 years infected in 2006 
compared to 2004 (UNAIDS 2006).  The 2007 UNAIDS report shows that 68% of the 
global number of people living with HIV, are in Sub-Saharan Africa and that eight 
countries in this region (including South Africa) accounted for approximately one-
third of all new HIV infections and AIDS deaths globally (Joint UN Programme on 
HIV/AIDS 2007). 
 
Great strides have been made in terms of our collective understanding of the causality 
and epidemiology of the disease, the structure and function of the virus as well as HIV 
treatment, especially since 2000 with the emergence of more antiretroviral treatment 
options for the adult population.  It is estimated that global access to antiretroviral 
therapy (ARVs) has increased three-fold from 400 000 patients on treatment in 2003 
to 1.3 million in 2005, with Highly Active Antiretroviral Treatment (HAART) 
(minimum of three ARVs) being the standard of care across the globe (Sharland et al. 












Infected Children. 2005).  Sub-Saharan Africa has led this treatment scale-up as a 
result of resources and support from UNAIDS and WHO‟s 3 x 5 initiative
1
, with the 
number of people receiving treatment globally during this period  increasing from 100 
000 in 2003 to 810 000 in 2005.  It was estimated that approximately 350 000 
premature deaths  were averted in the developing world in 2005 as a directly result of 
the up-scaling of ARV treatment access (World Health Organization 2006a). 
According to UNAIDS/WHO, more than 1.6 million people living with HIV were 
receiving ARV therapy in low and middle income countries as of June 2006 
(UNAIDS 2006).  
 
Access to comprehensive HIV care and HAART for children in resource-rich settings 
has led to increased survival and improvement in quality of life.  Despite evidence 
that HAART has improved the prognosis, growth and survival as well as quality of 
life of children in the „developed world‟, research in paediatric HIV treatment in 
children younger than 15 years, living in resource-poor settings has not received the 
same priority and focus as that of research amongst the adult population (Verweel et 
al. 2002) , (Hutton & Oleske 2005), (Benjamin, Jr. et al. 2004; Brown, Lourie, & Pao 
2000). This is even truer in respect of factors influencing paediatric adherence among 
children younger than 7 years.  This may be due to the fact that the relatively small 
numbers of vertically infected children in resource-rich settings do not “warrant the 
investment” and that prevention strategies, namely, PMTCT have been largely 
effective. 
 
Without any intervention, approximately one third of all children born to HIV-
infected women will become infected themselves (World Health Organisation 2004).   
In the WHO 3 x 5 progress report  (World Health Organization 2006b) it is noted with 
concern that access to prevention of mother-to-child transmission therapy remains 
unacceptably low in resource-limited settings with “fewer than 10% of HIV-positive 
pregnant women receiving antiretroviral prophylaxis before or during childbirth.” The 
report further states that in 2005, 660 000 children under the age of 15 needed access 
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to antiretroviral treatment, representing 10% of the unmet global need and that nine 
out of ten children in need of treatment live in sub-Saharan Africa.   
 
Clinical trials have shown that the PMTCT using dual therapy
2
 can reduce 
transmission rates to 1.9% (Lallemant et al. 2004).  In resource-poor settings this rate 
has been reduced to approximately 6% (Coetzee 2005).  This implies that even with 
good PMTCT coverage and optimal reduction in vertical transmission rates between 
2-6% of HIV infected pregnant women will transmit the virus to their children.  Thus 
there will always be a need for ARV treatment for children, with adherence being a 
key component of treatment success. 
 
1.2 The global burden of paediatric HIV infection  
 
The estimates for the burden of HIV disease in children is less evident from 
epidemiological data due to the lack of specific reporting on children up till 2006 
when UNICEF encouraged countries to provide child specific data
3
.  A report released 
by UNAIDS on 26 November 2007 estimates the number of children infected globally 
at 2.5 million while the number of new infections among children was estimated at 
420 000 in 2007. Ninety percent of these children live in resource-limited settings and 
are therefore without universal access to antiretroviral treatment.  It further reports 
that new data indicated a levelling off of the global adult HIV prevalence and a 
decline in the number of new infections.  However, South Africa has the dubious 
„honour‟ of having the largest number of HIV infections amongst the adult 
population, in the world (Joint UN Programme on HIV/AIDS 2007). 
 
Global mortality estimates amongst children under the age of 15 years, reflecting 
mostly vertically acquired infection, has declined from approximately 560 000 in 
2001 to 380 000 in 2007 (Joint UN Programme on HIV/AIDS 2007).  However, in 
sub-Saharan Africa, HIV/AIDS has become one of the leading causes of mortality in 
children under the age of five.  A meta-analysis of nine perinatal trials conducted in 
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 This intervention involved using AZT given to the mother from 28 weeks in pregnancy. A dose of 
Nevirapine to the mother during labour and to the child within 72 hours of birth as well as a course of 
AZT to the child for 7 days after birth. 
3
 All PEPFAR funded ARV programmes require a breakdown of ages of children on treatment etc. as 












East, West Africa and South Africa revealed the stark contrast between mortality rates 
for infected and uninfected infants.  Cumulative mortality rates for uninfected 
children at 12 and 24 months were 4.9% and 7.6% respectively compared with 
mortality rates among HIV-infected children of 35.2% and 52.6% respectively. An 
interesting observation from this analysis was that regardless of the child‟s HIV 
status, children whose mothers had died had a 3.5 times higher mortality risk.  In-
utero infection was a strong predictor of mortality and more than 50% of HIV-
infected children died within the first two years of life.  (Newell, M.-L., Coovadia, H., 
& Cortico-Borja, M. 2004) 
 
In November 2004, WHO and UNICEF held a technical consultation on: "Improving 
Access to Appropriate Paediatric ARV Formulations" (UNICEF/WHO Technical 
Consultation 2004: 4).  The meeting concluded that: 
 
“There are still very little reliable data on the number of children infected with 
HIV; progressing to serious clinical disease (and death) and reaching the 
immunological /clinical criteria for initiating ARV treatment. This lack of data 
hampers the ability of planning and procurement for HIV treatment and care 
programmes. In addition the insufficient articulation of burden of paediatric 
disease has also delayed both the political and technical response, as reflected 
in the absence of paediatric focus in national plans, targets and care 
strategies.” 
 
While the WHO developed a 3 x 5 strategy
4
 to increase access to antiretroviral 
treatment in resource-limited settings, the main efforts in programme implementation 
appears to have benefited adults more than children.  This view is borne out by the 
fact that all supporting programme infrastructures such as counselling and testing, 
monitoring, adherence support etc. have been aimed at adults.  ARV scaling up efforts 
largely ignore the practical implementation of the roll-out for children such as 
appropriate drug supply and skilled paediatric health care workers, among other 
things (see Table 1.1), which limit access to treatment for children. A report compiled 
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 The progress report of 2006 acknowledges the failure of this programme in meeting its target of 3 
million people on treatment in resource-limited  settings  by 2005. This initiative failed to treat even 
50% of people in need of  treatment according to The International Treatment Preparedness Coalition 












by the Global Movement for Children
5
 concludes that only one in twenty HIV-
infected children, who required treatment in resource-limited settings during 2004/5, 
received it.  At present children receive mostly adult formulations such as tablets and 
capsules which need to be cut or „opened‟ and diluted in water.  There are few 
paediatric syrup formulations amongst the ARV regimens.  Even when syrup 
formulations are available they are not readily used in resource-limited settings due to 
the prohibitive costs. Hence, many children are still dying needlessly despite the era 
of HAART.  
 




 Doctors and nurses trained in paediatric HIV management and treatment. 
 Paediatric ARV treatment literacy counselling skills  
Health service 
resources 
 Child-friendly scales and stadiometers to measure height and weight (for 
appropriate ARV dosing based on body surface area or weight band) 
especially for young infants. 
 Access to laboratory facilities to do C4 cell counts, liver function tests and 
viral loads. 
 Paediatric phlebotomy equipment. 
 Paediatric nutritional intervention strategies and resources 
 Pharmacy space to store large volumes of paediatric syrups (which take up 
more space than adult formulations (tablets and capsules) 
ARV drugs  Affordable  
 Palatable for children 
 Appropriate formulations (syrups vs. tablets) for infants and young children 
  
Data released by MSF at the XVI International AIDS Conference in Toronto in 2006, 
confirmed that children living in resource-poor settings have good outcomes on 
HAART but that the major obstacle to ARV roll-out in these settings, was the fact that 
paediatric formulations are “excessively overpriced, costing up to six times more than 
adult equivalents”  (Médicins Sans Frontières 2006).  They argued that the majority of 
children infected with HIV live in resource-limited settings hence the lack of interest 
in investment by pharmaceutical companies into the development of paediatric 
formulations.  
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1.3 The burden of HIV infection in South Africa 
 
Statistics for the period during which the study was conducted, show that South 
Africa had amongst the highest ante-natal prevalence (30.2% of pregnant women 
attending public health facilities in 2005 and 29% in 2006) of HIV in the world. This 
generalized epidemic is however heterogeneous with the highest prevalence reported 
in KZN (39.1%) and the lowest in the Western Cape (15.7%) (Department of Health 
2007).   
 
Another study based on demographic modelling, suggested that women, aged 25-49 
and female youth (aged 15-24) had the highest prevalence rates viz. 21.2% and 16.9 
%, respectively compared to males 15.4% and 3.7%, respectively.  It is estimated that 
there were approximately 527 000 new infections amongst adults by mid 2006 
(Dorrington et al. 2006). The data suggest that women in South Africa (particularly 
those of childbearing age) are particularly vulnerable to HIV infection.  This has 
implications for children born to women infected with HIV. 
 
1.4 The burden of paediatric HIV infection in South Africa  
 
Children under the age of 15 years comprise 32 % of South Africa‟s population 
(Statistics South Africa 2007).  One estimate is that there are 2.2 million orphaned 
children in South Africa, half of whom have lost parents to AIDS (United Nation 
Children's Fund 2004).  However, the true extent of HIV infection among children in 
South Africa is unknown.  According to the results of the Human Sciences Research 
Council‟s (HSRC) survey (household survey using saliva HIV testing) approximately 
7% of South Africa‟s children aged between two and nine years were infected with 
HIV in 2003 (Human Sciences Research Council 2004).   
 
Demographic modelling using the annual national antenatal surveys among pregnant 
women attending antenatal clinics at public health facilities is probably our best 














Dorrington et al (2006), using this method calculated that in one calendar year an 
estimated 38 000 babies were born with HIV infection, a further 26000 infected 
through breastfeeding and that approximately 235 000 children are among the 
estimated 5.5 million people living with HIV in South Africa in 2005.  In the same 
study it was established that HIV prevalence rates in the Western Cape (the Province 
in which this study was conducted) rose to 15.7% among pregnant women (CI: 11.3-
20.1) in 2005 during the period of this study which commenced in October 2004.  The 
Western Cape Province has approximately 70 000 births per annum of whom 
approximately 10 000 births are born to HIV-infected women in the province.  
Despite the Prevention of Mother-to-Child HIV Transmission programme 
implemented in Khayelitsha (Cape Town) since January 1999 and in all other 
antenatal facilities in the public health sector in Western Cape by 2004, many children 
still become infected.  With vertical transmission rates of between 5% to 10%, and 
good PMTCT coverage, we can still anticipate approximately 500 to 1000 infected 
children annually but more if there are gaps in PMTCT. The number of infected 
children in the province was estimated at 11 000 during the period 2005.  This reflects 
cumulative survival (Dorrington R, 2006).  
 
1.5 Child Mortality in South Africa: the role of HIV infection? 
 
Maternal mortality data in general and child mortality data in particular, is relatively 
poor in South Africa with high levels of underreporting as well as a lack of a central 
reporting structure (Bradshaw et al. 2005).  However, the WHO reports that South 
Africa is one of nine countries where under-five mortality is increasing with 66 deaths 
per 1000 live births estimated for 2003 with a projected 1.6 percentage increase per 












Table 1.2: Under-five mortality rates: estimates for 2003 
 Member State Per 1000 live 
births 
Uncertainty Annual Average percentage change 
    1990-1994 1995 -1999 2000 - 2003 
1 Botswana   112 96 - 128          2.6 8.9 3.5 
2 Cambodia    140 124-158 0.9 2.4 1.2 
3 Côte d‟Ivoire 193 161-223 2.2 1.5 0.7 
4 Kenya 123 108-138 2.7 1.6 0.8 
5 Kuwait 12 11-13 … -4.0 2.1 
6 South Africa 66 58-74 -0.3 1.3 1.6 
7 Swaziland 153 140-166 0.0 5.2 2.5 
8 Turkmenistan 102 93-112 -1.7 2.2 1.0 
9 Zimbabwe 126 111-141 2.4 5.4 2.5 
Source: World Health Organisation Excerpt from: Annex Table 2a 
http://www.who.int/whr/2005/annex/annexe2a_en.pdf accessed 12/11/2007 
 
The Medical Research Council‟s report on the National burden of disease study in 
2000 estimated the infant mortality rate to be 60 per 1000 live births while the under 
five-mortality was estimated at 95 per 1000 live births.  Thus, approximately 60 000 
children under five die in South Africa each year (Bradshaw, et.al. 2005).  The three 
leading causes of child mortality are HIV/AIDS which account for 40% of <5 child 
deaths while low birth weight and diarrhoeal diseases together account for 30% 
(Nannan et al. 1998).  If one recognises the association between maternal HIV 
infection and low birth weight (Dreyfuss et al. 2001); as well as the fact that 
diarrhoeal disease is one of the symptomatic features of HIV infection, then the 
contribution of HIV infection to the cause of mortality is increased substantially 
(Griffin 1990).  Prevention of HIV infection and management of the disease 
particularly in women and children will therefore have the potential to have a major 













1.6 Prevention of HIV infection in children: PMTCT in South Africa 
 
Approximately 75% of government clinics were providing PMTCT services by July 
2007 and National Health‟s target was to have all clinics providing this service by 
December 2007 (PEPFAR 2007).  However, HIV testing amongst antenatal clinic 
attendees in the country in 2005/6 was 45.2% with virtually no increase in numbers 
since 2004/5 (Barron et al. 2006).  
 
In August 2006, WHO recommended that countries change the PMTCT regimen from 
monotherapy (single-dose NVP given to mother and baby at birth), to dual therapy for 
mothers with CD4 counts >200 cells/mm
3
.  Dual therapy involves giving the mother 
and child AZT and NVP.  It further recommend HAART for pregnant women with a 
CD4 count of less than 350 cells/mm
3
 or at stage three of the disease (World Health 
Organization 2006c). By in August 2007 South Africa had not yet adopted this 
protocol (The US President's Emergency Plan for AIDS Relief 2006 ).  Appeals from 
clinicians and civil society in the HIV/AIDS sector, including the Treatment Action 
Campaign, to government led to the adoption of the new PMTCT guidelines by the 
Policy Committee of the National Health Council on Friday 25
th
 January 2008 
(Department of Health 2008).  This will provide the impetus and resources for the 
dual-antiretroviral prophylaxis PMTCT intervention to be implemented across South 
Africa. 
 
In contrast, the Western Cape Province has comprehensive coverage and 
implementation of the PMTCT programme.  By May 2003 approximately all 
antenatal (300 sites) and child health clinics including mobile services offered the 
programme.  Since 2002, dual therapy (AZT and Nevirapine) was implemented as a 
pilot project with full implementation since 2003.  Dual therapy is given to both 
mothers and children with the exception of women with a CD4 count of less than 200 
who are offered triple therapy during pregnancy with a view to continuing therapy 
after delivery.  Children were tested for HIV infection at 14 weeks
6
 of age using the 
HIV DNA Polymerase Chain Reaction test (PCR).  A study conducted in Khayelitsha 
in 2004 reported a 6% transmission rate using this regimen (Coetzee et al. 2005) 
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On the other extreme in Kwa Zulu Natal (KZN) it is reported that even at sites where 
PMTCT
7
 is delivered only between 49-80 percent of women at ante-natal clinics 
accept voluntary counselling and testing.  Among those who are tested positive only 
between 10-60% get the intervention and less than half of their babies get tested after 
birth.  The transmission rate is estimated at 20.8% in this province (Rollins et al. 
2007).  It is expected that once the new PMTCT national policy is implemented, it 
will impact positively on vertical transmission rates.  The current high transmission 
rates in some parts of the country imply that there will be a vast pool of HIV infected 
children, who were born during these past years during which women had limited 
access to effective PMTCT interventions, who will require ARV treatment in future if 
they survive their first few years of life. 
 
Data on vertical transmission rates were not gathered routinely in South Africa at the 
time of writing.  Despite PMTCT coverage in approximately 80% of public health 
facilities, indications are that the national PMTCT programme is not currently 
successful as the 2006 antenatal clinic survey found that 29 percent of attendees (168 
000 women) were HIV infected but only 44% of them had received the ARVs to 
prevent vertical transmission (Department o  Health 2007b). 
 
1.7 Access to Antiretroviral Treatment in South Africa 
 
1.7.1 Historical overview of HIV and AIDS Policy   
 
The development of strategic policy documents to address the HIV epidemic in South 
Africa has a fifteen-year history.  A brief overview of this history illustrates the 
progress that has been made (though it may be argued that we have not gone far 
enough with what we had at our disposal). 
 
In 1992, the National AIDS Co-ordinating Committee of South Africa (NACOSA) 
was launched with a mandate by former President Nelson Mandela to develop a 
national strategy on HIV and AIDS.  Cabinet endorsed this strategy in 1994 (this was 
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against the background of the demise of Apartheid and the rising epidemic among the 
heterosexual population identified in the 1980s.)  HIV infection was first thought to 
be prevalent only among gay men in South Africa).  In 1990, the first national 
antenatal survey was conducted.  This became an annual form of surveillance 
providing the statistics on the trajectory of the South African epidemic and the basis 
for modelling studies in later years.  
 
In 1997, a review of the National AIDS Co-ordinating Committee of South Africa 
(NACOSA) made the need for a multi-sectoral approach to the epidemic apparent.  
This led to the development of the National Strategic framework for HIV, AIDS and 
STIs (National AIDS Plan) initiated by the Minister of Health, Dr Manto Tsabalala-
Msimang in July 1999 in response to President Thabo Mbeki‟s challenge to all sectors 
of society “to become actively involved in initiatives designed to address the 
HIV/AIDS epidemic” (Department of Health 2000: 5). At that stage, in 1999 the HIV 
prevalence among pregnant women in the country was 22.4%. 
 
The 2000-2005 Strategic Framework for HIV, AIDS and STIs included fourteen 
instances in which children were referred to. However, the main thrust of attention to 
children was in the context of “AIDS orphanhood” and one objective related to the 
development and implementation of “programmes to support health and social needs 
of children affected by HIV/AIDS” including the facilitation of adoption of AIDS 
orphans (p.25).  In not addressing HIV-infected children, the intention of the 
document was clearly not to improve access through identification, care and treatment 
of HIV-infected children, since this document was written in the pre-ARV era.  
 
The period between 2000 and 2005 was a very volatile period in relation to 
government‟s response to the epidemic, international and civil society‟s expectations 
and the HIV epidemic trajectory in the country.  
 
In 2002, the High Court ordered the government (in the light of its refusal to 
implement the PMTCT programme nationally) to make Nevirapine available to 













In 2003, government approved a plan to make antiretroviral treatment publicly 
available and this programme has been rolled out since April 2004.  The launch of the 
National ARV-rollout necessitated yet another policy document on AIDS which 
superseded the 2000-2005 Plan and the “Operational Plan for comprehensive HIV and 
AIDS Care, Management and Treatment for South Africa” (Operational Plan), was 
launched in November 2003.  The goal of the 2003 Operational plan was for at least 
one service delivery point in each district to be able to provide ARV treatment at first, 
followed by continued rollout of services.  
 
In preparation for the ARV rollout, the government drafted guidelines to assist service 
providers in the management of patients on ART.  The guidelines, based on those 
formulated by WHO, provide a detailed description of administration of ART in 
adults and children, management of adverse events in these two groups, and 
adherence to therapy, including the management of post-exposure prophylaxis.  The 
goals of the ARV programme:  how patients are to be selected for ARVs, and what 
regimens are to be administered are detailed in the document. Tuberculosis (TB), 
which commonly co-exists in patients infected with HIV, is also discussed. The 
national ARV treatment guidelines serve as the minimum standards to be followed by 
service providers. However, this plan was deficient in the attention given to children 
and adolescents in key areas such as early identification and entry into care and 
human resource skills and competencies specific to paediatrics (Michaels et al. 
2006a).  Further details of this critique are elaborated below. 
 
1.7.2 Critique of South African National Operational Plan (2003)  
 
A review of the deficiencies of this initial ARV roll-out plan in respect of paediatrics 
is necessary to provide a policy context for the service provision in respect of children 
infected with HIV during the period of the reported study. 
 
1.7.2.1 Access points to ARV treatment 
 
The operational plan outlined several “entry points” for ARV treatment.  It noted that 












recommended that “a paediatric monitoring task force be established, and charged 
with coordinating protocols for infant diagnostics and monitoring with the PMTCT 
program and the NHLS” (p.170).  However, the plan was silent on strategies for 
strengthening and expanding the testing of HIV-exposed and the identification of 
HIV-infected children beyond the PMTCT programme. 
 
The issue of disclosure of the child‟s HIV status to the child is unique to the 
management of children.  There is never an instance where an adult‟s HIV status is 
kept a secret from him or her (except, possibly in the case of mentally challenged 
individuals), but in practice this is very common in the management of paediatric 
patients.  The plan did not refer specifically to any special considerations regarding 
the counselling needs consequent on testing children of varying ages nor about the 
counselling needs of caregivers. 
 
1.7.2.2 Antiretroviral Therapy in Paediatrics 
 
Several issues regarding ART in children were covered in the plan, including the 
following: (1) confirmation of HIV-positive diagnosis, (2) guidelines regarding 
initiation of treatment, (3) national paediatric drug regimen protocol, (4) the use of 
cotrimoxazole for prophylaxis of opportunistic infections and (5) Nevirapine 
resistance monitoring.  However, in the ensuing discussion on “changing or stopping 
antiretroviral treatment,” adverse event reporting, patient-drug readiness training, 
adherence, and adherence strategies, no reference was made to children or to the 
specific circumstances regarding children on treatment (e.g., caregiver issues).  The 
issue of paediatric treatment was notably absent in the section entitled “special 
considerations” (p. 40), which included guidelines for the South African Military 
Health Service and Correctional Services. 
 
A discussion paper on the paediatric ARV rollout in South Africa examined the 2004-
2006 national plan (Shungking & Zampoli 2005) and concluded that children‟s issues 
were not addressed comprehensively but instead restricted to clinical and technical 
issues. For example, family care or comprehensive considerations of the mother-












children who did not have an identifiable caregiver and the special needs and 
vulnerabilities of infants, school-going children, and adolescents were not considered.  
 
However, a separate document that predates the operational plan, “Policy guidelines 
for youth and adolescent Health”(Department of Health 2001) addressed some of the 
needs of HIV-infected adolescents. This document contained comprehensive policy 
guidelines for South African youth and adolescents aged 10 to 24 years, and 
acknowledged that adolescents and youth living with HIV/AIDS constituted a 
vulnerable group.  It stated that the lives and well-being of infected youth could be 
improved if (1) their living environment was non-discriminatory, (2) they had 
adequate shelter and nutrition, (3) they had access to treatment for opportunistic 
infections, and (4) they were supported.  A major weakness of this and subsequent 
plans, is the lack of attention to the specific needs of the very young child (<2 years) 
including the monitoring of ARV provisioning to this age group. 
 
The Operational Plan made provision for nutrition-related interventions, consisting of 
vitamin syrup and a supplement meal, for HIV-infected children under 14 years (p.42) 
(Department of Health 2003). It is under the heading of „nutrition‟ that the issues of 
caregivers and child-headed households as well as the need for “appropriate” 
counselling are referred to for the first time.  However, this reference to counselling 
only alluded to nutritional management and neither antiretroviral treatment literacy 
nor medicine administration strategies were mentioned. 
 
1.7.2.3 Continuum of Care Services 
 
The nature of childhood conditions and diseases lends itself to frequent up-and-down 
referral between various health service levels and services.  It may therefore be even 
more critical in the case of paediatric HIV care and treatment, to have a care 
coordinator.  However, the plan did not elaborate on how to implement the principle 
















There were no explicit accreditation criteria for paediatric ARV treatment service 
points in the plan, instead it was assumed that the criteria were generic and did not 
exclude paediatric sites (Department of Health 2003). However, in the case of 
paediatrics, the criteria requiring availability of a trained care team on-site with 
representation of all relevant professions (clinicians, nurses and counsellors) may be 
difficult to achieve since not all clinicians are proficient in paediatric HIV 
management.  In addition, most service points familiar with the care of young 
children, particularly primary care clinics (EPI, IMCI) are nurse-driven services.  The 
lack of skilled paediatric trained personnel has been a major barrier to delivering ARV 
treatment for children less than six years of age (Michaels 2006b). 
 
1.7.2.5 Planning for and Monitoring the Paediatric ARV Rollout 
 
There was insufficient attention to child-specific aspects of monitoring and evaluation 
of the ARV program and subsequently, fewer resources allocated to facilitate access 
to treatment for children less than 14 years of age.  The lack of stratification of child 
age groups has led to a lack of monitoring of the numbers of very young children on 
ARVs in South Africa.  Although it was explicitly stated in WHO‟s 3 x 5 global target 
that approximately 10 to 15 percent of the total number of people on treatment should 
be children (World Health Organization 2003a), the projected number of patients on 
treatment in South Africa‟s Operational Plan did not distinguish between children and 
adults.  The operationalization of the monitoring process for the ARV roll-out was 
deficient regarding information about the number of children on treatment since the 
report form only required the number of paediatric ARVs to be reported.  
 
It should be noted that this issue was brought to the attention of the National Health 
Authorities by the author and colleagues during a rapid situational analysis of the 
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paediatric ARV roll-out in South Africa at a meeting held 22 September 2005 
(Michaels 2005).  The added voice of the Joint Civil Society Monitoring Forum led to 
the revision of the departments reporting system for the ARV roll-out and since the 
end of 2005, the report required that the total number of children under 14 years be 
reported separately (Osler, M. 2007. Personal communication, 9 August).  
 
1.7.3 The Plan Beyond 2006 
 
The revised HIV/AIDS and STI National Strategic Plan (NSP)(Department of Health 
2007a) launched in April 2007, describes terms for a national roll-out of ARV 
treatment and is estimated to cost approximately R25 billion. The Plan was finally 
hailed as “bold” and “one of the best responses to the epidemic in terms of a national 
framework” which aims to decrease new HIV infections by 50% and brings treatment 
support to at least 80% of HIV-infected people by 2011.  It recognizes that young 
people in the age group 15-24 should be the focus of all interventions, especially 
behaviour change based prevention (News 24 2007).  The lack of specific targets and 
allocation of responsibilities in the previous plan is acknowledged and rectified in the 
2007-2011 NSP.  The document outlines guiding principles, which includes the 
following child-specific reference: 
 
“Protecting and Respecting Children: The impact of HIV on the rights of 
children is enormous.  Respect for the best interests of the child dictates that 
children‟s rights and needs must be at the forefront of all interventions for HIV 
prevention, treatment and support” (Department of Health 2007a:56). 
 
South Africa is a signatory to two major treaties which afford protection of children‟s 
rights, namely,: the United Nations Convention on the Rights of the Child (Secretary-
General of the United Nations. 1989) and the African Charter on the Rights and 
Welfare of the Child (ACRWC) (Secretary General of the Organisation of the African 
Union 1990).  In addition, the South African Constitution, Act 108 of 1996 outlines 
the States‟ obligation in protecting the rights of the child.  The clear intent to protect 
the rights of children, including the right to life and basic health care services, is 
evident in the commitment to the principles enshrined in the above-mentioned 












regard to HIV and AIDS the issue of children‟s access to testing, care and treatment 
remains a policy as well as an implementation challenge in South Africa. 
 
During 2005, child activist groups and concerned paediatricians in South Africa, 
signalled the need to factor children into the targets for ARV treatment access in a 
more systematic and specific manner (Children's Rights Centre 2005; Department of 
Health 2005).  
 
South Africa is a member of the African Union and a signatory to the United Nations 
General Assembly Special Session (UNGASS) Declaration.  In May 2006, the 
African Union agreed that by December 2006 its countries would include “revised, 
quantified national targets for prevention, PMTCT, AIDS treatment and care and 
support that are consistent with, and contribute to, the Africa wide targets (African 
Union 1990: 7).  While the South African health system strains under the additional 
load created by HIV infection, there is a concerted effort to give attention to 
children‟s access to HIV management and treatment as demonstrated in the 2007-
2011 National Strategic Plan on HIV and AIDS. 
 
Nineteen goals are specified.  Each goal specifies several specific objectives together 
with five-year targets and assignment of roles amongst lead agencies responsible for 
the achievement of these targets.  Nine of the nineteen (47%) goals incorporate 
objectives and interventions which mention or affect children directly.  These range 
from legislation, social security, education, mental health, developmental monitoring 
to HIV prevention and HIV management and treatment.  The plan has many 
ambitious goals and implementation strategies, some of which require policy and 
legislative changes (Michaels & Eley 2007). 
 
1.8 ARV Roll-out Progress in South Africa (2003 -2006) 
 
South Africa has one of the largest antiretroviral treatment programmes in the world.  
There is no doubt that the need for treatment remains far greater than what is 
available.  UNAIDS estimated that approximately 800 000 people in South Africa 












Treatment Preparedness Coalition 2006).  In November 2006, the Department of 
Health issued a press release stating “The accumulative number of both children and 
adult patients put on antiretroviral therapy by September 2006 was 213 828” 
(Department of Health 2006)  of whom 21 550 were children younger than 14 years;  
clearly below the UNAIDS estimate of those in need of treatment.  By December 
2006, South Africa only achieved 36% of the National ARV roll-out targets set in 
2003 for the number of persons on treatment (Joint Civil Society Monitoring Forum 
and Department of Health 2007).   
 
According to the WHO 3 x 5 strategies for increasing access to treatment (World 
Health Organisation 2003a), 10% of those on treatment should comprise of children 
younger than 14 years.  In this regard, South Africa has met the target.  However, this 
apparent achievement belies the fact that most of the children on treatment are found 
at a few urban hospitals (International Treatment Preparedness Coalition 2006). 
 
1.8.1 The Western Cape ARV Programme 
 
1.8.1.1 Historical Background to ARV Roll-out 
 
The Western Cape experience deserves special mention since this was the location for 
the study and it was the first Province to have Provincial government support for the 
implementation of both PMTCT and ARV programmes at public health facilities.  It 
provided the necessary data and experience for the decision by government to 
implement the National ARV roll-out programme. 
 
The HAART programme was initiated as a “pilot project” at three clinics in 
Khayelitsha (Western Cape Province) in 2001, both ahead of the National ARV roll-
out and amidst strong National government opposition.  During the years between 
2001 and the end of 2003, this programme was financed and managed by Medécins 
Sans Frontiéres (MSF).  The HAART programme in Khayelitsha was adult focussed 













In the Western Cape, approximately 700 children were on HAART by March 2004, 
with approximately two thirds of these children treated at the three tertiary hospitals 
(Red Cross Hospital, Groote Schuur Hospital and Tygerberg Hospital).  Treatment 
was predominantly research and donor funded at this time.  The majority of these 
children were under the age of 6 years and thus dependent on caregivers for their 
access to health care and adherence to treatment.  By the end of the study period 
(October 2006) the number of children on treatment in the Western Cape had risen to 
2611 (Bock.P. 2006 ). 
 
The Western Cape Provincial Health Department works closely with clinicians and 
academics to ensure that protocols and policies are adapted to address the needs and 
meet the targets for the antiretroviral treatment programme.  A strategic decision was 
made to encourage the tertiary hospitals to transfer stable paediatric patients on 
HAART out to the primary care clinics and then have paediatricians mentor and train 
clinic staff to manage and treat infected children.  This strategy was implemented 
since the end of 2005. 
 
1.9 Key Barriers to Paediatric Access to Treatment in South Africa. 
 
Access to ARVs hinges on disease staging using laboratory and clinical indicators.  
The current practice of taking blood from veins for CD4 counts and viral load testing 
poses a particular challenge in young children and infants because of the lack of 
skilled personnel willing and trained to do this task.  Phlebotomy skills will enable 
early identification of infected children for entry into care.  HIV care that can improve 
the quality of life for children infected with HIV includes cotrimoxazole prophylaxis, 
growth monitoring, nutritional interventions, and treatment of opportunistic 
infections.  This in turn calls for a level of clinical expertise relevant to paediatrics.   
 
Major challenges to the paediatric rollout as perceived by health care workers 
surveyed in South Africa, included clinic space constraints, lack of adequately trained 
staff, lack of clinical capacity and a “fear of treating children” (Michaels 2006a).  In 
particular, the need for nurses to be skilled in taking blood from children was cited.  












PMTCT program and well baby (immunization) clinics.  Concerns raised by 
respondents included fewer drug options for children and lack of services for 
adolescents.  Widespread poverty and unemployment and the impact of these factors 
on access to health care; transport and distance were reported as barriers to accessing 
paediatric HIV care due to limited paediatric ARV sites.  The lack of community 
awareness about ARV services for children and the benefits of such services for 
infected children was another concern raised.  Counsellors and pharmacists expressed 
other concerns surrounding community awareness and support for children with HIV 
as well as  mentioning issues regarding medications including dosing, maintaining 
stock levels and monitoring of adherence.  Many health care workers cited the 
emotional challenge of working in the currently constrained system. 
 
Thus, several child-specific challenges beset the South African pubic sector health 
care system, with inadequate paediatric formulations being among these.  The lack of 
appropriate paediatric ARV formulations is not unique to South Africa and global 
lobbying for the development of paediatric ARV‟s is occurring through groups such 
as MSF (SA), Treatment Action Campaign and the Global Movement for Children 
(Global Movement for Children 2006). Lack of adequately trained human resources to 
deal with paediatric HIV care and treatment is one of the primary barriers to access in 




There is a paucity of data relating to paediatric HIV infection, management and 
treatment on a global scale.  Sub-Saharan Africa bears the greatest burden of HIV in 
the world and children are not specifically targeted for intervention due to a lack of 
child-specific monitoring and allocation of resources.  Paediatric HIV infection has 
become a rare event in most resource-rich settings due to the effective implementation 
of PMTCT programmes.  This however is not the case in resource-limited settings 
where the provision of services and access to PMTCT programmes are more 
challenging.  Lack of early identification of HIV-infected children together with a 
lack of skilled human resources to manage paediatric HIV infection effectively, has 












From a public health perspective, those who have access to antiretroviral treatment 
and those who decide who gets access, have an obligation to preserve the integrity of 
the limited number of ARV‟s available (i.e. preventing resistance as far as possible).  
One way in which this can be done is by ensuring near perfect adherence to treatment, 
a very challenging prospect considering that ARV treatment is life-long and in the 
case of a child who is vertically infected, this includes various stages of growth and 
development. 
 
In Africa, the AIDS pandemic has taken its toll on families, resulting in many children 
being orphaned and left in the care of multiple caregivers or living in child-headed 
households (United Nation Children's Fund 2004).  These unique aspects; adherence 
by proxy (via a caregiver) and multiple caregivers, make paediatric adherence to HIV 
treatment very challenging. 
 
In summary, chapter 1 explored the epidemiology of HIV infection, firstly on a global 
scale and then in South Africa, with particular emphasis on the statistics during the 
period of the study, namely, 2004-2006.
9
  An overview of child related mortality in 
SA highlighted the impact of HIV infection on children.  The progress of the PMTCT 
programme in SA (the main prevention strategy affecting children) was provided in a 
manner which contrasts two of the Provinces in the country, demonstrating the 
heterogeneity of the epidemic.  A brief historical overview of the development of the 
HIV strategic policies in SA gives the reader background to the development of the 
SA National Operational Plan (2003-2006) governing the period of the study.  A 
detailed critique of the Plan was presented in respect of child-specific issues as well as 
commentary on the HIV/ AIDS and STI National Strategic Plan 2007-2011 before 
concluding with the key barriers to paediatric access to treatment in SA. 
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1.11 Study Rationale  
 
The rationale for this study is supported by the fact that the burden of paediatric HIV 
is and will remain large for South Africa and many developing countries and therefore 
there is a need to address and improve paediatric adherence to treatment. Whereas 
there was some literature on adherence among adults, including South Africans, there 
was very little on children generally and practically nothing on young children, 
particularly in South Africa
10
 (Stone et al. 2004; Chesney 2003; Orrell et al. 2003; 
Coetzee et al. 2004; Durvasula et al. 2002).   
 
The consequences of poor adherence to antiretroviral treatment in children are the 
same as that of no access to treatment, namely, increased morbidity and mortality.  In 
addition, resultant viral resistance cannot easily be addressed since there are limited 
options for treatment in general and for children, in particular.  Antiretroviral 
treatment is for life and this „time frame‟ will be longer in children than in adults and 
thus the need for longer maintenance on first line treatment is essential in paediatrics. 
These reasons demand that paediatric adherence be studied and that the „best‟ 
measures and predictors of adherence are understood in order to facilitate optimal 
adherence.  
 
Information from studies amongst adults cannot be generalized to the paediatric 
population.  Paediatric HIV and treatment is different to that of adults.  There are 
clinical as well as social differences.  Firstly, the majority of children younger than 
seven years have contracted the disease through vertical transmission while their 
immune systems have not had an opportunity to mature.  HIV disease progression in 
infants and young children is therefore compressed into a relatively short space of 
time compared to adults for whom the time from infection to AIDS is considered 
approximately ten years.  Secondly, the long-term effects of HAART in children are 
largely unknown due to the limited research in this area compared to clinical trials 
involving adults.  Finally, young children are dependent on caregivers for access to 
health care as well as adherence to medication and treatment.  These reasons, amongst 
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others, necessitate the investigation of paediatric adherence to HAART in general and 
in resource-poor settings in particular. 
 
This study is important in the context of paediatric HIV management in Sub-Saharan 
Africa.  The gains in lower drug prices for ARVs have influenced access to 
antiretroviral treatment for more people in Southern Africa.  This has potentially 
increased access to HAART among the general population and in a limited way to 
children.  The drug prices for paediatric formulations still remain prohibitive, for 
example, Zidovudine syrup could cost up to 5 times more than the adult formulation 
(Médecins Sans Frontières 2006).  However, with increased international lobbying 
and pressure from United Nation‟s Children‟s Fund (UNICEF), it is envisaged that 
access to treatment among children will increase, especially in Sub-Saharan Africa 
which bears the brunt of the AIDS epidemic. 
 
It is widely acknowledged that prevention of mother to child transmission is the ideal 
way of “managing” the epidemic among children.  However, there is a legacy of 
infected children born prior to the PMTCT intervention being available in many parts 
of Southern Africa including South Africa, who have survived.  In addition, there are 
children born to HIV infected women who live in areas where there is coverage of 
PMTCT, but for various reasons, these women do not access, due to „overstretched‟ 
health systems or lack of „uptake‟ and finally there are children born to HIV infected 
women who are infected despite their mother‟s participation in PMTCT programmes. 
Thus, paediatric HIV infection will remain a challenge to Sub-Saharan Africa in 
general and South Africa in particular for a long time. 
 
Few studies on HAART adherence have focused exclusively on children between the 
ages of birth to seven years, as is illustrated in Chapter 2.  This study is therefore 
timely because it commenced during the implementation of the National roll-out of 
antiretroviral treatment in South Africa.  It focuses on two key issues regarding 
paediatric antiretroviral treatment in resource-poor settings, namely, identifying 
methods for measuring adherence and factors influencing adherence among children 
younger than 7 years of age in order to inform the development of appropriate 

















This chapter provides an overview of the contextual issues regarding paediatric 
adherence to HAART and reviews the literature against which the study is framed.  
 
Firstly, terminology and definitions of adherence are outlined.  Secondly, an overview 
of the various methods of adherence measurement and concepts of thresholds of 
adherence are presented.  Thirdly, factors influencing adherence among children, are 
reviewed.  These factors are conceptualized within four sub-d mains, namely, child, 
caregiver, Socio-economic and health system factors.  Finally, a brief overview of 
adherence enhancing tools is provided. 
 
The review draws mainly on paediatric studies with the aim of focussing exclusively 
on children younger than 7 years of age.  However, there was a paucity of specific 
data for this age group. Most paediatric adherence studies involved wide age ranges.  
It should be noted issues related to adolescents and young adults infected with HIV, is 
beyond the scope of this review and research cited which includes this age group, is 
incidental to the focus on children.  All references to children in this and subsequent 
chapters, refer to those aged younger than 14 years.  The choice of this definition to 
define the parameters of the present study is motivated by the fact that 
pharmaceutically; children older than 14 years are treated using the adult treatment 
regimen in South Africa.  However, studies included in the review have wide age 
ranges (up to 21 yrs, at times) and do not necessarily adhere to the same definition. 
 
Further, because adult caregivers play a central role in the adherence of children, the 
review was extended to studies among HIV infected adult populations in 
consideration of caregiver characteristics which may influence adherence.  The review 












issues and where relevant evidence is available from adult studies, these are cited and 
acknowledged. 
 
A gap identified in the review is the lack of sufficient data on paediatric populations 
in resource-limited settings.  As noted below in the review methodology section, only 
thirteen paediatric adherence studies were identified from resource-limited settings. 
Thus, in exploring what is known about paediatric adherence, material is drawn from 
both developed and resource-limited settings. 
 
2.2 Review Methodology 
 
An electronic search of English language published literature and conference 
proceedings on paediatric adherence from 1998 to July 2007 was conducted.  The 
search strategy involved searching the following databases:  PubMed, ISI Web of 
Science, Psych Info, Ebsco Electronic Journals Services and Silverplatter, Science 
Direct. In addition, manual searching of references from retrieved articles provided 
additional sources of information.  Abstracts of the following AIDS Conference 
proceedings were searched: 12th World AIDS Conference, Geneva, 1998;  
International AIDS Conference (2002 and 2007) ; 2nd International Conference on 
HIV Treatment Adherence, 2007; 45
th 
Interscience Conference on Antimicrobial 




 International AIDS Society 
Conference on HIV Pathogenesis, Treatment and Prevention, 2007; 2
nd
 International 
IAPAC Conference on Adherence, 2007 and the Paediatric AIDS Clinical Trial Group 
Meeting Proceedings, 1998 and 1999. 
 
The following combinations of search terms were used:  “HAART adherence 
Children”; “HIV and children”; “paediatric adherence”; “p(a)ediatric ART”; 
“adherence children”; “HIV compliance”; “factors HAART adherence”; “HIV and 
caregiver”; “adherence and measurement”; “adherence measure”; “pharmacy refill 
and HIV”; “caregiver and self-report”; “clinical outcomes and HIV children”; 
“pharmacokinetics and HIV”; “P(a)ediatric intervention and HIV”; “disclosure and 
HIV”; “social grants” and “adherence”;  “adherence” and “resource-limited settings” ; 












Only 13 relevant paediatric adherence studies (Table 2.4) were located including 
studies located in: Africa (9), India (2) and Asia (2) among paediatric populations but 
excluding studies conducted exclusively among adolescents.  This paucity of data led 
to the author reserving critical appraisal by not excluding studies on the basis of 
quality though several included adherence measurement as incidental to clinical trial 
outcomes and not as the main focus of the study; or, adherence studies had small 




The terms „compliance‟ and „adherence‟ both refer to the patient‟s ability to follow a 
treatment plan.  However, in the literature, the term „adherence‟ has gained popularity 
in the context of HAART due to the fact that the term compliance connotes 
controlling, unequal power relations.  In contrast, „adherence‟ implies collaboration 
between patient and provider and extends beyond medication management, to 
encompass a comprehensive treatment plan.  The term “adherence” is used in this 
dissertation to reflect this broader concept. 
 
2.4 Definition of Adherence 
 
The concept of adherence to medical treatment appears to be a complex one in general 
but more so with regard to paediatric adherence.  The various definitions postulated 
from different perspectives are explored. 
 
The classic definition of adherence is “the extent to which a patient‟s health-related 
behaviours correspond with medical advice” (Eldred 1997).This definition therefore 
leads to the conclusion that non-adherence applies to both the overdosing and the 
under dosing of medication (Urquhart 1992).  
 
Another, more HIV-specific definition has been postulated: 
“the ability of the person living with HIV/AIDS to be involved in choosing, 












medication regimen to control viral (HIV) replication and improve immune 
function”p.186 (Simoni, et al. 2003) .  
 
This definition is limited to treatment as drugs while the definition below is much 
more inclusive of all treatment-related „behaviours‟. 
 
A conceptual definition for paediatric adherence postulated by De Civita & Dobkin 
(2004) indicates that paediatric adherence involves a triadic partnership involving the 
medical team, caregiver and child.  They define paediatric adherence as: 
 
“… the manifestation of
 
multiple treatment-related behaviours prescribed by a 
medical
 
team, which is influenced by development and contextual 
characteristics,
 
shaped by disease, and interpreted by the caregiver and 
individual
 
child.”(De Civita & Dobkin 2004: 158) 
 
This is a more operational definition of adherence and one that guides us to study 
factors that influence the “manifestation of multiple treatment-related behaviours” in 
order to promote full adherence to treatment. 
 
Clearly, when one talks about a patient being “adherent”, the implication is that 
they‟re taking 100% of their medication, 100% of the time and are consequently 
likely to have undetectable viral loads (in the case of treatment naïve patients 
commencing HAART).  Anything less would be understood as „non-adherent.‟  
Previous adherence experience with other chronic medications has led us to believe 
that this goal of 100% adherence to HAART is both unattainable and unrealistic. For 
example, average adherence rates for antihypertensive medications were found to be 
50% in a study by  (Sackett, et al. 1975)) and even for medical regimens to which 
adolescents would be motivated to comply, such as acne medication, data showed a 
49% adherence rate (Flanders 1984). 
 
The quest for consensus around a definition of adherence is not unique to HAART. 
Definitions of adherence for well-established disease management programmes such 
as Tuberculosis control have no agreed definition of adherence either.  However, it is 












taken during at least one of the two phases of TB treatment.  Some studies have put 
this „compliance‟ rate between 70-80% (Urquhart 1992). 
 
Defining adherence success is complex because of the lack of specific measures and 
tests for HAART adherence.   
 
2.5 Measuring Adherence 
 
There is no „gold standard‟ for measuring adherence to HAART but several methods 
have been employed.  Adherence measurement tools for HAART fall broadly into 
three categories, namely, (1) subjective measures of adherence based on self-report or 
others‟ report of adherence (e.g. clinician), including medical chart review.  (2) 
Objective measures of adherence such as pill counts, pharmacy refill records, clinic 
attendance records, use of mechanical or electronic pill monitors that document when 
medication bottles are opened (e.g. MEMScaps) and (3) Physiological methods or 
indicators such as plasma drug level testing, undetectable viral load results and 
increased CD4 count.  The latter mentioned measures are used to indicate treatment 
response rather than measuring adherence per se.  Some studies use multiple methods 
of monitoring but by far the most popular methods are subjective measures of 
adherence assessment.   
 
Most information regarding these methods is obtained from studies conducted 
amongst adults.  These methods have limitations particularly when applied to 
paediatric adherence monitoring.  For example, „pill counts‟ are complicated when 
paediatric syrups are used.  Children often have multiple caregivers and the primary 
caregiver may prepare medicine doses ahead of time for the other caregiver to 
administer at a later stage, thereby negating the findings of electronic measuring 
devices such as Medication Events Monitoring Systems (MEMScaps).  Furthermore, 
syrups are often spat out or vomited and thus doses repeated, leading to the often 
erroneous conclusions of over 100% adherence in medicine measure.  Caregivers‟ 
reports‟ may differ from the child‟s and a study in the USA found kappa statistics for 
agreement between adults and their children for adherence variables ranging from 












2.5.1. Self-report adherence questionnaires 
 
Patient self-report is the most common measure used in studies of adherence to 
antiretroviral treatment.  For example, in their review of adult focused adherence 
literature, Fogarty et.al. found 50 of 57 abstracts and 15 of 18 articles used subjective 
methods in their studies on adherence (Fogarty et al. 2002).  Likewise, a meta-
analysis of studies to determine estimates of adherence among adults in North 
America and Sub-Saharan African populations, found 71% of  31 studies in North 
America and 66% of 27 studies in Africa, used self-report as a measure of adherence 
(Mills 2006). A review of paediatric adherence studies found 13 of the 32 studies 
reviewed used caregiver self-report as the measure of adherence (Simoni,J. et al. 
2007). 
 
There are several variations of the self-report questionnaire (Table 2.1).  Self-report 
adherence questionnaires tend to adopt two main approaches, namely, (1) to identify 
attitudes or obstacles to adherence (Morisky, Green, & Levine 1986) , (Frick et al. 
1998), (Pekovic et al. 1998) and (2) a more direct approach to determine adherence 
(dosing questions) on specific days before a clinic visit (Bangsberg DR, Hecht, & 
Charlebois 2000) ;(Chesney 2000a) ;(Fletcher, Pappius, & Harper 1979). 
 
Self-report questionnaires vary with respect to the time frame covered from between 
2-day to 7-day recall prior to clinic visit, with 3-day self-report being the most popular 
method based on the premise that it reduces the probability of recall bias.  No 
empirical studies have been conducted to determine whether one interval is better than 
the other.  The most commonly used version of the self-report questionnaire amongst 
adult patients, is the Adult AIDS Clinical Trials Group (AACTG) questionnaire 
(Chesney 2000a).  The Paediatric AIDS Clinical Trial Group (PACTG) developed a 
paediatric adherence questionnaire module (QLW1 p1041 dated 30-01-04) which was 
piloted and refined during the period 2004–2006.  This questionnaire was the self-
report instrument used in the present study. 
 
An adaptation of the AACTG self-report questionnaire known as The CASE 












CASE Adherence Index” is a composite measure composed of three simple questions 
addressing three different aspects of ART adherence: difficulty taking ART 
medication on time, frequency of missed ART doses and time since most recent 
missed ART dose”(p.859).  The authors found that this method was highly correlated 
with the validated AACTG three-day recall self report questionnaire as well as being 
predictive of virological response.   
  
Another version of the self-report adherence questionnaire was developed, known as 
Medication Adherence Self-Report Inventory (MASRI), using 12 items with two 
broad themes(Walsh, Mandalia, & Gazzard 2002).  The first section of the 
questionnaire relates to the medication taken while the second section addressed the 
timing of doses.  Likert scales and visual analogue scales were used as response 
formats.  High self-reported adherence was inversely correlated with viral load.  
 
The Morisky scale is an attitudinal questionnaire.  It consists of four questions with 
dichotomous responses and the range of possible responses is 0 to 4.  The items are: 
(1) “Do you ever forget to take your medicine?‟  (2) „Are you careless at times about 
taking your medicine?‟  (3) „When you feel better, do you sometimes stop taking your 
medicine?  (4) „If sometimes you feel worse when taking the medicine, do you stop 
taking it?‟  Some of the shortcomings of this tool include the fact that the responses 
are not time linked with the result that „non-adherent individuals‟ rather than non-
adherent behaviour are identified.  It does not provide information about how many 
doses have been missed.  Inclusion of this information is important since patients with 
favourable attitudes to treatment, may not be 100% compliant and may miss doses 
„accidentally‟ (Morisky, Green, & Levine 1986). 
 
The Morisky scale was modified by eliminating item 3 since many HIV infected 
individuals using HAART are asymptomatic; and item 4 was re-formulated to “If at 
times you feel worse, do you stop taking your medicine?‟ (Knobel et al. 2002).  
However, the more important modification was in combining the two approaches 
outlined above by adding three questions covering dosing behaviour.  (1) „Thinking 
about the last week.  How often have you not taken your medicine?‟  (2) „Did you not 
take any of your medicine over the last weekend?  (3) „Over the past 3 months, how 












referred to as the Simplified Medication Adherence Questionnaire (SMAQ).  The 
main purpose of the SMAQ is to identify non-adherent patients.  The study also 
looked at the association thereof with virological outcomes among 3004 adult 
patients.  This validation study demonstrated sufficient internal consistency 
(Cronbach‟s alpha 0.75) and satisfactory reproducibility when tested by two different 
health providers (overall agreement of 88.2%, kappa 0.74).  Furthermore, adherence 
was positively associated with virological outcome in this study. 
 
The evidence for the association between caregiver self-report and virological 
outcome is conflicting.  While some studies found an association between self-
reported adherence and a reduction in viral load, others did not.  In addition to the 
studies cited above, Fletcher also found that self-report was a valid measure of 
adherence and better than pill counts 
 
and Haubrich  found an association between 
self-report and viral load ( Fletcher, Pappius & Harper, 1979; Haubrich et al. 1999). 
 
On the other hand, Gao and Nau (2000) highlighted the discordance of the different 
measures of self-reported adherence.  They found the percentage of adherent patients 
incongruent between the three self-report measures used.  For example, among their 
65 adult patients, adherence was 29.2% using a Morisky-type scale but 78.5% using a 
2-day self-report  tool and 95.4% when using a 2-week self-report tool (Gao & Nau 
2000).  
 
Measurement of adherence is critical in the management of patients on HAART. 
Evidence outlined above suggests that a self-report questionnaire is a valid 
measurement tool but should be interpreted with caution because it may be prone to 
social desirability bias (Chesney 2000).  It is likely that in the context of paediatric 
adherence caregiver self-report may be subject to this form of bias too, due to the fact 
that caregivers do not like to be seen as „negligent‟.  This assertion is supported by the 
results from a study which found that adherence (measured by self-report) was 
significantly associated with the identity of the individual who responded to the 
adherence questionnaire.  The “Full adherence” rate was 47% when the child 
responded while it went up to 65% when the biological parent  responded and still 
further to 78% when someone other than the child‟s biological parent responded (Van 












Amongst adults self-report estimates have been observed to be between 
approximately 10 and 20% higher than those resulting from pill count data as well as 
electronic monitoring devices (Bangsberg et al. 2000; Wagner & Rabkin. 2000; 
Chesney 2000; Liu et al. 2001;Kimmerling, Wagner, & Ghosh-Dastidar 2003). 
 
Yet another form of self-report is elicited using a visual analogue scale (VAS).  This 
is usually a diagrammatic scale representing percentage doses missed over a specific 
period of time, for example, a 30-day visual analogue scale.  The patient has to 
indicate on the scale their estimate of the percentage pills/doses missed or taken 
(depending on the investigator‟s preference.  A study conducted in Uganda used a 30-
day visual analogue scale whereby adult patients (N=34) had to indicate the 
percentage pills missed in the past 30 days (Oyugi et al. 2004).  They found that VAS 
results corresponded highly with the other measures in their study such as 3-day self-
report, pill counts and MEMS (Pearson‟s correlation co-efficient of: 0.82, 0.86 and 
0.77 respectively).  Furthermore, all measures were highly correlated with viral load 












Table 2. 1:  Types of Self-Report Instruments 
Instrument Description Originator 
Authors 
Morisky Scale Attitudinal questionnaire consisting of 4 questions with 
dichotomous responses and the range of possible responses is 
0-4.  It does not provide information about amount of doses 
missed. Purpose of the scale is to identify non-adherent 
patients. 





A modification of the Morisky Scale which includes 
additional questions regarding dosing behaviour.  The 
purpose of the instrument is to identify non-adherent patients. 
(Knobel, et al. 
2002) 
Adult AIDS Clinical 
Trials Group (AACTG) 
Adherence questionnaire 
Direct method of determining number of doses missed in 3 
days prior to clinic visit.  The main purpose of the instrument 





Likert scales and visual analogue scales used as response 
formats. 
(Walsh, Mandalia  
& Gazzard 2002) 
Paediatric AIDS Clinical 
Trials Group (PACTG) 
Module 1- self-report to determine recognition of medication 
and doses missed in 3 days prior to clinic visit.  
Module 2 – self-report on reasons for non-adherence 






(Van Dyke  et al. 
2002) 
 
Visual Analogue Scale 
(VAS) 
This is usually a diagrammatic scale representing percentage 
doses missed, over a specific period of time, for example, 30-
day visual analogue scale.  The patient has to indicate on the 
scale their estimate of the percentage pills/doses missed or 
taken (depending on the investigator‟s preference.) 
(Oyugi et.al, 2004); 
(Muller et al. 2007) 
 
The administration of the self-report tool is not standard in the sense that some are 
administered by the health care provider while in other instances they are self-
administered.  For example, the self-report tool developed by Chesney et al (2000) for 
the Adult AIDS Clinical trial group was piloted among 75 adult patients on HAART.  












reading ability (Knobel 2002).  The form of administration of the questionnaire may 
influence the responses. 
 
2.5.2. Pill Counts 
 
The simple method of counting remaining pills at a patient‟s follow-up visit is 
favoured by clinicians in a routine adult clinic setting.  However, these methods are 
labour intensive and though considered “objective”, are presumptive.  While pill 
counts are potentially more accurate than self-report they do not allow one to know 
whether the medication was actually taken by the patient, nor whether the absence of 
pills reflects usage.  Paediatric formulations add a dimension of difficulty regarding 
measuring syrups.  Measuring instruments and consistency of the syrups may result in 
measurement inaccuracies.  It is also prone to „wastage and spillage‟ (the child 
vomits, spits and fights of administration) thus leading to overestimation of usage and 
thus adherence.  Therefore using this method alone will result in an overestimation of 
adherence rates in paediatric populations (Patterson et al. 2000; Turner & Hecht 
2001). 
 
2.5.3. Pharmacy refill records 
 
Pharmacy refill records are often favoured by researchers and clinicians but is usually 
used in conjunction with other measures such as self-report or pill counts (Ostrop, 
Hallett, & Gill 2000).  Adherence is usually calculated as the total number of refill 
collections/total number of scheduled collections.  The calculation may include the 
definition of „on-time‟ collections e.g. within 2-5 days of scheduled collection date, 
depending on the estimated number of doses issued.   
 
The review by Steiner & Prochazka (1997) cited forty one HAART adherence studies 
using pharmacy refill adherence measures.  Of the studies that assessed the validity of 
pharmacy refill measures (which they termed “refill compliance”), most found 
significant agreement between pharmacy refill and other adherence measures 
including measures of drug presence (e.g. serum drug levels).  However, pharmacy 












inconsistently associated with the total number of drugs prescribed.  Despite the above 
limitations, the authors recommend this method of adherence measure which they 
indicate is useful in the absence of direct medication consumption measurement.  The 
authors suggested that pharmacy refill records were a feasible measure for population 
wide surveys. 
 
In a study of HIV infected adults in the US, HAART adherence, as measured by 
pharmacy refill, was significantly correlated to viral load as opposed to self-report 
where only in the case of 100% self-reported adherence was there a correlation with 
viral load (Grossberg, Zhang Y., & Gross 2004). 
 
2.5.4. Clinic attendance/ follow-up visits 
 
As with pharmacy refill, scheduled clinic attendance is used as a proxy measure of 
adherence, although less frequently.  Adherence is calculated as the total number of 
actual visits / total number of scheduled visits during the follow-up period (Natu 
2007; Goetz MB 1998; Sorensen et al. 2002).  Caregivers who are non-adherent with 
appointments are more likely to be non-adherent in giving the child medication.  In 
this respect this measure is more predictive in identifying non-adherent than adherent 
patients (Katko et al. 2001). 
 
2.5.5. Electronic Monitoring Devices (EMD) 
 
An electronic monitoring device was first used in 1970 to assess adherence to anti-
tuberculosis treatment (Moulding, Onstad, & Sbarbaro 1970).  The concept was 
subsequently developed further by Dobbs and Cramer (Cheung et al. 1998; Cramer et 
al. 1989).  It has been used extensively in research unrelated to HIV, especially to 
increase adherence to chronic medication among the elderly in the developed world 
(Kruse et al. 1992).   
 
With the advent of HIV medication, this technology is exemplified by the Medication 
events monitoring system (MEMScaps).  This system involves an electronic chip in 












is opened.  Results are subsequently downloaded to a computer programme for 
analysis and results.  This technology is expensive and not generally available.  It has 
therefore been used mostly in clinical trials and research settings (Muller 2007;Oyugi 
2004; Patterson 2000).  The most commonly reported summary EMD measure is the 
percentage of doses taken.  Other common measure include the number of days with 
correct dosing; percentage days of under or overdosing; percentage of days with 
correct doses and timing of doses, potentially leading to a more comprehensive 
picture of the adherence profile of patients. 
 
Researchers are cautioned that whilst this device provides an objective measure of 
adherence and more valid data than several other methods (such as self-report, pill 
counts etc.), there are potential pitfalls.  These include lack of clarity associated with 
EMD data and the impact of data management decisions on adherence data reported 
(Fennie, Bova, & Williams 2006).  That is, the device collects longitudinal data on the 
number of times the container is opened and timing of opening.  The underlying 
assumption is that each opening represents a medication administration event.  This 
may be an erroneous assumption when multiple doses are removed to transfer to 
pillboxes (while away from home, etc) or the container may be opened without the 
intention or consequence of taking the medication.  The use of pillboxes in 
conjunction with EMD is a major constraint to the interpretation of data if the 
clinician or researcher is not informed of this practice.  In addition, there may be times 
when the patient is not responsible for their own medication administration e.g. during 
periods of hospitalization.  Another obstacle is simply the malfunction of the 
electronic caps, leading to data error.  Despite being heralded as the “virtual „gold 
standard‟ for compiling drug dosing histories in ambulatory patients, these methods 
still have significant limitations (Vrijens, Gross, & Urquhart 2005; McNabb et al. 
2003). 
 
2.5.6. Physicians‟ Estimate 
 
The management of HIV-infected patients on antiretroviral treatment is generally 
clinician-driven although, WHO is advocating „task shifting‟ including the increase in 












Physicians‟ estimate their patients‟ adherence to medications and base their treatment 
and management decisions on these estimates.  In a system where continuity of care is 
arranged and valued (as in chronic care clinics), it would follow logically that 
clinicians have a good idea how their patients are responding to treatment.  However, 
physician‟s estimates are considered the least reliable method of adherence 
measurement.  Patterson et al reported that physicians predicted patient adherence 
incorrectly in 41% of cases compared with nurses who only did so 30% of the time  
(Patterson 2000). 
 
This poor estimation ability is not limited to physicians delivering HIV care as evident 
in research from the early 1980s.  For example, Gilbert et al.(1980) evaluated 
adherence estimates made by 10 physicians of 74 patients taking the medication 
digoxin for the treatment of cardiac failure.  Adherence was concurrently assessed 
using pill count and drug serum levels.  In this study the physicians only correctly 
predicted non-adherence 10% of the time.  The length of time the physician was 
caring for the patient had no effect on their low predictive ability:  Similar results 
were found for patients with whom physicians had relationships for more than 5 
years. 
 
Several other HIV-related studies have corroborated the finding that physician 
estimate of adherence is both an unreliable and a poor measure of adherence.  In their 
review of studies on physicians‟ estimates of HAART adherence, Murri et al. (2002) 
found discordance between reference measures of adherence (such as pill counts, 
MEMs, self-report, drug serum/plasma measures) and physicians‟ estimates, to be 
between 34% – 45%. 
 
However, two studies were found that conflict with these findings and both were 
conducted among paediatric populations.  Farley et al (2003) found correlation 
between viral load and Physician/nurse estimates of adherence, while no association 
was found between caregiver self-report and viral load.  Naar-King et al (2006) 
conducted a cross-sectional study using the average viral load obtained over the 12 
months prior to the study to correlate adherence measures and found that physician 
estimate of adherence correlated with average viral load (r=-0.39; p <0.05) (Naar-












These findings among paediatric physicians may be indicative of the rapport 
established between patient and doctor due to more frequent interactions or may also 
reflect different kinds of doctor-patient relationships.  Both these studies were 
conducted in the USA where the rate of paediatric infection is lower than in resource-
poor settings and thus paediatric HIV case loads may be much lower resulting in 
better continuity of care (that is, the patient is seen by the same physician each time). 
 
In summary, despite two studies to the contrary, the evidence suggests that 
physicians‟ estimates of adherence is a poor predictor of adherence or non-adherence 
and thus not feasible as an adherence measure.  
 
2.6. Virological and Immunological Outcome Measures 
 
Laboratory outcomes, as assessed by CD4 cell counts and viral load tests are standard 
biological markers to monitor HIV disease and are often used as proxies for inferring 
adherence.  It should be noted that virological and CD4 count data are used to 
determine treatment response rather than adherence per se, though it is clear that these 
are related.  The principle is that when the treatment is working, the viral load is 
reduced to undetectable levels (< 400 copies per ml) and the CD4 count increased 
indicating reconstitution of immune status.  However, in reality response to treatment 
is more complex than this simple explanation implies.  In infants, HAART has been 
found to be clinically and immunologically effective despite a high rate of virologic 
failure (Paediatric European Network for Treatment of AIDS 2004). 
 
2.6.1. Viral Load Assays (HIV RNA) 
 
Viral loads are traditionally used to assess treatment success or failure and not as a 
primary measurement of adherence, though it is inferred that the patient is adherent in 
order to affect viral suppression.  A Dutch study among paediatric patients found that 
virologic failure was associated with poor „compliance‟ and younger age of patient, 
independent of baseline viral load and receipt of pre-treatment (van Rossum, Fraaij & 













Many more studies with larger sample sizes have been conducted among HIV-
infected adults.  However, some of the earlier studies lacked specific measures of 
adherence and mainly determined clinical outcomes amongst patients on antiretroviral 
treatment.  For example, a study involving 2444 adult patients found that the first few 
months after initial suppression were the greatest risk period for treatment failure.  In 
addition, patients with a good immunological response were less likely to rebound 
(those with the lowest levels of viral load-measured to below 50 copies/ml- were 
significantly less likely to experience virological rebound than those whose viral load 
was below 400 copies/ml)(Mocroft et al. 2003).  One may deduce that those who 
managed to achieve high levels of adherence in the first few months and thus suppress 
viral replication were more likely to achieve long-term treatment success.  This 
statement is supported by two studies among adults aimed at „maintenance HAART 
therapy‟ after 3-6 months „induction therapy‟.  Results were analyzed for those who 
did not achieve undetectable viral loads during the induction period and for those who 
experienced viral rebound to greater than 200 copies per millilitre during the 
„maintenance‟ period.  The results showed that patients with rebound had significantly 
poorer adherence as measured by pill counts and blood levels of Indinavir.  The 
authors concluded that drug resistance may not be the reason for viral rebound and 
that „poor adherence (including adhering to dietary restrictions) and sub-optimal anti-
HIV drug potency might be factors contributing to viral rebound and inability to reach 
viral suppression.  These study reports underscore the importance of strict adherence 
to dosing with HAART (Deschamps, Flandre & Calvez 2000); (Havlir et al 2000); 
(Markowitz 2007). 
 
However, there is evidence to suggest that it is problematic to deduce immediately 
that a patient on ARV treatment is non-adherent because he/she has virological 
failure.  It is possible to have virologic failure in the face of good adherence.  
Patterson et.al (2000) demonstrated that adherence was not necessarily directly 
correlated with virological success or failure.  In the latter study, the electronic 
measuring device (MEMScap) was used to monitor adherence amongst adults.  
Results showed that 22% of highly adherent patients experienced virological failure 














Likewise, Steele et.al (2001) found no association between measures of adherence 
(caregiver report, pill count and electronic cap monitoring devices) and viral load 
suppression among a paediatric population.  The finding of no association may, 
however, be a result of the study‟s small sample size (N=34).  On the other hand this 
lack of association may be a function of virological response in children. Young 
children tend to have high viral loads (Mofenson et al. 1997; Palumbo et al. 1995) and 
high initial viral load is a risk factor for treatment failure,as measured by viral load 
suppression (Watson & Farley 1999).  The same study suggests that the major impact 
of treatment is early on in the course of treatment (approx. the first 6 months) and 
initial viral load response predicts long-term success, regardless of the baseline viral 
load.  However, adherence is but one factor which impacts on achieving undetectable 
viral load and viral loads may fluctuate even when patients are adhering strictly to 
treatment.  The above evidence suggests that viral load by itself should possibly not 
be used as a surrogate marker for adherence in infants. 
 
Study findings regarding association between adherence measures and virological 
outcome have been conflicting.  Several researchers report correlations between 
adherence measures and viral load while others do not (Oyugi 2004).  Thus, 
correlation with viral load is often used to verify treatment adherence measures but 
correlations are not consistently found. 
 
There are many reasons for these conflicting findings.  One of the most critical 
reasons is variable drug exposure due to variability in adherence, with dose-timing 
being a fundamental component of drug exposure.  For example, secondary analysis 
by Vrijens and colleagues of the findings of a study by Gross et al. (2001), found that 
“changes in viral load were most significantly driven by within-patient dose timing 
errors” (Vrijens, Gross, & Urquhart 2005: 227).  This aspect is often unaccounted for 
or ignored in data collection on adherence.  However, only the use of electronic 
measuring devices, lends itself to the collection of accurate dose-timing data as 













2.6.2. CD4 cell count monitoring 
 
Immune reconstitution is the goal of HAART, especially in children.  As viral load 
decreases, CD4 cell count is expected to increase.  For children, the CD4 percentage 
is the best measure of immune function and is expressed as a proportion of CD4 cells 
of the total lymphocyte count (Table 2.2).  This is considered preferable for decision-
making on antiretroviral treatment initiation.  The reason for this is that absolute CD4 
cell counts are age dependent and variable, with wide ranges between children.  CD4 
counts are usually very high in infancy and decline until the age of approximately 6-8 
years when it reaches adult values (Paediatric European Network for Treatment of 
AIDS 1998).  The CDC categorizes paediatric HIV disease staging according to 
clinical and immunological severity using CD4percentage which is less variable, 
although it also decreases with age (Table 2.2).  Monitoring CD4 percentages enables 
clinicians to monitor disease progression.  Data on outcomes of children on HAART 
in Médicins Sans Frontières Programmes in 12 countries demonstrate that children 
initiating HAART with CD4 cell % > 5% have better outcomes and a greater chance 
of survival (> 80%) (O'Brien et al 2006).  However, a study among infants in South 
Africa, concludes that CD4% is not the overriding predictor of disease progression but 
that clinical, immunological and virological indicators are three independent 
predictors of disease progression (Eley et al. 2006). 
 
Table 2.2: Immunological classification 
Immunologic 
category 
Age of child 
< 12 months 1-5 years 6-12 years 
CD4 count L               
(%) 
CD4 count L                 
(%) 
CD4 count L                 
(%) 
1: No evidence of 
suppression 
1500             
( 25%) 
1000             
( 25%) 
500              
( 25%) 
2: Evidence of 
moderate suppression 
750-1499              
 (15-24%) 
500- 999                
 (15-24%) 
200-499                 
(15-24%) 
3: severe suppression <750              
 (<15%) 
<500              
 (<15%) 
<200              
 (<15%) 
Revised human immunodeficiency virus paediatric classification system: immune categories based on 
age-specific CD4+ T-lymphocyte count and percentage* 
*Modified from CDC. 1994 Revised classification system for human immunodeficiency virus infection 
in children less than 13 years of age.  MMWR 1994;43 (no.RR-12) PP.1-10.   Source: (Kline 2004).  
 
In young children (under 2 years) however, the predictive value of CD4 cell 












children over 2 years.  A study among children (aged 2-18 yrs) in the USA found that 
HAART was associated with increases in CD4 cell counts despite high „virologic 
failure‟.  CD4 cell counts and the proportion of naïve cells were also reportedly higher 
than in adults.  The authors suggest that this may be a reflection of higher thymic 
activity in children (Essajee et al. 1999).  These results indicate that relying solely on 
CD4 cell outcomes to assess adherence to medication may lead one to erroneous 
conclusions.  It should be noted that CD4 cell count/ percentage is used to monitor 
treatment response rather than adherence however, the results are often used to imply 
adherence to treatment.  Clearly, this is an erroneous assumption. 
 
2.6.3. An Emerging treatment monitoring Tool: Growth velocity  
 
Viral load monitoring is not available in all resource-limited settings.  The WHO 
recommends that where possible, viral load monitoring be conducted at baseline and 
monitored throughout the course of treatment.  The alt rnative is to monitor clinical 
outcomes such as growth and health status (World Health Organization 2006d). 
 
A potential indicator for measuring treatment response, specifically in children, is 
growth.  HAART has been shown to have a positive effect on height and weight in 
children with HIV-1 infection.  According to a study conducted in the Netherlands, 
the positive growth effect is sustained for at least 96 weeks (study duration) in 
patients who respond virologically to HAART.  According to the authors, catch up 
growth typically affects weight before affecting height (Verweel et al. 2002).  
 
A group from the Duke Clinical Research Institute is also investigating the prediction 
of treatment failure based on height velocity as a marker for treatment response 
(Benjamin 2004).  In a retrospective cohort study using data from the Paediatric AIDS 
Clinical Trials Group (PACTG: protocol 300) trial, they developed a clinical 
predictive model, and compared the utility of the clinical model, to the change in HIV 
RNA viral load as diagnostic tests of antiretroviral treatment failure.  The clinical 
model incorporated treatment regimen, age, and height velocity.  According to the 
authors the clinical model performed similarly to using changes in viral load.  These 












cost method for evaluating treatment response amongst children in resource-limited 
settings.  However, the model was tested using data from children in resource–rich 
settings where growth patterns may differ from those in resource poor settings, where 
malnutrition and HIV infection may impact differently on growth.  In addition, the 
findings were most pertinent to children aged 36 months and younger who received 
mono or dual antiretroviral therapy.  Thus, this clinical predictive model will need to 
be tested in resource-poor settings.  
 
2.7. Quantitative thresholds for “good adherence” 
 
To date there is no universally accepted definition of patient adherence to HAART as 
discussed at the beginning of this chapter.  Adherence rates are usually treated as 
continuous variables expressed as percentages.  Where adherence is treated as a 
dichotomous variable, however, researchers use a threshold percentage to differentiate 
between adherent and non-adherent patients.  The quest for the threshold or cut-off 
point for describing adherent patients has resulted in a range of thresholds from 80% - 
100% deemed acceptable in scientific papers (Chesney 2003; HIV/AIDS Project 
Development and Evaluation Unit 2001; Simoni et al. 2007; Steele et al. 2001).  
Generally, the tendency is to use > 95% doses as the benchmark for adherence (Mills 
2006; Weiser et al. 2003; Patterson 2000).  This threshold is generally obtained by 
correlating adherence rates, using various measures, with virological suppression. 
Across the adult adherence literature it is commonly understood that >95% of doses 
(especially PIs) are required to avoid resistance and ensure viral load suppression, 
hence the threshold of >95% of doses taken is widely used as a threshold to indicate 
adherent and non-adherent adult patients (Chesney 2000; Puthanakit et al. 2005; 
Hansudewechakul et al. 2006; Reddi et al. 2007). 
 
A significant limitation in the review of the literature on paediatric adherence is the 
fact that it is not possible to establish an overall trend of adherence rates.  Studies vary 
in the methods of adherence assessment, paediatric age groups are not sufficiently 
stratified (for example, age ranges between 4 months -16 yrs are reported) and various 
definitions of adherence and thresholds used (Giacomet et al. 2003; Nabukeera-












and „non-adherent‟ categories differ in thresholds used to describe adherence. These  
range from as low as „75% of PIs taken‟ (Watson & Farley 1999); > 80% of doses 
taken (HIV/AIDS Project Development and Evaluation Unit 2001); >90%  of doses 
taken (Katko 2001) and even >93% (Garvie, Lensing, & Rai 2007) , to the most 
commonly used threshold of  >95% of doses taken, (Hansudewechakul et al. 2006); 
(Puthanakit et al. 2005a).  Some have used terms  such as „full adherence‟ meaning 
100% doses taken (Arrivé et al. 2005; Natu 2007).  Thus, a meaningful mean pooled 
estimate across studies cannot be accurately determined due to the above-mentioned 
discrepancies.  
 
An attempt has been made to determine estimates of adherence across general HIV-
infected populations on antiretroviral treatment.  The most recent and comprehensive 
review of the literature is that of Mills et.al (2006b).  They conducted a systematic 
review and meta-analysis of studies evaluating adherence to antiretroviral therapy 
(ART) conducted among HIV-infected patients in North American and Sub-Saharan 
African populations conducted up to April 2006.  It should be noted that studies 
conducted exclusively among children, were excluded from the analysis.  A pooled 
estimate of adherence of 55% and 77% for North American and Sub-Saharan African 
populations, respectively, was derived.  Regrettably, no sub-group analysis was 
conducted for the paediatric populations within these studies.  This is likely due to the 
paucity of adherence data for this population. 
 
According to a review of literature on paediatric adherence studies, estimates of the 
proportion of adherent children range from 17% to 100%, in developed country 
settings and 26% to 98% in resource-limited settings (Vreeman et al. 2007).  This 
review did not include a meta-analysis. 
 
Adherence studies among caregivers of children on HAART in developed countries 
indicated that non-adherence to treatment is common.  A study in the Netherlands 
among approximately 40 children (ages not reported) found that 38% of children had 
problems maintaining adherence indicated by virological response (De Groot 2000). 
Watson & Farley (1999) found 42% of children in their study were non-adherent (less 
than 75% of Protease Inhibitors (PIs) taken).  The Reaching for Excellence in 












among HIV-infected adolescents with only 41% reporting “no missed doses” 
(Murphy et al. 2001). 
 
In contrast, several studies in developing countries report relatively high rates of 
adherence. In South Africa, Eley et al. (2004) found  that between 60-80% of their 
Cape Town cohort (N=80) achieved >95% adherence over a 10-month period.  Using 
MEMScaps, Müller et al (2007) found a 79.5% (N=72) adherence rate amongst their 
cohort, in Cape Town.  A study in Kwa Zulu Natal, reported 89% of the cohort (N= 
151 ) achieved >95% adherence(Reddi et al. 2007).  Amongst Thai cohorts (N=107), 
a mean rate of 87% and 90% adherence was reported, respectively, using >95% doses 
taken as the threshold.  (Puthanakit 2005; Hansudewechakul 2006).  
 
Furthermore, „full adherence‟ (100%) was reported for 95.4%, 70.5%, 67%, 30% of 
cohorts in India, Kenya, Côte d'Ivoire, and Uganda, respectively (Natu 2007; 
Nyandiko et al. 2006; Fassinou et al. 2004; Bikaako-Kajura et al. 2006).  These 
studies demonstrate that a high level of adherence is achievable among treatment 
naïve paediatric populations in developing country settings and that levels of 
adherence can be highly variable across different settings.  Having said this, these 
studies did not consistently report correlation of the adherence measure with 
virological outcome. 
 
The studies reviewed have variable follow-up periods ranging from between 3 months 
and 24 months, while some are cross-sectional studies (which are inappropriate study 
designs for adherence monitoring).  The metric of estimate of adherence varies 
between studies.  For example, Watson & Farley (1999) expressed the adherence 
estimate of 52% for the cohort, based on the proportion who “missed more than one 
dose in the previous 180 days” while Van Dyke (2002) report an adherence estimate 
of 70% , meaning those who “reported full adherence in the past 3 days”.  Thus, there 
is no standardized quantification of adherence or the metric of estimate.  However, 
there is a tendency to report adherence cut-offs above 95% to indicate adherence or to 













2.8. Factors influencing adherence in children 
 
Adherence may be considered a multidimensional concept.  Ensuring a constantly 
high rate of adherence in a routine clinic setting is challenging.  The fact that someone 
starts out being adherent doesn‟t mean that over time this level of adherence will be 
maintained by the individual.  Non- adherence in an individual increases the risk of 
the development of resistant virus, rendering the antiretroviral treatment ineffective 
(Bangsberg, Hecht, & Charlebois 2000).  If this resistant virus is transmitted, it will 
result in the secondarily infected person being resistant to treatment despite being 
treatment naïve.  In addition, non-adherence eventually results in unfavourable health 
outcomes and increased mortality risk, resulting from immune suppression (Hogg et 
al. 2000).  It is for this reason that clinicians and public health specialists are 
grappling for the „best way‟ to ensure near-perfect adherence to antiretroviral 
treatment since anything less will jeopardize the nation‟s long term treatment success. 
 
Identifying the correlates of adherence and implementing evidence-based adherence- 
enhancing strategies is therefore of primary importance to ensuring treatment success.   
According to the World Health Organization, 
 
“The ability of patients to follow treatment plans in an optimal manner is 
frequently compromised by more than one barrier, usually related to different 
aspects of the problem.  These include the social and economic factors, the 
health care team/system, characteristics of the disease, disease therapies and 
patient-related factors” (World Health Organization 2003b:12). 
 
The literature on paediatric adherence to ARV especially among young children is 
scant especially with regard to the age groups birth to 6 years.  A review of literature 
published during the period 1981-2002 found 12 empirical studies in which adherence 
to antiretroviral therapy among children and adolescents was a primary outcome 
measure. Nine of these studies included children under the age of 12 years in their 
study population. However, median ages of the study populations range from 
approximately 4 years to 8 years (Steele & Grauer 2003).  It should be noted that there 
are not many studies which have focused on children between the ages of birth to six 












years reviewed by Steel et.al (2003), were designed to identify correlates of 
adherence, the rest reported estimates of adherence only. 
 
The following section explores the various findings from the literature, relating to 
factors influencing adherence amongst children as previously outlined above, namely, 
child, caregiver, Socio-economic and health systems factors will be explored (see 
Table 2.4 for a summary).  It should be noted that in paediatrics the child‟s refusal to 
take medication is linked to palatability of medication; hence, this issue will be dealt 
with under a separate heading, namely Treatment Regimen Characteristics (section 
2.8.2), with its related issues such as side effects and pharmacokinetics. 
 
2.8.1. Child characteristics  
 
Children differ from adults in their understanding and reactions to illness based upon 
their level of development.  Challenges of adherence facing adolescents are 
particularly pronounced due to their development l stage (a time in their lives when 
they don‟t want to be different from their peers, being one challenge).  Several 
studies(Ledlie 2001;Goode et al. 2003; Murphy 2001) have reported on these 
challenges but exploration of factors influencing adolescents is beyond the scope of 
this review.  
 
It has been suggested that health care providers should assess the influence of 
developmental factors on adherence periodically and adjust interventions to improve 
adherence as the child matures (Farley J 2001). 
 
Children generally dislike taking medication and some ARV syrups are unpleasant to 
taste, making it more difficult to administer as long-term medication.  The child‟s 
refusal of medicine should not be underestimated as a major factor affecting 
adherence as revealed in a study among Saudi children (Al-Omran, MacAdam, & 
Gard 2000).  Non-adherence to HAART has been cited as a significant behavioural 
health problem amongst adults and children alike (Garvie et al. 2003).  The 












the decline in adherence over time.  This is however, not unique to ARV therapy 
(Jacobson et al. 1990).  
 
Child factors such as age (infancy, childhood, adolescence) or developmental stage, 
clinical stage, change in health status, knowledge of HIV status, frequency of school 
attendance and refusal of treatment have been identified as correlates of adherence 
(Chesney 2000; Wedekink & Pugnatch 2001; Pontali 2005; Reddington et al. 2000). 
 
An association between treatment adherence and socio demographic factors is not 
consistently found among studies. 
 
2.8.1.1. Evidence for association between child characteristics and viral load/ 
adherence  
 
Child age, child‟s knowledge of his/her HIV status, less depressive symptoms and 
child stress, decreased child responsibility for medications and improved health status 
including virological and immunological outcomes were factors which were 
positively associated with adherence (Belzer et al. 1999;Martinez et al. 2000; Arrivé 
2005; Van Dyke 2002; Murphy 2001).  For example, with regard to age, Gibb et.al 
(2003)
11
 found that caregivers of children older than 10yrs and those with 
symptomatic HIV disease were more likely to report full adherence to HAART 
regimens . 
 
Factors such as severity of illness prior to ARV initiation have been found to impact 
positively on adherence.  A study in Uganda found that no hospitalization or only one 
episode prior to ARV initiation was associated with poor adherence (Nabukeera-
Barungi 2007).  This implies that when children are sicker at initiation of HAART, 
adherence tends to be better, possibly due to the „Lazarus effect‟
12
. 
                                                 
11
 The authors were part of the PENTA 5 (Paediatric European Network for Treatment of AIDS) trial 
which is a randomized, partially blinded, multicenter, comparative study involving HIV-infected 
children aged 3 months to 16 years who were naïve to ARV therapy. 
12
 This is a term which has been popularised in the era of HAART since it describes the dramatic 
recovery that patients experience who were „near death‟s door‟ when they started HAART and after a 












2.8.1.2. Evidence for no association between child characteristics and viral load 
/adherence 
 
A study among children in the USA found no significant association between 
treatment adherence and any of the baseline characteristics such as age at entry into a 
study, weight, race/ethnicity and gender  (Van Dyke 2002).  A study in Cotê d‟ Ivoire 
found that older child age was inversely associated with adherence (Arrivé 2005). 
 
Several more studies among paediatric populations support the findings that 
adherence is not related to child‟s knowledge of their HIV status; nor structural social 
support, satisfaction with social support and health status including virologic or 
immunologic outcomes (Martinez et al. 2000;Murphy et al. 2001;Van Dyke et al. 
2002; Giacomet et al. 2003; Mellins et al. 2004)  
 
2.8.1.3. Why do studies give such conflicting findings? 
 
The studies cited above, are highly variable in study design, sample size and the wide 
age ranges studied.  It is therefore unclear which studies have the definitive answer as 
to which demographic factors impact on adherence.  It may be possible that these 
factors become significant under various conditions and that the inability of 
researchers to control for „unknown‟ issues related to the contextual location of the 
study, has a mediating effect, rendering these variables significant under certain 
conditions but not under others. 
 
In addition, the few studies among young children lack sufficient power and rigour. 
For example, among the thirteen studies conducted in resource-limited settings, 
sample sizes ranged from 40 to 279 with the median sample size of 80 while sample 
sizes in studies conducted in resource-rich settings ranged from 10 to 129.  In 
addition, prospective study designs provide more rigour for adherence studies.  It is 
encouraging to see that studies emerging from resource-limited settings are favouring 
this study design, with nine of the thirteen studies employing prospective study 













2.8.2. Treatment regimen characteristics 
 
Treatment regimen characteristics include: dosing schedule, number and size of pills, 
taste of liquid or powder formulations, storage and food interactions (Boyle 2000; 
Pugatch et al. 2002; Fletcher CV 2004). 
 
Palatable formulations do not exist for many available paediatric antiretroviral 
therapies (ARVs).  In paediatric management, dosages can become quite confusing 
for the caregiver, since dosages are increased as the child grows in height and weight 
especially for children under the age of 6 years.  At each visit, dosages are calculated 
according either weight or body surface area which could result in a change in 
instructions to the caregiver regarding the amount of either syrup or tablets the child 
should receive subsequent to that visit.
13
   
 
Increased amounts of syrups could lead to administration problems due to the fact that 
it is not particularly palatable and could cause the child to avoid repetition of an 
unpleasant taste or experience by refusing medication.  For example, the dosage of 
Nelfinavir given in the PACTG 377 study
14
 (55 mg/kg BID), meant that an average 6 
year old was required to take 5 tablets or 25 scoops of Nelfinavir powder with food, 
twice a day (Van Dyke et al. 2002).   
 
Paediatric ART formulations are generally supplied in formulations children find 
difficult to tolerate (viscous and bitter or gritty powders diluted with water or large 
capsules, which may have to be dispersed in water due to the inability of the young 
child to swallow capsules).  These characteristics do not only pose a problem with 
palatability for the child but also complicates medication administration for the 
caregiver (i.e. opening capsules, ensuring mixtures are prepared with clean water, or 
cutting tablets).  While there has been no study that has specifically found significant 
quantitative results to indicate that palatability is a major barrier, these have been 
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 In the Western Cape Province the use of a standardized weight band/dosing chart was initiated in 
2007 by paediatricians at Red Cross Children‟s Hospital to decrease the frequent dose changes in 
young children and eliminate the need for complex calculations for dosing. 
14
 The PACTG 377 was a multicenter, randomized clinical trial that compared change from current 
therapy to 1 of 4 drug regimens each of which contained BID stavudine (d4T).  A total of 193 children 












cited as the most common reasons for „difficulty in administering‟ medication (Pontali 
2005). 
 
2.8.2.1. Medication Side Effects  
 
There is incomplete knowledge of pharmacology of antiretroviral therapy in children 
and the effects of nutritional status, age and immunological responses are not well 
understood or sufficiently documented (UNICEF/WHO Technical Consultation 
2004).  
 
Antiretroviral therapy has been associated with short and long-term adverse effects 
among adults and is an often cited reason for intentional non-adherence (Catz et al. 
2000).  A Canadian study, aimed at estimating the frequency and possible predictors 
of intentional non-adherence to HAART, found that 11% of patients enrolled in the 
study reported intentional non-adherence with between 4% and 7.4% reporting this 
activity over the preceding year depending on the symptom group.
15
  Investigators 
also found that patients who reported at least one severe symptom were more than 
twice as likely to report intentional non-adherence and each additional objective side 
effect that required clinical action was associated with a 25% increase in the risk of 
intentional non-adherence (Heath 2002).  
 
A few studies among paediatric populations cite side-effects as a reason for missed 
doses and/ or a barrier to adherence (Temple et al. 2003; Soza-Vento & Fritz 2007). 
Significant short and long-term adverse events cited among paediatric populations 
include nausea, rashes, hypersensitivity reactions, lipodystrophy and anaemia as well 
as long-term toxicities (Pontali 2005; Gibb et al. 2003). 
 
Among fifty seven children aged between 3.8 yrs and 16.8 years and followed up for 
48 weeks after initiation of treatment, the most common treatment-related effects, of 
at least moderate severity, were rash (30%), diarrhoea (18%), neutropenia (12), and 
biochemical abnormalities (12%).  Serious side effects were uncommon (Starr et al. 
1999).   
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Children are reported to suffer the same metabolic abnormalities as a result of 
HAART as adults which are attributed to Protease Inhibitors (Ramos et al. 2003).  
The most common metabolic abnormalities encountered by adults are 
hypercholesterolemia, hypertriglyceridemia and insulin resistance.  Other 
abnormalities include peripheral fat wasting, visceral fat accumulation, and 
hypertension (McComsey et al. 2003). 
 
In the context of adherence, patients‟ perceptions of severity of side-effects may differ 
significantly from the clinical definition of severity, that is, the side-effect may be 
„serious‟ enough for the patient to decide to stop using the medication causing an 
unpleasant side-effect and thus impacting on the patient‟s daily quality of life (Adam, 






Pharmacokinetics is relevant to the discussion of adherence since the manner in which 
the body absorbs or excretes the drug may influence its effect on potency and 
therefore virological outcome. 
 
There‟s a paucity of data evaluating the pharmacokinetics of antiretroviral treatment 
in children.  Dosage selection for children is often based on insufficient empirical 
data.  With the increased advocacy and pressure for funding of paediatric 
pharmacokinetic clinical trials, it is envisaged that this matter will be addressed in the 
near future (Médicins sans Frontières 2006; Global Movement for Children 2006). 
The lack of paediatric appropriate formulations available, especially in resource-
limited settings, result in adaptation of adult formulations by cutting or crushing 
tablets and dissolving in liquids, which further exacerbates the problem of ensuring 
adequate dosing in children.  
 
There are unique aspects of paediatric pharmacology as opposed to adults since (1) 
paediatric dosing is based on age, weight /or body surface area; (2) physiological 
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 PK defined as the study of the bodily absorption, distribution, metabolism and excretion of drugs. 












changes as a result of maturation produces differences in absorption, distribution, 
excretion and metabolism of drugs (van Rossum et al. 2002).  
 
The majority of the pharmacokinetic data for PIs in paediatric patients has been 
obtained in older children.  However, the ability of an agent to cross the blood-brain 
barrier may be particularly important when choosing antiretrovirals for paediatric use, 
since HIV-related encephalopathy is a major problem in HIV-infected children (King 
et al. 2002).  
 
Inter-individual variability in pharmacokinetics, in general, may produce different 
effects resulting in some patients having very high drug concentrations, and thus at 
risk for toxicity, while others with low concentrations are at greater risk for drug 
resistance and treatment failure.  The pharmacokinetics of nucleoside reverse 
transcriptase inhibitors differ significantly among neonates, infants and older children 
(King et al. 2002). 
 
Food can increase or decrease the absorption and bioavailability of some drugs and 
contribute to PK variability.  For example, it is recommended that Ritonavir/Lopinavir 
and Nelfinavir require administration with food for optimal absorption while 
Didanosine must be given on an empty stomach. In addition, a high-fat or high-
protein meal slows the absorption of Zidovudine (Raiten, Grinspoon, & Arpadi 2005).  
 
The current approach supported by WHO of dosing according to weight bands, while 
expedient for „demystifying‟ paediatric HIV management and time-saving, may in 
fact create more clinical problems in individual paediatric patients.  Therapeutic drug 
monitoring may be indicated in paediatrics.  This approach is used extensively in 
resource-rich countries to optimize dosing in children(Verweel et al. 2006; van 
Rossum, Fraaij, & de Groot 2002).  However, it is not feasible in resource-poor 
settings where the number of children in need of treatment is escalating rapidly and 
thus costs of such monitoring will be prohibitive.  As a solution, more 
pharmacokinetic trials are required in these settings to indicate the optimal dosages of 
HAART in order to prevent treatment failure or toxicity.  The results of PK studies 
conducted in resource-limited settings are not encouraging for the use of adaptations 












These adult capsules were not designed for partial intake and thus this option is far 
from optimal. 
 
The complexity of drug-dosing in paediatric populations is highlighted by King et.al 
(2002) when they conclude their findings from a review of PK studies of ARVS 
among neonates, infants and children compared to adults, by stating:  
 
“It is imperative that clinicians treating HIV-positive children understand the 
significance of developmental changes for the pharmacokinetics of 
antiretroviral drugs, in order to optimize treatment strategies, minimize 
toxicities and provide the least intrusive regimens for their patients and 
families” (King et al. 2002: 1132). 
 
The difficulties of dosing in paediatrics, given the limited paediatric-friendly 
formulations is exacerbated in resource-limited settings where cost drives the choice 
to compromise, adapting adult formulations in order to give children access to 
treatment.  However, studies are showing that this method of treating children is not 
optimal.  For example, a study in Malawi compared plasma levels of liquid 
formulations of Nevirapine, Stavudine and Lamivudine with plasma levels of these 
drugs in children who received divided tablets
17
, and compared the bioequivalence of 
branded and generic formulations of both liquid and tablet products in HIV-positive 
children.  The median age of the children (N= 9) was 7.2 years.  The researchers 
concluded that dosing with a divided tablet is not bioequivalent to using liquid 
formulations but generic liquid and branded liquid formulations were bioequivalent 
(Corbett & et al 2005).  
 
More evidence to caution against this practice result from a study in Uganda.  The 
study was conducted to determine the efficacy of using adult formulations adapted for 
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 “The use of quartered tablets for dosing of children has been pursued in African countries because of 
the lack of availability of liquid formulations in some places and for some drugs. The difficulty in 
storing and reconstituting liquid formulations, the difficulty in calculating doses of liquids based on 
body weight and surface area, the higher price of liquid formulations and the widespread use of the 
fixed dose combination product Triomune, which combines nevirapine, stavudine and lamivudine. 
Medicins Sans Frontieres, for example, has reported that it is far easier to achieve good adherence to 
quartered tablets in children than it is to ensure that accurate doses of liquid formulation are given 












paediatric (by the practice of cut or quartered fixed-dose adult tablets), found poor 
virological outcomes and high rates of treatment resistance amongst the cohort.  Only 
59% had virological suppression (<400 copies per ml) at 12 months and this rate 
declined to 33% at 24 months.  Eighty eight percent of those with virological failure 
were resistant to at least one NRTI and one NNRTI and among these, 28% were 
resistant to all drugs in the first line regimen.  In addition, 30% of children had 
suboptimal levels of Nevirapine and 20% had suboptimal levels of Efavirenz (Ahoua 
L et al 2007).  
 
Similarly, a study in South Africa found suboptimal therapeutic levels of  Efavirenz in 
20% of children their study (Ren et al. 2007).  It should be noted that there is no 
paediatric formulation for Efavirenz in use in South Africa‟s public health sector and 
adult capsules are used by opening the capsule and dispersing the contents in water 
for administration in young children. 
 
These results highlight that the practice of quartered/ cut tablets and dissolving adult 
dose capsules for dosing in children, according to weight bands, may lead to drug 
resistance or toxicity because of under or over dosing.  
Clearly, the „science‟ of paediatric HIV care and Management has several gaps in 
knowledge.  The increased access to treatment, required to stem the tide of perinatal 
HIV infection still prevalent in Sub-Saharan countries, demands that more focus is 
given to clinical and pharmacokinetic trials involving children and child-specific 
issues, since data from adults cannot merely be extrapolated to the paediatric 
population.  Furthermore, these trials should always be underpinned by adherence 
monitoring. 
 
2.9. Caregiver characteristics 
 
2.9.1. Knowledge and beliefs about treatment 
 
Adherence is a challenge in children since it depends on the behaviour of the primary 
caregiver/parent who ensures that the medication is taken.  Reddington et.al (2000) 












regarding their perceptions of their ability to administer the prescribed doses; beliefs 
about the medication and concerns regarding disclosure of the child‟s HIV status, 
indicating that caregiver characteristics impact either positively or negatively on 
adherence in children.  It has been proposed that children maintain better adherence 
when caregivers believe in the treatment rationale and when the child (when older) 
can be involved in the decision-making (Chesney 2003).  A study by Katko and 
colleagues (2001) in the USA among a paediatric population with a mean age of 7.5 
yrs, suggests that caregivers who are unable to describe the medication regimen were 
unlikely to adhere to the medication regimen, though this factor, in contrast, was a 
poor predictor for identification of caregivers who were adherent. Adherence rates in 
this study ranged from 22 to 100% with only 34% of caregivers giving at least 90% of 
prescribed medications.  
 
Caregiver knowledge of treatment and self-efficacy
18
 positively affects adherence 
especially in the presence of higher social support and social disclosure of HIV status 
(Nicholson et al. 2005).  
 
The impact of knowledge of treatment on adherence is highlighted by a study in the 
USA among a paediatric population ranging in age between 2 and 12 years.  They 
found that significant deficits in caregiver knowledge of regimens and that this was 
significantly associated with non-adherence resulting in a mean of 49% adherence, 
based on pharmacy refill which correlated with viral load outcome (Marhefka et al. 
2004).  Similarly, findings from a qualitative study among caregivers of children on 
treatment found that adherent patients „internalized‟ the knowledge about treatment 
more strongly than non-adherent; that adherent caregivers had the ability to overcome 
obstacles to adherence in their children because they believed the benefits of 
treatment outweighed the difficulties and finally that adherent patients developed 
better problem-solving capacities.  This study further found that the “knowledge, 
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 Caregiver self-efficacy was measured using a scale developed for use by the adult AIDS Clinical 
Trials Group (ACTG). Caregiver‟s intentions/confidence in carrying out health-related behaviors (e.g., 
asking questions, keeping appointments, adhering to medication regimens) was measured using 33 
items modified from the Adherence Self-Efficacy Scale. Responses were on a 5-point Likert scale 
ranging from 0 „„I‟m sure I can‟t‟‟ to 4 „„I can all of the time‟‟. A total score was the mean of responses 













motivation and capacities evolved in a progressive way related to individual
 
stages of 
coping with human immunodeficiency virus (HIV)”
 
(Hammami et al. 2004:e591) 
 
2.9.2. Educational status 
 
The aforementioned findings may be explained by educational status of caregivers as 
is supported by the results of a study in Saudi Arabia where maternal education was 
found to be a significant factor influencing health outcomes in children in general(Al-
Omran, MacAdam, & Gard 2000).  
 
The impact of caregiver educational level and socio-economic factors is evident in the 
review of adherence studies among adult patients on HAART, by Fogarty and 
colleagues (2002).  They found at least five studies reporting significant associations 
between educational level and literacy, lack of stable housing and income and 
adherence.  They report that when an association was found, the direction was 
consistent in that low literacy, education, income and lack of stable housing, were 
negatively associated with adherence.  
 
Regarding substance abuse, the above-mentioned authors report that there are as many 
studies reporting no association, as there are studies which found a negative 
association and in fact one study documented that those with a history of substance 
abuse had „better adherence‟! (Fogarty et al. 2002). 
2.9.3. Caregiver relationship to child 
 
Another factor influencing paediatric adherence is the relationship of the caregiver to 
the child.  The results from the PACTG 377 study suggests that adherence was lower 
when biological caregivers responded compared to non-biological caregivers ( 65% 
vs. 78%;p=0.04), respectively (Van Dyke et al. 2002).  Consistent with this finding, 
Katko et.al (2001), reported that the only significant difference in demographic or 
disease characteristics of patients who had at least 90% adherence was in the 
proportion of patients for whom the biologic mother was the primary caregiver 
(p=0.04).  Only 8% of children with biologic caregivers had >90% adherence while 












2001).  These studies were conducted among paediatric populations in the USA with 
median age of 6.3 yrs and mean age of 7.5 yrs respectively.  These findings may be 
confounded by the HIV status of the caregiver whereby biological caregivers are more 
likely to be HIV-infected and possibly not in good health which may result in 
compromised care-giving ability (Mellins et. al 2004).   
 
To date, these findings regarding biological caregivers have not been verified in 
resource-poor settings.  The results of a Kenyan paediatric adherence to HAART 
study determined that there was no statistically significant difference in adherence 
rates between orphaned and non-orphaned children (73% vs. 71%; p=0.86).  This was 
a 34 month prospective study and the median age of the children was 6 years 
(Nyandiko et al. 2006). 
 
2.9.4. Family/caregiver resilience 
 
Families and primary caregivers provide children with information and support that 
will help children cope with difficult situations.  Thus, the family‟s level of coping 
will affect the child‟s psychological adjustment and response to treatment.  The 
literature supports a relationship between the child‟s ability to cope or adjust to 
situations and parental stress and distress (Banez GA & Compas 1990; Brouwer et al. 
2000).   
 
The literature is not unanimous in its conclusion about the impact of HIV infection on 
families.  Some investigators report that children with HIV and their caregivers 
evidenced less distress than uninfected children and their caregivers (Bachanas et al. 
2001), while others have reported the opposite (Wiener, Vasquez, & Battles 2001; 
Mellins et al. 2000; Brandt 2007). 
 
The HIV infected individual‟s ability to cope with stressful life situations have an 
impact on the ability to adhere to treatment.  A Swedish study, which explored the 
association between self-reported adherence to antiretroviral treatment and degree of 
sense of coherence (as measured by the 29-item Sense of Coherence (SOC) scale), 














(p=0.004) and higher viral loads (p=50.02) and that  measurement at 
12 months predicted non-adherence, the lower the SOC, the more missed doses (p < 
or =0.01) (Cederfjäll et al. 2002). 
 
2.9.5. Socio-economic status and Race/Ethnicity 
 
In Nigeria, socio-economic status (measured by the patient‟s ability to pay for 
treatment ) was not associated with adherence (Mukhtar-Yola et al. 2006). 
 
Analyses according to race classification conducted by American researchers have 
found differences in adherence between groups.  A study conducted during the period 
1996-1998 among Medicaid recipients found that African-American recipients took 
longer to commence treatment and were least likely to consistently use the treatment 
than their White peers.  In this study African Americans accounted for 58% of the 
patients on treatment but 40% of African American pati nts vs. 30% of White patients 
reported that they had discontinued their treatment by 1998 (Crystal et al. 2001).  
 
A study conducted in the US among HIV infected children on HAART, found that 
adherence was less for „white‟ than „non-white children‟ (40% vs. 73% full 
adherence) but did not differ between „black‟ and „Hispanic‟ children(Van Dyke et al. 
2002). 
 
In response to assumptions that adherence required for successful ART will not be 
achieved in resource-poor settings which led to calls for caution in expanded access 
programs in these settings, a review of studies in Africa demonstrated that this 
assumption should be refuted.  Adherence was found to be “no worse a problem in the 
described resource-poor cohorts than developed countries” (Orrell 2005: 3).  Thus, in 
















If we accept that most caregivers are adults, then reviewing the impact of gender on 
adult adherence to HAART may be useful in extrapolating caregiver adherence 
practices in relation to paediatric ARV treatment. 
 
The evidence amongst adult HIV-infected patients shows that gender is not predictive 
of adherence but there may be specific factors which impact differentially on males 
and females regarding adherence (Stone 2000;Arrivé et al. 2005; Fogarty et al. 2002).  
Women (mothers, grandmothers, aunts) are generally the majority caregivers of 
children.  According to Stone (2000), studies have shown that women are more likely 
to succeed in taking and adhering to HAART when they trust and have an established 
relationship with their health care provider.  Other factors which favour adherence in 
women are: finding a regimen with minimal or no side effects; when they are 
provided with the results of viral load levels and CD4 counts coupled with 
information on their clinical health status and general health issues and have 
relationships with significant others in their lives such as children, partners, friends or 
other family.  Preliminary results of a survey conducted in the homes of sixty-three 
HIV positive women on ARVs, showed that women were most likely to report 
„unintentional‟ reasons for missing doses.  The best predictor of non-adherence in this 
group was an inability to describe the effect of antiretroviral medications on viral load 
that is, their lack of knowledge of HIV and treatment (Durante et al. 2003).  This 
study did not include men and therefore the effect of gender cannot be determined. 
 
It is believed that most women in care-giving roles often neglect their own care at the 
expense of those for whom they are caring.  This belief may lead one to an erroneous 
assumption that mothers (female caregivers) may ensure better adherence for children 
on HAART.  As previously mentioned above, at least three paediatric adherence 
studies have reported the converse with regard to biological mothers (Van Dyke et al. 
2002); (Katko, Johnson, Fowler, & Turner 2001); (Giacomet et al. 2003).  In addition, 
a Cape Town based study on depression among HIV infected adults which showed 












increased disability predicted current major depression among this group of patients 
(OR=1.13)(Olley et al. 2004a). 
 
A study among males (mean age 44.1 yrs) and females (mean age 43.4 yrs) in the 
USA found higher mean adherence for men than women (79.6% vs. 71.6%, 
respectively).  Factors associated with adherence in males in this study were self-
efficacy and intent to follow medical recommendations while practical, (such as „busy 
with other things‟, „being away from home‟) rather than cognitive barriers impeded 
women‟s adherence.  Only perceived barriers was significantly associated with 
adherence in women (r= -.43; p=0.03).  For men, perceived benefit of treatment (r = 
.36, p< .001), intentions to adhere (r = .39, p< .001), MOS
19
 scores (r = .54, p < .001), 





A Cape Town based study investigating psychological adjustment of HIV-infected 
mothers living in poverty, found that HIV status had a significant, independent impact 
on levels of depressive symptoms and that HIV infected women „exhibited 
significantly more symptoms of depression and anxiety than sero-negative women, 
regardless of their stage of disease‟ (Brandt 2007). 
 
Another study among HIV infected adults in Cape Town, found that 56% of the 
subjects were diagnosed with at least one psychiatric disorder, with major depression 
being the most common (Olley et al. 2004b).  
 
In psychological discourse, it is commonly understood that hopelessness and negative 
feelings reduce motivation for self-care.  In several studies depression and stress rank 
among the most significant correlates of non-adherence for HAART (Chesney 2000; 
Gordillo et al. 1999; Holzemer et al. 1999; Murphy et al. 2001; Patterson et al. 2000). 
A  study investigating the role of psychosocial factors in paediatric adherence to ARV 
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therapy, found that higher caregiver and child stress (p < 0.05) were more strongly 
associated with adherence problems(Mellins et al. 2004).  
 
2.10. Socio-economic Factors  
 
2.10.1. Housing  
 
A study in Cotê d‟ Ivoire found that there was no association between residential area 
and adherence (Arrivé et al. 2005).  However, housing instability was found to be 
associated with non-adherence in a study among children and adolescents in the USA 
(Belzer et al. 1999). 
 
2.10.2. Social Welfare 
 
There is a paucity of data regarding the influence of social welfare on adherence 
among paediatric populations.  However, many patients attending public health 





The Constitution of South Africa grants the right to social services to every child in 
section 28 (1) (c) and everyone has the right to have access to social assistance if they 
cannot support themselves and their dependants (section 27(1) (c).  For example, the 
Child Support Grant gives effect to this right to social security (Dutschke 2007). 
 
2.10.3. Stigma, Discrimination & Disclosure 
 
Issues such as stigma and discrimination have a major influence on the patient‟s 
ability to adhere to HAART.  The fear of stigma may prevent the patient from taking 
medication while away from home to avoid explaining the reason for taking 
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grants than any other middle-income or developing country. South Africa‟s welfare system is 
considered generous.  It provides means-tested non-contributing old-age pensions for the elderly, 
disability grants for those too ill or incapacitated to work and child support grants for the caregivers of 












medication.  Stigma and resultant fear of disclosure impact adversely on the patient‟s 
ability to take medication outside of the home environment.  Studies among adults 
and caregivers of children found that one of the common reasons given for missing 
doses were because they were away from home‟ (Chesney 2003), or visiting relatives 
or out with friends.  Caregivers reported missing doses because they left the child in 
someone else‟s care to whom they had not disclosed the child‟s status (Gibb et al. 
2003).  
 
A study in the USA conducted by Reddington et.al (2000) concluded that caregivers‟ 
perceptions that adherence is too difficult or concerns about loss of privacy may 
adversely affect their ability to adhere to complicated medication regimens. 
 
The authors of a Cape Town study among HIV infected adults on predictors of 
depression, concluded that the significantly higher prevalence rate of depression 
found in the sample (compared to past community surveys), may have reflected high 
levels of stigmatization and stress faced by HIV/AIDS patients in South Africa.  They 
further recommended that this finding, regarding stigmatization, should be addressed 
to ensure adherence to HAART in the context of overcrowded households and 
perhaps difficult ad hoc child care arrangements resulting in the loss of privacy 
(Olley, Seedat, & Stein 2004b).  
 
An underlying theme which runs through the literature is the fear of stigma and 
discrimination which creates a major dilemma for caregivers, children and health care 
providers around the issue of disclosure of the child‟s HIV status to both the child and 
others.  In the context of paediatrics, it is difficult to separate the discussion of  
disclosure of the child‟s HIV status to the child, from discussions about disclosure of 
the child‟s HIV status to others because caregivers fear accidental disclosure to 
others by the child (Lesch et al. 2007). 
 
Reluctance to disclose the child‟s HIV status to the child is more common amongst 
biological parent/s than amongst other caregivers.  A study in Europe across ten 
paediatric sites, found that among 182 caregivers who responded, 92% were HIV 
infected and caring for 226 children, of whom 62% were also infected.  However, 












dependent on the age of the child as well as the relationship of the caregiver to the 
child.  Biological caregivers were less likely to disclose the child‟s HIV status to the 
child, than others were.  Also, uninfected parents and other caregivers were more 
likely to want professional help to disclose to the child, than biological caregivers 
(Thorne, Newell, & Peckham 2000).  Behavioural scientists have explained that this 
phenomenon of biological caregiver avoidance of disclosure, may be a result of 
parental guilt for infecting the child as well as avoidance being used as a coping 
strategy (Austin 2003; Keogh et al. 1994). 
 
In the context of paediatric HIV treatment, disclosure to at least one other person who 
may act as a „secondary‟ caregiver to the child has become increasingly important as a 
factor which may influence paediatric adherence.  In developing countries, the death 
toll due to AIDS has left many children orphaned resulting in multiple caregivers 
taking responsibility for the various needs of the child.  Lack of disclosure to a 
secondary caregiver may result in non-adherence for the child should the primary 
caregiver be indisposed.  In a Ugandan study, lack of disclosure beyond the primary 
caregiver was found to be a barrier to adherence but that „complete
21
‟ disclosure to the 
child was associated with adherence(Nabukeera-Barungi et al. 2007). 
 
Byrne and colleagues report that in their clinical experience, strong family support 
and full, early disclosure to the child seems to be important for successful adherence.  
Furthermore, they found that families who are secretive about the diagnosis among 
themselves and with the community seem to have the most trouble with achieving and 
maintaining adherence (Byrne et al. 2002).  These observations were supported by 
findings in a Ugandan study which showed that complete disclosure to the child and 
strong parental relationships were associated with adherence (Nabukeera-Barungi et 
al. 2007). 
 
Non-disclosure to children of their HIV status appears common, even in settings 
where children have been on treatment for a number of years.  In an intervention 
study to improve adherence among children, Berrien and colleagues found that 65% 
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of the subjects did not know their HIV diagnosis at the beginning of the study.  
Children who did not know the diagnosis ranged in age between 1.5 to 12 years of age 
(mean 8.7 years) for the intervention group, and 5 to 11 years (mean 8.4 years) in the 
control group (Berrien et al. 2004). 
 
In as much as disclosure is relevant to adherence, it is evident that perceptions of 
stigma and experiences of discrimination will influence adherence to treatment.  A 
study conducted among young adults in Soweto, South Africa found that adherence 
decreased considerably with fear of being stigmatized by the sexual partner (OR = 
0.13 95%, CI 0.02-0.70) (Nachega et al. 2004).  However, a fuller discussion of 
disclosure and its influence on adolescents, important as it is for HIV management is 




The number of HIV infected children who are orphaned, is growing in Sub-Saharan 
Africa but there is insufficient data on the impact of orphanhood on adherence.  
Several factors may prevent these children accessing care in the first place, such as 
non-disclosure of their status and multiple caregivers.  However, a study in Kenya 
found that once in care, no association was found between non-adherence and orphan 
status (Nyandiko et al. 2006).  However, intuitively, we may anticipate many 
difficulties in South Africa with child-headed households and orphaned children 
trying to work to support siblings, thus having no „responsible adult‟ to take care of 
them or infected siblings.  It is also more likely that children living in these 
circumstances may only be identified for treatment once hospitalized and then access 
to treatment may be hampered by difficulty to identify a suitable primary caregiver.  
Once this person is identified, they may not necessarily be the de facto caregiver 
which may impact negatively on the child‟s ability to adhere to treatment. 
 
2.10.5. Social Support  
 
Studies have found that factors, such as self-efficacy and perceived social support 












studies among adolescents reported the opposite, that is, that neither structural social 
support, nor satisfaction with social support was associated with adherence (Murphy 
et al. 2001). 
 
Reddington et.al (2000) concluded that caregivers of non-adherent children may have 
had less instrumental social support, indicated by their degree of concern about 
disclosure of their and their child‟s HIV status. 
  
2.11. Health Service factors  
 
Health Service factors include „structural barriers‟ to access to treatment such as 
distance from the service (transport costs), user fees for medication or medical care 
and waiting times, which are hypothesized to influence adherence.  In addition, the 
provision of treatment education to the patient/ caregiver prior to initiation of 
treatment as well as adherence counselling, have been found to impact on adherence 
(Chesney 2003; Working Group on Antiretroviral Therapy and Medical Management 
of HIV Infected Children 2005; Pontali, Feasi, & Toscanini 2001; Murphy et al, 
2001).  It has been suggested that this counselling and education takes place within a 
context which is sensitive to language and cultural characteristics of patients (Shah 
2007).  Patient–provider relationships were shown to influence adherence and 
supportive providers help patients overcome barriers to adherence (Chesney 2003).  A 
qualitative study among adolescents reported that creating a strong relationship 
between the health care provider and the patient before starting treatment was helpful 
in motivating the patient to remain on treatment (Huba et al. 1997).  
 
In the absence of the identification of specific factors being predictive of change in 
adherence over time, „duration on treatment‟, has been cited as being associated with 
non-adherence.  
 
An issue which is emerging as critical to adherence, though not framed in this way in 
the literature, is the fact that HIV infection is a family disease.  In the context of 
paediatric perinatal HIV transmission, this link is even more emphatic.  DeMatteo and 












“…Surveillance reporting reflects information on infected adults and 
children but not family groupings.  Yet with HIV several family 
members and multiple generations as well as single or both parents 
may be infected, highlighting the importance of 'family HIV' as a 
framework for health policy and programme development.  At issue is 
the problem that medical and other institutions view issues of 
surveillance, treatment and care through the lens of the infected 
individual, rather than being family focused.  Often it is only in the 
context of identifying support, or barriers to support, for the medically 
diagnosed individual that biological or socially created families 
become a focus of concern.  The failure to situate both chronic and 
life-threatening illnesses within the family setting has serious quality of 
life and planning consequences for parents and children living with 
HIV infection as well as other illnesses.” (DeMatteo et al. 2002: 278) 
 
The proposal made later in this dissertation, to locate HIV management within the 
framework of a family-centred- model of care is based on the assumptions outlined 
above. 
 
2.12. Adherence enhancing Tools 
 
Individualized schedules and patient diaries, pillboxes, electronic reminders and 
clocks and cell phone technology (short message service) have been used as „patient 
reminders‟ to support adherence.  It should be noted that patients may have their 
preference and ultimately what works for a particular patient (as a reminder) should 
be considered the „best method‟. 
 
A study which tested several tools to remind patients to take their medication and thus 
improve adherence was conducted among 64 HIV-infected adult patients starting 
antiretroviral treatment.  The study was based on the premise that „forgetting a dose‟ 
is the most common stated reason for suboptimal adherence, indicating a potential 
benefit of reminder devices (Ostrop, Hallett, & Gill 2000).  The tools included 
individualized schedules, dosettes (pill boxes) and electronic reminder devices.  Of 
the subjects who entered this study, 60.9% (n=39) used at least one adherence tool.  It 
was found that patients who used schedules or dosettes had similarly high rates of 
adherence (95% and 94% respectively) compared to those who used electronic 












are currently practiced in our setting (eg. Pillboxes) are effective tools for improving 
adherence. 
 
Electronic reminders such as wrist watch alarms and beepers as well as patient diaries 
have been employed to engage children in medication adherence behaviour (Working 
Group on Antiretroviral Therapy and Medical Management of HIV Infected Children. 
2005).  However, these strategies are only feasible in resource-rich settings since the 
cumulative costs to make these available to all patients on HAART are prohibitive in 
resource-limited settings.  Other memory prompting strategies which enable the 
caregiver or child to utilize triggers in their environment may be more feasible in 
resource-limited settings.  
 
The cell phone may be a feasible memory prompting strategy even in resource-poor 
settings.  Pilot studies in Cape Town, South Africa found cell phone usage amongst 
71% of patients attending public health clinics.  The use of cell phone technology to 
support adherence has been successfully piloted in the TB programme to reduce the 
load on the DOTS intervention strategy which is the standard of care.  This Phone 
Prompted Self Administered Therapy (PSAT) is a system whereby selected patients 
are released from the requirement of direct observation and are prompted by the text 
message service of the GSM (Global System for Mobile Communications) to take 
their medication daily.  Of the 300 patients involved in the pilot there were only five 
treatment failures, and WHO has singled out the scheme as an example of best 
practice (World Health Organization 2003c). 
 
2.13. Interventions to improve paediatric adherence 
 
There is a paucity of published data relating to interventions aimed at increasing 
paediatric adherence to HAART especially in children younger than six years of age.  
In their review, Simoni and colleagues only found eight studies which were mainly 
small feasibility or pilot investigations, investigating paediatric adherence-enhancing 














The limited literature on paediatric adherence to antiretroviral treatment reviewed 
above, suggests that non-adherence is influenced by characteristics of the child such 
as developmental stage, the inability to swallow pills or refusal to take medication. 
Caregiver characteristics which influence adherence are drug use, health status, stress 
and coping ability, health beliefs, lack of social support.  The characteristics of the 
health care provider which influence adherence are: patient dissatisfaction with care, 
provider perceptions of patients‟ ability to adhere to treatment and the medication. 
Medication characteristics such as unpleasant taste, complexity of regimen, that is, the 
number of pills/medication to be taken, food stipulations and dosing requirements, 
further impact on adherence.  Interventions therefore need to be aimed at identifying 
deficits, which may involve any one of the above-mentioned areas and be context 
specific or multifaceted.  Among young children who rely completely on adult 
caregivers for the medication, issues directly relating to the caregiver, need to be 
explored for intervention.  
 
Caregivers surveyed in one study felt that the most helpful interventions for 
improving adherence would be modifications to medications to improve convenience 
and palatability as well as increased access to medical advice(Reddington et al. 2000).  
The authors have further suggested that support for adherence should be tailored to 
the individual family‟s needs and while a variety of interventions should be made 
available, this support may be less necessary with the development of more 
convenient dosing and palatable medications.  This suggestion however, implies that 
the most significant barrier to paediatric adherence is related to the medication 
characteristics.  This view is too simplistic as illustrated by the range of factors shown 
to impact on adherence in the present review. 
 
A summary of interventions is tabled in Table 2.3.  The results of the interventions 
indicate minimal impact in most instances, considering the amount of resources 
invested in the interventions.  However, it should be noted that most of the 
interventions were apparently „as a last resort measure‟, that is, children who were 
consistently non-adherent or had unsuppressed viral loads over time thus probably the 
most likely cases to fail.  Several factors were identified to impact on adherence in the 













The various types of interventions are outlined below with most of the interventions 
modelled on the „directly observed therapy‟ (DOT) model.  Most of these DOT 
interventions were conducted via hospital admission including invasive procedures 
such as gastronomy tubes.  This increases the cost of this type of intervention which 
can be prohibitive in resource-limited settings where in-patient beds are limited for 
very sick children and thus clinically well children will be very low on the priority list 
for hospitalization. There are few researchers who have conducted a cost analysis of  
paediatric HAART adherence interventions (Cunningham et al. 2006; 
Hansudewechakul et.al. 2006). 
 
Interventions to enhance paediatric adherence to HAART either focus on skill 
enhancement relating to medication administration among children and caregivers or 
on knowledge, behaviour and psychosocial influences or a combination of these 
approaches. 
 
2.13.1. Patient Education 
 
A study involving home visits by nurses focused on HIV/AIDS information/education 
and resolution of barriers to adherence in the home environment in the USA. Pill 
counts were also done by nurses during home visits the purpose of which was to 
“point out success or misconceptions about treatment”.  This was a randomized 
controlled intervention design with patients (N=37; 20 intervention and 17 controls) 
either randomized to either the home intervention or control group. The results 
indicated that while knowledge and refill history improved significantly in the 
intervention group in the, the impact of this intervention on viral load and CD4 counts 
were reportedly minimal.  However, improvement in adherence was associated with 
improvements in CD4 and viral load outcomes even after 6-11 months after the 
intervention.  Mean pharmacy refill score was 2.7 in the intervention group and 1.7 in 
the control group; p < 0.002 and slight improvement in self-reported adherence was 
noted in the study group (Berrien et.al. 2004).   
 
In another „patient education‟ intervention, a system of ongoing HIV education and 
care training for children and caregivers was established in Chiang Rai Hospital, 












involving 57 child-caregiver pairs was reported.  The intervention involved pre-
HAART education and discussion of critical issues such as disclosure, adherence for 1 
day.  Children and caregivers were targeted with children‟s training involving the 
choice of a DOT supervisor (1 or 2 adults); medication reminder tools & adherence 
support materials (self-record diary, weekly pillboxes and wristwatch).  Caregiver 
training involved drug preparation (cutting of tablets and administration tips) as well 
as guidance on how to implement DOT with emphasis on being supportive and non-
judgmental.  The duration of the intervention was as follows:  Pre-HAART initiation 
(1 day education at health facility); 1 home visit by nurse 3 days after initiation; one 
day education on Day 14 and once a month for 6 months; thereafter once every 3 
months.  Adherence measures were taken at these visits.   
 
The results showed that ninety percent of children (N=110 with median age of 9 yrs) 
achieved >95% adherence in the first six months compared to 87% in the subsequent 
6 months. However, results showed that no single intervention was associated with 
strict adherence over time (>12 months)(Hansudewechakul 2006).  Two factors found 
to negatively impact on adherence during the first 6 months, but not in the subsequent 
6 months, were, being cared for by a grandmother and older age of children (above 
the mean of  9.3 yrs (p=0.05).   
 
The cost of this intervention was estimated at approximately $25 per child per month.  
 
2.13.2. Patient education regarding clinical practice to avoid potential 
barrier: An example. 
 
Interim results from the Children with HIV Early Antiretroviral Therapy (CHER) 
study suggest that giving ARVs to children as young as six weeks old, irrespective of 
immunological or health status, results in reduced mortality.  One of the aims of the 
study was to determine whether early initiation of treatment for a limited period (1 or 
2 yrs) could be beneficial to facilitate the building of the infant‟s immune system in 
order to delay disease progression.  The trial was underway at the time of writing 













The implications of this study are that paediatric treatment protocols may be revised 
with guidance from WHO in the following: very young children who test positive for 
HIV infection, irrespective of health status, will be given ARVs at diagnosis.  In the 
light of the evidence from the present adherence study which illustrates the 
complexities of medication administration and paediatric adherence, the 
implementation of such recommendations should be approached with caution by 
ensuring that caregivers are adequately prepared for this event.  There may be several 
factors which may impact on biological mothers‟ decisions to continue ARV 
treatment once they leave the health facility. Such decisions may hinge on issues such 
as denial of the child‟s HIV status or having the perception that the child is not „sick‟ 
enough to warrant ARVs or needing to consult with significant other people in their 
lives such as partners and elders.  The public education around ARV treatment to date 
is that not everyone who is HIV infected requires antiretroviral treatment.  The „new‟ 
approach to treating all HIV infected infants will require public awareness of the 
reasons why this differs from the main message regarding antiretroviral treatment. 
 
2.13.3. Directly Observed Treatment 
 
An intervention was conducted to determine whether prolonged detectable viral load 
could be attributable to poor adherence.  The researchers demonstrated that directly 
observed therapy administered for as little as four days (4 children in hospital and 2 at 
an HIV programme sponsored summer camp) in children aged between 3.3 and 11.5 
years was successful in lowering viral load by as much as 70% (0.5 log10 drop in viral 
load ) (Gigliotti, Murante, & Weinberg 2001).  
 
However, for Roberts et al. (2004) employing an „Enhanced DOT‟ strategy for six 
families of children with constant detectable viral loads over many years did not yield 
as successful an outcome.  Their approach involved an initial referral to a home health 
nurse who visited families in their homes and then DOT (during a four day 
hospitalization) supplemented by hospital based caregiver training and at two weeks 
post-discharge.  There results showed no sustained improvements in adherence except 
in the two cases reported for medical neglect that were later placed in foster care with 












participation in this intervention were children who had not had virological 
suppression „for years‟ and thus were most likely to face several barriers to adherence. 
In Cambodia, 117 children with „late stage‟ HIV-infection, in a village were 
administered DOT HAART by Child Care Workers working for a NGO for a period 
of six months.  An evaluation of outcomes showed that 22(18%) died within the first 
6 months and CD4 counts increased substantially for the rest over a 6 month period 
(Myung et al. 2007). 
 
2.13.4. Gastrostomy  
 
For families who demonstrate poor adherence because they struggle with medication 
administration due to the child‟s inability to swallow, or constant vomiting of 
medication etc, gastrostomy tube insertion may be the appropriate intervention (in 
combination with behavioural therapy or clinical intervention, depending on the 
cause).  A one year retrospective chart review found 17 children who had gastrostomy 
tube insertions for improvement of medication adherence (Shingadia et al. 2000).  
Ages ranged from 1.25-11.8 years with a median age of 2.9 years.  The intervention 
was reportedly successful with all 17 patients described as “adherent” on their charts, 
one year after the procedure.  However, only for 10 children was a >2-log reduction in 
viral load found.  Co-incidentally, these 10 children all had a regimen change at the 
time of the procedure.  It is hypothesized that the regimen change minimized the 
impact of viral resistance secondary to non-adherence. Furthermore, caregivers found 
the devices acceptable and reported reductions in medication administration time and 













Figure 2. 1: Gastronomy Tube  button on a child's abdomen. 
 
Source: Shingadia et.al. (2000) PEDIATRICS Vol. 105 No. 6 June 2000, p. e80 
 
2.13.5. Multi-systemic Therapy 
 
Though the present review does not focus on adolescents, this intervention deserves 
mentioning since it could be used for younger age groups, despite its prohibitive cost. 
The young child is utterly dependent on the family and caregivers and usually reflects 
the dynamics in the household and related social systems, in their behaviour.   
 
An intervention approach currently being explored for adolescents infected with HIV 
and non-adherent to treatment in the USA, is called “Multisystemic Therapy” (MST).  
According to (Cunningham et al. 2006: 45 this is “an empirically supported, 
comprehensive community-based treatment for adolescents presenting serious clinical 
problems (e.g. Violence, drug abuse) and their families”.   
 
This approach has recently been adapted to improve adherence and health outcomes 
in urban youths with chronically poorly controlled type 1 diabetes and piloted among 












aged 1-16 years participated with significantly decreased viral load from referral to 
end of treatment, persisting to 3-month follow-up.  An interesting finding of this study 
was that caregiver –reported adherence did not change as a result of the intervention. 
This intervention required 46 therapy sessions over 7 months and may not be feasible 
in resource-limited settings. 
 
The treatment theory underlying MST draws on social-ecological and family systems 
theories of behaviour.  The approach involves mental health specialists who work 
with a youth and his family at the community level (school, home). They conduct 
home visits approximately three times a week over a period of 6 months.  During the 
intervention cognitive-behavioural therapy and structural family therapy is provided 
to effect change within and between the systems in which the youth operates and that 
directly or indirectly influenced the non-adherent behaviour.  However, this is a 
prohibitively expensive intervention (especially for resource-limited settings), costing 
approx. $5500-$6000 per case (Cunningham et al. 2006).   
 
2.13.6. Pill Swallowing Training 
 
Due to the lack of appropriate and suitable ARV formulations for children, it is 
believed that simplification of children‟s doses (eg. By taking it in pill form, thereby 
reducing the volume of unpleasant medication), may lead to better adherence. Garvie 
and colleagues conducted a retrospective patient chart review of 23 paediatric patients 
aged 4 to 21 years who referred for pill-swallowing training by an experienced 
paediatric psychologist over a period of two years.  An explanation is not given in the 
publication for the inclusion of young adults up to the age of 21.  Mean age at referral 
was 7.9 years. 
 
Patients (N=23) participated in individual training sessions in which the appropriate 
swallowing technique first was modelled by the trainer (the clinic paediatric 
psychologist), then practiced by the child.  The child practiced using pieces of gummy 
worm candy cut to size to emulate commensurate placebo gel cap sizes before making 
the transition to lactose-filled placebo gel caps.  These were swallowed in gradually 












required before progressing to the next size.  The number and the length of sessions 
were determined by the individual patient‟s rate of progress.  The target gel cap size 
was dictated by their prescribed or desired treatment regimens.  Each child 
participated in as many sessions necessary to achieve success (e.g., reach target pill 
size) or until it was determined that the child was not developmentally ready to 












Table 2.3:  Empirical Interventions to improve Paediatric Adherence to HAART 
Intervention Description Results Authors 
“Home based intensive nursing intervention 
 
Duration: 8 structured sessions over a 3 month period. 
 
N=37 (20 intervention and 17 controls) 
 
HIV knowledge and adherence (measure by pharmacy refill) 
increased in study group (mean refill score was 2.7 in the 
intervention group and 1.7 in the control group; p _ 0.002). 
Improvement in adherence was associated with improvements in 
CD4 and viral load outcomes even after 6-11 months after the 
intervention. The authors speculate that the experienced home 
care nurse was key to the success of the intervention. 
 
(Berrien et al. 2004) 
 
Country: USA 
HAART initiation and treatment support intervention: 
Involved pre-HAART education and discussion of critical 
issues such as disclosure, adherence etc.(1 day) 
Duration (12months):  
 
N=57 
During first 6 months, 90% were „strictly adherent.  Between 6-
12 months, 87% were strictly adherent.  
Use of adherence tools declined over time but was not 
significantly linked to a decline in adherence.  
 As-treated analysis showed that, at 6 and 12 months of therapy, 
64% and 61% had a viral load < 50 copies/ml, and 94% and 
93% had < 400 copies/ml, respectively as opposed to Intent-to-
treat analysis which showed that, 53% and 58% had a viral load 
< 50 copies/ml and 77% and 88% were <400 copies/ml, 
respectively. 
(Hansudewechakul et al. 2006) 
 
Country : Thailand 
A short course DOT intervention 
Duration: hospitalization over 4 days 
 (2/4 had DOT administered at HIV sponsored summer 
camp. N=6 children 
Children aged between 3.3 and 11.5 years. DOT “by 
hospitalization”  was successful in lowering viral load by as 
much as 70% (0.5 log10 drop in viral load ) 





DOT (Multidisciplinary In-patient care) 
Duration: Length of stay for each patient was not 
reported. 
After discharge, the patient was seen weekly in the 
outpatient paediatric clinic for viral load and adherence 
monitoring. 
 
N=21 (23 hospital admissions) 
A retrospective analysis of the data revealed that the 
intervention resulted in an immediate and sustained (up to 6 
months) reduction in viral load and increase in CD4 count.  
Mean age of participants was 12.6 years. Over half of the 
patients in the study maintained 1 log10 or more decrease in viral 
load 6 months after discharge. Additionally, 
more than one third of patients in the study attained an 
undetectable viral load by 6 months after discharge. 
 














Enhanced DOT intervention 
Duration: four day hospitalization + home health nurse. 
(2 cases were referred to the state authorities as „neglect‟ 
due to un co-operation from caregivers). 
 
N= 6 families 
The results showed no sustained improvements in adherence 
except in the two cases reported for medical neglect, which were 
later placed in foster care with subsequent improved virological 
outcomes. 
 
(Roberts et. al. 2004) 
Country: USA 
Community based DOT 
Child Care workers employed by an NGO, administered 
DOT to children, twice a day. 
N=117 
22(18%) of the children died within the first 6 months.  CD4 
count increases reportedly comparable to those found in US and 
European studies (but not specified).  Staffing costs estimated at 
$5 per child per month. 
(Myung et al. 2007) 
Country: Phnom Penh, 
Cambodia 
 
Gastrostomy Tube Insertions.  
 
A one year retrospective chart review of  children who had 
gastrostomy tube insertions for improvement of 
medication adherence    
 
N=17 
Ages ranged from 1.25- 11.8 years with a median age of 2.9 
years.   
The intervention was reportedly successful with all 17 patients 
described as “adherent” on their charts, one year after the 
procedure.  A >2-log reduction in viral load was only found in 
10 children. It should be noted that authors report that these 10 
children all had a regimen change at the time of the procedure. 





Multisystemic Therapy (MST) 
Duration: This intervention required 46 therapy sessions 
over 7 months. 
  
N=19 
Children aged 1-16 years participated with significantly 
decreased viral load from referral to end of treatment, persisting 
to 3-month follow-up. An interesting finding of this study was 
that caregiver –reported adherence did not change as a result of 
the intervention.   
(Cunningham et al. 2006).   
 
Country: USA 
Pill Swallowing Training 
Duration: The number and the length of sessions were 
determined by the individual patient‟s rate of progress. or 
until it was determined the child was not developmentally 
ready to acquire the skill. In general, sessions lasted 
between 15-30 minutes. 
N=23 
Modal number of sessions required to acquire the pill-
swallowing skill was 1 session. Younger children (aged 4–5 
years) required a median of 2 training sessions, and older 
children required 3 sessions. 
A significant improvement in adherence from baseline to 6 
months post–pill-swallowing training completion was observed, 
as were significant related improvements in CD4_ T-cell% and 
viral load. 
. 
















The term “adherence” in the context of HIV medication is not clearly defined. As a 
result, evaluation of adherence is subject to the evaluator‟s definition and standard, 
resulting in relative „successes‟ of interventions to improve adherence.  However, 
there is a common understanding of the parameters required to evaluate HAART 
success, namely, virological suppression, immune reconstitution, correct dosing and 
administration of medication with minimal or no side-effects.  However, virological 
suppression is considered the alternative „gold standard‟
22
 and goal of HAART. 
 
Several methods are employed to measure adherence.  By far the most common 
method of adherence assessment found in the literature is a subjective method of „self-
report‟ and in the case of young children “caregiver self-report” using the range of 
self-report instruments, including, to a lesser extent, visual analogue scales. However, 
electronic monitoring devices are commonly used as a reference measure in research 
studies in the developed world but are not yet widely used in resource-poor settings 
though there are a few exceptions (Müller et al. 2007; Oyugi et al. 2004). 
 
The literature regarding paediatric HAART adherence, is limited, especially in the 
very young.  It is not easy to extract data regarding ages among the study populations 
but there seems to be a trend towards studies with higher age groups with median ages 
ranging from 4 to 12 years and mean ages reported from 2.6 to 9.8 years.   
 
This chapter has summarized the factors influencing adherence into four domains 
namely, child factors including treatment characteristics, caregiver factors, health 
service factors and Socio-economic and social factors (see Table 2.2
23
).  From the 
above literature, it is obvious that the factors influencing adherence are not fixed in 
relation to being either barriers or facilitators of adherence.  This is true for both adult 
focused studies and the paediatric focused studies.  There is a need to continue to 
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 Pharmacologic measurement of plasma concentrations of the various antiretroviral agents is the „gold 
standard‟ for objective measurement of adherence.  However, it is not routinely available commercially 
and is prohibitive in terms of cost.   
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explore these factors and to identify those factors influencing specific patient cohorts, 
taking into account the contextual setting of both the service and the patients.  
 
Furthermore, it was illustrated by the review on empirical interventions to improve 
paediatric adherence to HAART that proactive interventions such as patient education 
and skills training at HAART initiation may be more successful than interventions 
introduced long after barriers to adherence have become entrenched in the patient and 
family system. 
 
It may therefore be wise to pause and consider the proposal of Vrijens and colleagues 
to create an explicit discipline within  biopharmaceutics concerned with “what the 
patient does with the drug” in addition to the other two, namely, pharmacokinetics 
(what the patient‟s body does to the drugs) and pharmacodynamics (what the drug 
does to the patients body). 
 
They have coined the term “Pharmionics” to describe this sub-specialty. They argue 
that: 
 
 “Pharmionics is the discipline concerned with the ways in which prescription 
drugs „„go‟‟ into use – in the broadest sense of the word „„go‟‟. This new field 
subsumes matters that meant little when prescription drugs had little 
therapeutic power, and were usually used singly rather than in complex 
combinations. Pharmionics has gained in importance as drugs have gained in 
both therapeutic strength and potential for harm if misused (p.227)(Vrijens, 
Gross, & Urquhart 2005). 
 
This review has identified several studies providing paediatric adherence data which 
are incidental to another line of investigation and therefore not rigorously collected 
nor measured. This proposed approach to the study of adherence (recognising it as a 
focussed discipline called „Pharmionics‟) may provide the impetus for provision of 
resources to enable methodologically sound and more rigorous studies which include 
the younger paediatric population in general biopharmaceutics and in HAART 
research, in particular (notwithstanding ethical dilemmas of research in young 













The present study will therefore add to the body of knowledge regarding adherence 
among a very young group of paediatric patients attending public health facilities and 
living in resource-limited settings.  
 
Until the point of implementation of the present study (October 2004), no other 
studies could be found in the published literature which focused on adherence 
measurement and factors influencing adherence among non-school going children in 
resource-limited settings.  Most studies published in resource-limited settings prior to 
2004, focused mainly on the clinical outcomes of antiretroviral treatment with 
adherence being incidental to the main clinical focus. 
Four measures of adherence are compared in the present study, namely, caregiver 
self-report, pharmacy refill, clinic visits and medicine measure/pill counts.  The 
choice of these measures was motivated by the search for an appropriate measure of 













Table 2.4:  Paediatric Adherence to HAART in resource limited settings 






















Disclosing the child's HIV sero-status only 
to the primary caregiver and having been 
hospitalised only once or not at all were 
associated with poor adherence. 
 




NIL NIL 95.4% NIL No 
 
 






NIL NIL NIL Yes Older child age associated with non-
adherence. No significant difference was 
found for characteristics such as gender (P 
= 0.236), parent status (P = 0.095), median 
age at study period (P = 0.162), home place 
(P = 0.230), and medications taken during 
the study period: Zidovudine (P = 0.072), 
Stavudine (P = 0.072), Didanosine (P = 
0.902), Lamivudine (P = 0.902), Efavirenz 
(P = 0.413), and Nevirapine (P = 0.413). 
4.  (Bikaako-Kajura et 
al. 2006) 
Uganda   
Cross-sectional 
study 




NIL NIL NIL Yes 
 
Overall, 12 (29%) of the children and their 
caregivers reported excellent adherence 
(never missed any).  
dose), 17 (40%) good adherence 
(occasionally missed  doses) and 13 (31%) 
poor adherence (frequently missed doses). 
Complete disclosure and strong parental 
relationships were related to good 
adherence and ART at the Mildmay Centre 
in Uganda. 
5.  (Hansudewechakul 







87% (next 6 
months) 



























in  conjunction 
with  pill counts 
 
NIL NIL 86% No 
 
No factors influencing adherence reported 
only that Treatment regimen and adherence 
are associated with virological success. 
7.  (Nyandiko et al. 
2006) 
Kenya 
34 mth Prospective 
study (median age 6 
yrs) 





measured but not 




Perfect adherence among children with 
known orphan status was 75% and was not 
significantly different between orphaned 
and non-orphaned children, 73% versus 
71%, respectively (P = 0.863). Orphan 
status was not a significant predictor of 
death (P = 0.836) or loss to follow-up (P = 
0.096). 
 
8.  (Muller et al. 2007) 
Cape Town, SA 




NIL NIL MEMS mean of 
79.8% with 68% 
taking doses 




Factors not reported 










NIL NIL NIL No  
 
 
10.  (Eley et al. 2004) 























11.  (Reddi et al.2007) 
KZN, SA 
1 yr Retrospective 
study 
89% NIL NIL NIL No  
 
 
12.  (Mukhtar-Yola et al. 
2006) 
Nigeria 
6 month prospective 





The social class of the patients did not 
significantly affect their level of adherence. 
Even though cost was identified as a barrier 
to treatment in our patients, those from the 
middle and lower social class who were 
able to buy their medication were just as 
adherent as patients from the upper social 
class. Side-effects did not pose a barrier to 
adherence in this study. 





















Table 2.5:  Factors influencing Paediatric Adherence 
Domain Variable Evidence from Studies Citation 
Child Characteristics Age/ developmental stage 
 
 Older age impacts negatively on 
adherence 
 Age (children > 10 years) 
associated with adherence 
(p=0.04) 
 No impact of age on adherence 
using two cut-offs (> 8 yrs and < 8 
yrs) 
 Younger child age related to better 
adherence 
 Child age unrelated to adherence 
 Social and emotional development 
influences adherence due to 
child‟s ability to self-regulate 
his/her perceptions of illness. 
 
 (Arrivé et.al 2005) Cote d‟Ivoire; 
(Mellins et al, 2004) USA 
 
 (Gibb,et al. 2003) Europe  
 (Giacomet et al. 2003) Italy ; (Van 
Dyke, 2002) USA 
 (Garvie et al. 2003) USA 
 (Martin et al. 2007) USA; 
(Martinez et al. 2000) ; (van 
Rossum et al. 2002) Netherlands 
 
 Gender  No impact of gender on adherence 
 
 (Giacomet 2003) Italy ; (Van 
Dyke et al. 2002) USA 
Child behaviour   child‟s refusal to take medication 
is a major barrier to adherence 
(also see comments under 
Medication characteristics) 
 Children sleeping through dosing 
times, cited as reasons for missing 
doses 
 Decreased child responsibility for 
medication impacts positively on 
adherence 
 (Al-Omran, MacAdam, & Gard 
2000) Saudi Arabia 
(also see under „medication                     
characteristics‟ 
 
 (Mukhtar-Yola et al. 2006) 
Nigeria 
Child‟s knowledge of HIV status  Children (older than 8yrs) aware 
of their HIV status were less 
adherent  
 Complete HIV disclosure to 
children and strong parental 
relationships promote good 
adherence (*NB 50% of cohort 
 (Giacomet et al. 2003) Italy 
 (Bikaako-Kajura et al. 2006) 
Uganda 












Domain Variable Evidence from Studies Citation 
were orphaned). 
 Child‟s knowledge of HIV status 
did not affect adherence 
Health status (improvement or 
deterioration) 
 No hospital admissions or only 
one associated with poorer 
adherence 
 Clinical features  (immunological 
status or stage)have no impact on 
adherence  
 Children with more advanced 
disease are more adherent 
 (Nabukeera-Barungi et al.2007) 
Uganda 
 (Giacomet 2003) Italy; (van 
Rossum et al. 2002) Netherlands 
 (Gibb et al. 2003) Europe 
(PENTA) 
 
 Orphan status  No significant difference in 
adherence between orphans and 
non-orphans (73% vs. 71%)*(NB. 
to be interpreted with caution, 
there was significant loss to 
follow-up among orphans in this 
study) 
 
 (Nyandiko et al. 2006) Kenya 
Medication Characteristics Medication characteristics (linked to 
child behaviour with regard to 
„unwillingness‟ to take medication) 
Characteristics: taste, palatability, 
size of pills, availability of liquid 
formulations, storage requirements 
(refrigeration of liquid formulations), 
adverse effects as well as  
PK properties: frequency of dosing, 
dosage, dietary restrictions, drug 
interactions. 
 Medication characteristics, a 
barrier to adherence resulting 
„unwillingness‟ to take medication 
 Frequency of doses has an inverse 
relationship with adherence. 
 More complex regimens (>4 
drugs)found to correlate with 
better adherence (postulated that 
these children were sicker and thus 
more likely to take meds) 
 Higher „pill burden‟ (4-drug) vs. 
(3-drug) regimens associated with 
non-adherence 
 (Temple, Koranyi, & Nahata 
2001) USA; (Gibb 2003) Europe ; 
(Soza-Vento & Fritz 2007) 
 (Boni et al. 2000) Italy 
 (Martin et al. 2007)   USA 
 (Van Dyke et al.2002) USA 
Adverse drug events  Adverse drug events, a barrier to 
adherence 
 Side-effects did not pose a barrier 
in adherence study 
 (Temple, 2001) ; (Goode et al. 
2003); (Soza-Vento & Fritz 2007) 
USA ; (Pugatch et al 2002) USA 












Domain Variable Evidence from Studies Citation 
 Nigeria 
 
Caregiver characteristics Maternal Health beliefs  Caregiver beliefs about treatment, 
a barrier to adherence 
 Stronger motivation based on 
perceived benefits of ARVs 
influence adherence 
 (Reddington et al. 2000); (Soza-
Vento & Fritz 2007) 
 (Hammami et al.2004) 
Number of perceived barriers  Number of perceived barriers to 
treatment, linked to caregiver 
beliefs about treatment, a barrier 
to adherence. 
 (Steele et al. 2001); (Marhefka et 
al. 2004) USA 
Relationship to child  Children receiving drugs from 
foster parents, more adherent than 
children receiving from biological 
parents (p < 0.05) 
 Good adherence (95.5%) found in 
cohort where majority of children 
had biological parents (16/25) 
 Giacomet (2003) Italy ; (Van 
Dyke et al. 2002) USA 
 (Natu & Daga 2007) India 
Caregiver knowledge of treatment  High caregiver knowledge of Rx 
significantly associated with 
undetectable viral load 
 Lack of info or research about 
effects of HAART, a barrier to 
adherence 
 Better regimen knowledge 
associated with better adherence 
 Internalization of medical 
knowledge  regarding HIV and 
treatment associated with 
adherence 
 (Nicholson et al. 2005) USA  
 
 
 (Goode et al. 2003) Australia 
 
 
 (Martin 2007) USA 
 
 (Hammami et al. 2004) 
Educational status (literacy)  No significant association between 
educational level and adherence 
 Low educational levels 
consistently linked to non-
adherence (A literature review) 
 (Martin et al.2007) USA 
 
 (Fogarty et al. 2002)  












Domain Variable Evidence from Studies Citation 
negatively on child‟s adherence 
Substance use  Caregivers with substance abuse 
problems impact on child‟s 
adherence (physician reports) 
 (Brackis-Cott et al. 2003) USA 
Mental health status  Psychological factors impact 
negatively on adherence  
 Higher caregiver stress was 
strongly associated with non-
adherence (p<0.01) 
 Parental anxiety associated with 
adherence.  A 7.6% increase in 
odds of poorer adherence found 
with increased anxiety. 
 Psychiatric illness an independent 
risk factor for non-adherence 
(p=0.04) 
 
 (Giacomet, 2003) Italy 
 
 (Mellins et al. 2000) USA 
 
 




 (Patterson et al. 2000) USA 
Socio-economic Characteristics Social support  No association between structural 
social support and adherence but 
caregiver knowledge and self-
efficacy is significantly associated 
with adherence in the presence of 
higher social support and social 
disclosure of HIV status. 
 (Martinez et al. 2000) 
Disclosure  Difficulties in taking or 
remembering drugs related to fear 
of disclosure 
 Knowledge of  child‟s HIV status 
by caregiver only, a barrier to 
adherence (non-disclosure) 
 Less disclosure to others led to 
non-adherence (p<0.05) 
 Recent disclosure increased 
adherence in children 
 (Gibb et al. 2003) Europe 
(PENTA) 
 
 (Nabukeera-Barungi et al. 2007) 
Uganda 
 
 (Mellins et al. 2000) USA 
 
 (Garvie, Lensing, & Rai 2007) 
Family coping skills  greater problem solving capacities 
to overcome practical barriers to 













Domain Variable Evidence from Studies Citation 
adherence impact positively on 
adherence 
 care-giving /family factors 
including worse parent-child 
communication influenced 
adherence negatively (p<0.03) 
 complications in day-to-day living 
impact negatively on adherence 
(leads to „forgetting doses‟) 
 
 




 (Murphy et al. 2003) USA 
Stable housing  Housing instability associated with 
non-adherence  
 (Belzer et al. 1999)  
Income  Cost of treatment identified as a 
barrier to adherence 
 (Mukhtar-Yola et al. 2006) 
Nigeria 
Health System factors Free or payment required services  Reasons cited for missing doses 
included running out of 
medication and not having funds 
to purchase more 
 (Mukhtar-Yola et al. 2006)  
Nigeria 
Patient –provider relationship  Physician report correlates with 
viral load (r=-0.39; 
p<0.05)*hypothesized reason: due 
to frequent contact and good 
rapport) 
 Physician report does not correlate 
with adherence (adherence 
incorrectly predicted 45% of time) 





 (Patterson et al.2000) USA 
Travel distance to facility  Long travel distances to facility 
(average 72 kms one way), was 
not found to be a barrier to clinic 
adherence (95.5% rate for cohort) 
  

















Chapter 3 outlines the study aims, objectives and methodology.  The physical context 
of the study (site selection, description and personnel) is described together with 
participant recruitment criteria and procedures.  The site description is purposely 
detailed. It includes a brief history in order to provide a context for the challenges 
presented to the researcher conducting operational research in a routine clinic without 
special adaptations considerate of the research being conducted.  An overview of the 
study design, description of the data management and approach to analysis is 
presented.  Finally, the ethical considerations are outlined. 
 
3.2. Study Aims and Objectives 
 
The study aim was to characterize paediatric adherence amongst children <7 yrs of 
age by identifying the measure of adherence most appropriate in a paediatric clinical 
setting and, identifying factors impacting on their adherence. 
 
3.2.1. Specific Objectives 
 
1. To determine the rate of adherence to HAART among children aged 0-6 
yrs attending Red Cross Children‟s War Memorial Children‟s Hospital‟s 
(RXH) infectious diseases outpatient clinic (IDC), using four measures of 
adherence: namely, (1) medicine measure/pill counts (2) caregiver self-
report (3) pharmacy refill (4) clinic attendance.  
2. To determine the agreement between the four measures. 
3.  To determine the agreement of the measures with virological outcome at 6 
months since ARV initiation. 
4. To identify child, caregiver, Socio-economic and health system factors 












5. To make recommendations for the design and implementation of 
adherence enhancing interventions in this setting.  
 
3.3. Site Selection 
 
There are three tertiary level public health paediatric ARV services in the Western 
Cape Province, namely, Groote Schuur Hospital (Ward G25), Tygerberg Hospital, 
KIDs Clinical Research Unit (KIDCRU) and RXH. Statistics for 31 March 2004 
(prior to commencement of the study), indicate that 78.4% (537/685) of all children 
treated with HAART in the province were managed at the three aforementioned 
referral hospitals (HIV/AIDS Directorate. 2004).  The ARV treatment provided at this 
stage (prior to the National ARV roll-out) in all three sites was donor dependent and 
therefore issued on a relatively limited scale.  RXH was chosen as the study site due 
to the fact that the majority of its patients were already on a provincial sponsored 
ARV programme and thus more children would have access to treatment thereby 
impacting positively on potential enrolment numbers.  The authorities were 
approached for permission to conduct the study at the site, which was granted (see 
Appendix 2). 
 
3.4. Study site Description 
 
To allow the reader to understand the service in which the study was conducted and 
the changes that staff and patients experienced during the period of the study, a brief 
overview of the history of the clinic will be presented.  
 
Red Cross War Memorial Children’s Hospital (RXH) 
Red Cross War Memorial Children's Hospital (RXH) is one of two tertiary (referral) 
hospitals in Cape Town associated with the University of Cape Town's Faculty of 
Health Sciences.  However, it is the only hospital on the African continent dedicated 
exclusively to the care of children (that is, no adults are managed at this hospital).  
The hospital provides specialist care for children with a wide range of medical and 
surgical conditions.  HIV infection is currently the dominant health problem. Between 












infected.  Approximately 31% of all deaths and 60% of deaths due to infectious 
diseases at the hospital are currently related to HIV infection (Grandin et al. 2006).  
 
Infectious Diseases Outpatient Clinic (IDC) 1990-2003 
The “HIV clinic” is referred to as the Infectious Diseases Outpatient Clinic.  This 
outpatient clinic was started at the hospital in 1990 in response to the growing number 
of children identified as HIV infected and in need of specialist follow-up.  HIV care 
included regular clinical monitoring including cotrimoxazole prophylaxis, treatment 
of minor infections, nutritional and micronutrient supplementation, as well as 
screening for and initiation of treatment for tuberculosis (ongoing TB treatment is 
provided at primary care level). 
 
In August 2002 a donor driven antiretroviral treatment programme for public sector 
patients was initiated at the IDC clinic (Eley et al. 2004). Treatment was offered to 
children and later (in 2003) to their infected caregivers, who met the criteria for 
initiation of antiretroviral therapy in an effort to provide a „family centred‟ approach 
to the management of HIV infection in children.  Since the hospital only received 
funding for services to children, the IDC clinic entered into collaboration with a non-
governmental organization (NGO) Absolute Return for Kids (ARK), to fund the 
service to the adults.  ARK provided the medical doctors to care for the caregivers, 
pharmacy support and ARV drugs to issue to the caregivers.   
 
The antiretroviral drugs were dispensed through a „research‟ pharmacy which was 
donor funded.  This pharmacy operated differently to the normal hospital pharmacy 
since it served a very small patient base, namely those attending the IDC clinic for 
ARVs and study participants in clinical trials.  There were therefore no long queues 
and long waiting times at the pharmacy and patients received careful instruction 
regarding ARV administration.  This setting was therefore not typical of routine 
patient care in the rest of the hospital and in the community.  Adherence monitoring 
was done and feedback given to patients regarding their adherence according to pill 
counts/medicine measures.  Reinforcement of knowledge of the dosing and 













The IDC clinic provided a comprehensive service including ongoing psychosocial 
counselling (provided by  NGO-appointed lay counsellors), a social work service; 
home visits for follow-up of defaulters and assessments for treatment initiation; 
placement in acute respite care when necessary, liaison with community based NGOs 
for welfare and post hospitalization medical support.  Weekly support group meetings 
are held on clinic days to provide caregivers of HIV infected children to receive 
information and share experiences thereby gaining support.  These groups are 
facilitated by the lay counsellors.  
 
IDC 2004 – 2006 
This total reliance on donor funding changed by 2004 with the governments‟ decision 
(in November 2003) to provide antiretroviral therapy through the public sector 
(Department of Health 2003).  Between February and November 2004, after the 
Western Cape province of South Africa began providing HAART to public-sector 
patients, the donor-funded programme was fully integrated with the provincial 
programme.  By the end of March 2006 the IDC site was one of 37 ARV accredited 
public sector sites and the largest paediatric ARV service in the Western Cape. The 
total number of patients receiving HAART in the Province at this time was 16300 of 
whom 2009 (12.3%) were children (Eley et al. 2006).  
 
There were a series of changes in the way patients in this study were managed at the 
IDC during the study period. These changes were as results of the shift from a donor-
funded service to a service integrated into the normal health services.  
From January 2005, all patients established on HAART at the IDC for at least 6 
months, were transferred to the main hospital pharmacy as a means of phasing out the 
ARV dispensing at the research pharmacy, as required by the new system.  Two 
„ARV‟ pharmacists, who were integrated in the main hospital pharmacy, were 
appointed by the Province.  This change led to ARV patients sharing the same 
experience of long queues at the pharmacy as all other patients in the hospital. 
In May 2005, there was a policy directive from the Provincial Health Department that 
all tertiary hospitals should „decant‟ their paediatric patients who were stable on 
HAART to the primary care clinics in their area of residence.  A decision was taken to 
close down the family clinic service in February 2005, and by May 2005, all adults on 













This referral resulted in an obligation on the part of paediatricians and IDC staff to 
mentor clinicians and health care staff at the clinics, in respect of paediatric HIV 
management and treatment. 
 
It should be noted that this policy was implemented during the recruitment and 
follow-up phase of the study which resulted in a diminished number of eligible 
participants for the study as well as the transfer and therefore „lost to follow-up‟ of 
enrolled participants.  This had a negative impact on the numbers available for 
recruitment and for retention of study participants. 
 
Patients transferred out to clinics could not be followed up by the study due to the 
following reasons: (1) the clinics are governed by different health authorities.  
Permission to access patients and patient records required formal application from the 
various authorities.  This was not feasible due to the resource constraints on the study 
and given the time lag for this process and the fact that patients were transferred to 
various clinics.  (2) There were differences in patient record systems available at the 
clinics compared to the hospital with regard to pharmacy refill records, clinic 
appointments and laboratory results.  These systems were manual and „study‟ patients 
obtained different patient identification numbers which would make it difficult for the 
researcher to link study participants in the new system.  However, we were successful 
in obtaining the viral load results of five patients who were transferred out to one 
particular clinic since this clinic was one of the outreach sites to which paediatricians 
from RXH rendered a mentorship service to strengthen paediatric HIV management at 
the site. 
 
A further factor to consider was that the IDC at Red Cross Children's Hospital has an 
active research programme.  During this study, there were several ongoing research 
clinical trials at the facility and some study participants were concurrently enrolled in 
other trials.  This meant that in some instances they were given additional medication 
such as INH prophylaxis/placebo or micronutrients in another study.  These study 
medications were given in addition to their antiretroviral treatment and added to their 
„pill burden‟ but not counted as part of their adherence assessment in this study.  













The standard of care for children on HAART during the study period included 
monthly pharmacy refills, clinic visits within 2 weeks to a month of initiation, 
thereafter monthly clinic visits until the patient is deemed „stable on HAART‟, at 
which point clinic visits may be bi-monthly while pharmacy visits remain monthly.  
In addition to various blood tests such as tests for anaemia, liver function, 
immunological (CD4 counts) and virological (HIV DNA Viral load) monitoring is 
conducted routinely.  The data on CD4 counts and viral load collected for this study 
was part of the routine service and not specifically for the purpose of this study. 
 
The health care team composition fluctuated during the period of the study starting 
with 1 full-time consultant and 1 clinical nurse practitioner who was working on 
research trials full-time but assisting on clinic days at the IDC.  Several principal 
medical officers, some of whom later took up positions in the clinic, volunteered their 
services.  Two lay counsellors, employed by and NGO provided interpretation 
services for IDC doctors, pre and post test counselling, support group facilitation and 
information to patients regarding HIV and antiretroviral treatment.  The number of 












Table 3.1:  Summary of Key changes during study period 2004-2006 












Research Stage Recruitment /FU Recruit/ F/U Recruit/ F/U Recruit/ F/U Recruit/ F/U Follow-up Follow-up 
No. of Children 
remaining in care 
329 351 357 471 414 391 288 
New patients 
starting ART 
38 63 66 108 69 61 132 
Cumulative Nos. 
Recruited 
32 56 77 92 97 121 135 
IDC Staffing 2 Research 
Pharmacists*;  
3 clinicians  
1Clinical Nurse 























 No staff 
changes 





































































* The research pharmacists did not provide a service to the IDC paediatric patients from January 2005.   
** The nurse previously part-time became full-time  












3.5. Site Preparation 
 
After Research Ethics approval and permission to conduct the study at RXH was 
obtained, the study was introduced to the staff of the IDC, where recruitment and 
follow-up would take place (Appendix 1).  A copy of the Standard Operating 
Procedure (Appendix 5) for the researcher/s was given to the staff which outlined 
eligibility criteria and recruitment procedures.  With permission, a notice informing 
rotating clinician‟s in the IDC about the study, was placed on the notice board in the 
staff tearoom.  The researcher was present at every clinic to recruit and inform new 
staff of the study. 
 
3.6. Study Overview 
 
The original plan was to utilize three types of study designs for the adherence study as 
outlined in Table 3.2.  However, because of problems arising from health systems 
constraints, two of these sub-studies were not pursued, namely, the retrospective study 
design and the qualitative study design for reasons outlined below. 
 
The implementation of the retrospective study design was abandoned due to the 
following reasons.  A meeting convened by the researcher and colleagues to discuss 
the study and obtain permission for accessing study sites (two tertiary hospitals and 
three primary care clinics) on the 21 September 2004, revealed that there had been no 
standardized system of data collection for children on ARV treatment across sites 
prior to that date.  The time frame for data collection (2002-2004) was prior to the 
government ARV roll-out programme and thus patients on ARVs were linked to 
research studies or drugs supplied by private donors.  This meant that dispensing 
records were not consistently available in a format that would have rendered 
satisfactory results for the review.  Moreover, data was not in electronic format and 
therefore was not easily accessible nor were patients on ARVs easily identifiable from 
the general hospital system, for selection into the study.  
 
An attempt to conduct a retrospective review at the study site in September 2004 












certain trials (not necessarily recorded in patient folders but with study pharmacist), 
patients receiving ARVs from donations or via their medical aid accounts did not have 
detailed records with regard to pharmacy issue and collection of ARVs recorded in 
patient folders.  This meant that there were going to be large gaps in the information 
available and high levels of missing data for key variables.  For example, in 
September 2004, there were approximately 280 patients on treatment at the IDC, 
however, up-to-date and complete pharmacy ARV dispensing records together with 
medicine return data was only available for approximately 120 patients.  This cohort 
was part of a research study which was conducted at the time. 
 
The decision was therefore made not to pursue this retrospective method of assessing 
adherence.  The retrospective nature of the data collection would have made it 
impossible to get meaningful data because of lack of standardized data and lack of 
consistent data to measure adherence across sites. 
 
No further reference will therefore be made in this report to the retrospective study. 
 
Two qualitative approaches were planned namely: (1) focus group discussions with 
caregivers of children on HAART (biological vs. non-biological caregivers) and (2) 
focus group discussions with Health Care workers in the IDC. 
 
One focus group discussion was conducted with a group of nine HIV infected 
caregivers in March 2005.  However, the group was reluctant to focus on the research 
issue and wanted a space to talk about their feelings regarding the transfer out of 
patients from the IDC to the primary care clinics, a shift in policy that took place in 
May 2005.  As a result, this discussion was not considered useful in achieving the 
aims of the focus group discussion.  In addition, several non-biological caregivers 
approached for participation in a separate focus group discussion refused; thus, it was 
decided to abandon this approach.  Similarly, staff turnover at the IDC was continuous 
due to rotation of doctors and only two staff members remained constant.  In addition, 












response of the Health care workers, and the planned approach
24
 was thus considered 
unfeasible.  Thus, no further reference will be made to the qualitative studies.  The 
reported research therefore involves a single prospective study incorporating cross-
sectional data collection at baseline and prospective data collected at three time points 
over the period of 6 months.   
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 In-depth interviews with Health Care providers involved in antiretroviral treatment of paediatric 












Table 3.2:  Overview of Study Designs 
 Retrospective Study Design Prospective Study Design 
Qualitative 
Study Design 
Study Population Children under 6 yrs on HAART Caregivers and their Children who commence HAART.  Participants in Prospective Study 
and Health Care Workers 
(HCWs) at the Infectious 
Diseases Clinic 
 
Study Site Three Paediatric HIV clinics in 
Metropole 
Red Cross Children‟s Hospital Red Cross Children‟s Hospital 
Number enrolled 300 135 12-20 Caregivers 
10 Health Care Workers 
AIM To determine the rate of 
adherence in children during the 
period 1 January 2002 to 31 
December 2002. 
1)To determine the rate of adherence to HAART among 
children aged 0-6 yrs attending Red Cross Children‟s War 
Memorial Children‟s Hospital‟s (RXH)  infectious diseases 
outpatient clinic (IDC), using four measures of adherence: 
namely, (1) medicine measure/pill counts (2) caregiver self-
report (3) pharmacy refill (4) clinic attendance.  
2) To determine the correlation between the four measures. 
3) To determine the correlation of the measures with virological 
outcome at 6 months since ARV initiation. 
4) To identify child, caregiver, Socio-economic and health 
system factors impacting on adherence to HAART among 
children in this setting. 
5) To make recommendations for the design and 
implementation of adherence enhancing interventions in this 
setting.  
 
To determine caregivers and 
health care workers perceptions 
of adherence support needs and to 
identify institutional, policy and 
staff barriers as well as enabling 
factors, to patient adherence. 
Data Collection Method A record review of all cases 
identified at each facility as 
having commenced treatment 
during the period 1 Jan-31 
Dec..2002. 
Extract pharmacy refill data from 
existing data bases, patient folders 
and pharmacy records at three 
institutions to enter onto case 
report form. 
Recruitment & enrolment of new patients on HAART between 
the periods, 1 October 2004 – 31 November 2005.  
Administered structured “baseline questionnaires” to all 
participants within one month after commencing treatment. 
 
Administer self-adherence questionnaire at M1,3,6; collect 
monthly data from pharmacy on CRF (prescription refills over 
period of 6 months), conduct meds/pill counts) at M1,3,6 
Capture monthly appointment schedules over 6 months. 
Capture CD4 and viral load results from lab reports at baseline 
Two Focus groups will be held 
with caregivers (biological 
parents and other). 
 
In-depth interviews will be held 
with the various categories of 
HCWs (doctors, nurses, 














 Retrospective Study Design Prospective Study Design 
Qualitative 
Study Design 
and 6 months. 
Capture data on changes in height and weight, hospitalizations 
and changes in household circumstances. 
A HCW team self-assessment 
will be facilitated by the PI.  This 
will be in the form of a team 
workshop.  Key members of the 
team will be identified before 
hand and encouraged to 
participate. 
Primary Analysis Sub-study Not undertaken Descriptive statistics for basic characterization of cohort. Crude 
bivariate comparisons (using Student‟s T-Test and ANOVA to 
compare means. Fisher‟s Exact tests and Yates‟ corrected chi-
square to compare proportions to identify basic unadjusted 
associations.   
 A series of chi-square tests conducted to determine a 
relationship between the categorical predictors/controls to avoid 
multi-co linearity in the regression models. Kruskal Wallis tests 
were used to examine logged base viral load with various 
controls. Sensitivity and specificity tests were conducted to 
determine cut-off points for adherence. Box-plots and 
Spearman‟s correlation were used to examine correlation 
between adherence measures and between adherence measures 
and viral load. 












3.7. Prospective cohort design 
 
A prospective cohort study design was used involving 135 children, who were 
enrolled between 1 October 2004 and 9 June 2006.  They were followed up for 6 
months.  The last follow-up assessment was conducted in November 2006. 
 
3.7.1. Study Population and Sample 
 
Primary caregivers and paediatric patient pairs, who commenced HAART treatment 
between 1 October 2004 and 31 June 2006, at Red Cross Children‟s Hospital‟s 
Infectious Diseases outpatient clinic, were enrolled into the study. 
   
*Definition of primary caregiver:  The person, with whom the child lives for > five 
days of the week and is responsible for the welfare of the child.  This includes 
grandmothers, aunts, uncles, foster parents as well as biological parents. 
 
Inclusion Criteria 
 Primary caregivers of children, younger than seven years of age at time of 
initiation of treatment, accompanying the child to hospital visits. 
 Children who are treatment naïve and commencing treatment on the day of 
enrolment or within one month prior to enrolment. 
 
Exclusion Criteria 
 Any child living in an institutional setting or children‟s home for long term 
care; or those waiting to go to foster homes, at the initiation of ARV treatment. 
 Children on treatment for more than 1 month prior to enrolment. 
 
The reason for the exclusion of institutionalized children was based on the experience 
that most of these children are usually accompanied to hospital by various caregivers.  
These are often volunteers who are not involved in the daily administration of 
medication and often do not have a history for the child.  They often accompany more 
than one child at a time.  Children in institutions usually receive their medications, 












adherence data for this group of paediatric patients is limited when considering the 
large numbers of patients in routine ambulatory non-institutional care. 
 
Children on treatment longer than 1 month were excluded for a two main reasons. 
First, because factors such as, knowing the names of drugs; knowledge of treatment; 
perception of side effect profiles of children; difficulty with administration of 
medicine and the perception of child health status at initiation, would be different for 
caregivers whose children were on treatment longer, compared to those whose 
children are just starting out treatment.  Second, several variables were used to 
contrast baseline characteristics (at initiation of treatment) with outcomes at 6 months.  
These variables would not be clearly defined with the inclusion of children starting at 
varying times before enrolment into the study. 
 
3.7.2. Measures of adherence 
 
Caregiver Self-report:  
Adherence was measured using the Paediatric AIDS Clinical Trials Group (PACTG) 
adherence questionnaire which is based on 3-day recall of missed doses preceding the 
clinic visit, as well as the correct identification / description of prescribed medication 
(Appendix 13).  This information was obtained at months 1, 3 and 6. 
 
Cumulative Adherence Formula for caregiver self-report:  
Cumulative Adherence was calculated as:  sum (number of doses taken yesterday)+ 
(number of doses taken 2 days ago) + (number of doses taken 3 days ago) /sum (total 
number of doses) for each Month.  This was averaged (that is, divided by the total 
number of months for which there was a measure) and expressed as a percent.  
 
In addition, mean adherence rates were calculated for each ARV, averaged over the 
follow-up period.  Cumulative frequency of missed doses per ARV was calculated 













Pharmacy refills:  
This information was abstracted monthly from the pharmacy chart in the patient 
folder.  Adherence was calculated by computing the percentage „on time‟ medication 
collections over the total amount required over a specific period.  „On time‟ 
collections were defined as 4 days around the given date but no longer than 2 days 
after the given date.  
 
Adherence Formula for Pharmacy refill:  
The number of „on-time‟ collections completed/expected number of collections for 
the study period multiplied by 100 
 
Clinic attendance:  
This information was abstracted from the patient folder and IDC ARV Case report 
form (Appendix 6).  Adherence was calculated as the percentage „on time‟ scheduled 
clinic appointments kept/the total number of scheduled visits within a specified period 
of time. On-time attendance was defined as „scheduled appointment kept‟. 
 
Adherence Formula for Clinic visit:  
The number of „on-time‟ visits completed / expected number of appointments for the 
period multiplied by 100. 
 
Cumulative Adherence Measure 
A cumulative adherence measure was calculated as follows: sum (adherence (%) 
Month 1 + adherence (%) Month 3 + adherence month 6)/ 3; where data was missing 
for any particular time point, the data was divided by the remaining data, for example, 
adherence Month 1 + adherence Month 3 / 2. 
 
Pill /medicine Counts: 
The researcher conducted the pill counts in a separate room, while the research 
assistant interviewed the caregiver at visits 1, 3 and 6 months.  Adherence was 
calculated as a percentage by computing the difference between remaining medication 
and issued medication/expected doses.  Remaining liquid formulations were 












Adherence formula for Medicine Measure: 
Total amount of medicine issued (expressed as millilitres in liquid form or number of 
capsules in capsule form) - amount of returned medicine (mls)/capsules / total 
expected dosing for preceding period of 1 month (mls/capsules) multiplied by 100.  
This was done separately for each ARV in the regimen, namely, three ARVs per 
child. 
 
[Note: An amount of medication carried over from previous month was added to the 
amount issued in subsequent month].  This was usually noted by the pharmacist to 
keep over prescription to a minimum. 
 
Virological and Immunological markers 
Viral loads and CD4 absolute counts as well as CD4 percentages, were abstracted 
from hospital records at baseline (date closest to initiation of ART) and at 6 months.   
Bloods are taken routinely (baseline and 6 months, thereafter annually) by IDC clinic 
staff.  The bloods are sent to the virology laboratory situated at Groote Schuur 
Hospital for testing. Results are posted electronically via the laboratory database to 
which the hospital has access. 
 
3.7.3. Sample Size Determination   
 
Due to the paucity of data regarding paediatric adherence to antiretroviral treatment in 
resource-limited settings, effect sizes were determined from literature from the 
developed world.  As outline in chapter 2, adherence to medical advice in general 
varies widely and in paediatric populations average approximately 50% 
(Fotheringham & Sawyer 1995).  However, studies in paediatric HIV have shown the 
size of the difference between adherent and non-adherent groups  ranged from 0% to 
40% when measuring adherence by caregiver self-report (Steele & Grauer 2003); 
(Reddington et al. 2000), to approximately 60% when measuring adherence by  clinic 













The above data has wide variability and the sample size for the present study was 
therefore based on „Cohen‟s rule of thumb‟
25
 for a medium effect of 0.50 to determine 
differences between groups (Table 3.3).  Using G*Power statistical software, the 
Table 3.3 was generated.  For 80% power with Alpha (  ) set at .05, the required 
sample size is 128.  This study recruited 135 participants.  It was hypothesized that a 
sample size of 135 would provide sufficient power to identify predictors for 
adherence or non-adherence that are in the order of odds ratios of 0.50 or conversely 
odds ratios of 2.0. 
 
For a sample size based on an effect size of 0.20 (small effect) with 80% power with 
Alpha at 0.05, the number of participants needed to be at least 788.  This number was 
prohibitive in terms of the amount of time it would have needed to recruit this size 
from one site (Appendix 9).  In addition, the lack of funding for the study made this 
target unfeasible. 
 
Table 3.3:  Power and Sample size calculation 
Effect size Alpha Power Sample size Actual Power 
0.50 0.05 .80 128 0.8015 
0.50 0.05 .70 102 0.7056 
0.20 0.05 .80 788 0.8017 
 
3.7.4. Research Personnel 
 
The researcher utilized the services of a research assistant.  There were two different 
assistants for the duration of the study.  The first one was a social science graduate 
enrolled in the MPH programme.  The research assistant had experience in conducting 
interviews for surveys.  He was trained in the use of the research instruments used in 
the study.  
 
In June 2005, the research assistant resigned from the university and a lay counsellor, 
based at the RXH, was recruited in the research assistant position.  She was an 
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experienced counsellor who was working at the hospital for approximately three years 
at the time of recruitment to the study.  She was trained by the researcher and 
mentored by the previous incumbent before he left.  There were only two interviewers 





All interviews were conducted in Xhosa or English (as required); no participants  
wanted to speak Afrikaans.  The researcher conducted all medicine measures/pill 
counts.  A document detailing the standard operating procedures was developed as a 
guide for the research assistant who was responsible for assisting the researcher with 
recruitment, enrolment and interviewing of patients (Appendix 5). 
 
3.7.5. Study Implementation 
 
In the following section, the recruitment, selection, enrolment and follow-up 
procedures will be explained.  Thereafter, a detailed explanation of each instrument 




All interviews were conducted in private in a separate room in the first language of 
the caregiver within the area in which the IDC clinic was operating.
27
  These 
interviews were conducted during the routine clinic visits to the hospital, while the 
participant was waiting to see the doctor or after they had seen the doctor.  They were 
allowed to interrupt the interviewing process to see the doctor if their names were 
called during the interview so that the normal flow of the clinic was not interrupted. 
The recruitment interviews at 1, 3 and 6 months, lasted approximately 30-45 minutes 
while the follow-up interviews took approximately 15-20 minutes.  Four data 
collection points were therefore available for analysis. 
 
                                                 
26
 This was not measured. 
27
 Note that the IDC does not have a dedicated space within the hospital from which it operates.  The 













3.7.5.2. Recruitment and selection Procedure 
 
Caregivers of children on ARVs were recruited from two sources in the hospital, 
namely, the outpatient IDC clinic or the in-patient wards.  The patients initiated on 
treatment in the wards were identified by the researcher on the Monday ward round 
where candidates for ARV initiation were brought to the attention of the IDC 
consultants by the ward medical personnel.  The researcher was invited to join the 
clinical team on these rounds for the purpose of recruitment.  In addition, patients 
were either referred to the study by the doctors at the outpatient clinic or identified by 
the researcher via the outpatient clinic register. 
 
The routine schedule for outpatients commencing ARV is to allow at least two visits 
to the counsellor and nurse for ARV treatment literacy training before actual 
medicines were dispensed.  However, patients referred from the wards were usually 
started on treatment in the wards and then referred for follow-up visits to the 
outpatient clinic after discharge.  
 
3.6.7.3. Enrolment Procedure 
 
The primary caregivers of eligible patients were approached and informed about the 
study and if he/she agreed to participate in the study, signed consent for participation 
in the study was obtained (Appendix 3).  A copy of the consent form was given to the 
participant and a copy kept in the study files.  The forms were in English and Xhosa 
and the caregiver was given a choice regarding whether they wanted to have a copy of 
the consent form in English or Xhosa.  The consent process was conducted in the 
participant‟s preferred language.  Enrolment procedures were completed at this visit 
(Table 3 2).  The majority of the patients attending the IDC are Xhosa speaking and 
all interviews were conducted either in Xhosa or in English.  No other languages such 
as Afrikaans were necessary. 
 
The following instruments were administered to the caregiver on enrolment: 
 An enrolment form which included contact information,  current health 












solicited from the caregiver and medical history, which was abstracted 
from the patient folder. 
 The Baseline questionnaire: Children who were only starting treatment on 
the day of enrolment, stopped at question H, which related to medication 




 The Centre for Epidemiologic Studies Depression Scale (CES-D) 
(Appendix 11).  
 Medical Outcome Study Social Support Survey – Revised (MOSSSS) 
(Appendix 12). 
 
The following procedures were completed by the researcher/assistant subsequent to 
the enrolment visit. 
 Completion of the medical enrolment form by abstracting information 




 A review of the patient folder for information related to baseline clinical 
condition and latest hospitalization prior to commencing HAART was 
conducted by the researcher. 
 The next appointment date (verified with clerk if not obtained from 
caregiver during the interview). 
 
3.6.7.4. Follow-up procedure (Months 1, 3, 6) 
 
The research assistant interviewed the patient and completed the prospective case 
report form, which captured any changes in circumstances and monitored growth and 
health outcomes.  The depression screening tool (CES-D) and the perceived social 
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 Socio-demographic and treatment Baseline Data Collection (completed within 4-6 weeks after 
initiation on HAART). This questionnaire was completed in two parts if (1) there were time constraints 
for the patient or (2) the questionnaire was administered on the day of ARV initiation.  At enrolment 
parts A to G were completed.  At 2wks adherence check visit or 1 month (whichever appointment was 
given by the doctors), the questionnaire was completed (parts H-I). 
 
29
 A nurse was approached to obtain the information from the hospital database due to the „limited 












support measure (MOSSSS) was administered at each interval, as well as the 
caregiver self-reported adherence questionnaire.   
 
While the patient was being interviewed by the research assistant, the returned 
medicine bottles were obtained by the researcher.  The contents were measured and 
recorded on the “Medication follow-up assessment form” (Appendix 7).  
 
The following procedures were completed by the researcher subsequent to the study 
visit. 
 
1. The patient‟s appointment visit date was captured in the clinic visit record 
database and it was determined whether the patient‟s appointment visit was on 




Note: An „on-time appointment was defined as „on time‟ 4 days around the 
given date but no longer than 2 days after the given date). 
2. Medicine issue amounts and refill dates were obtained from pharmacy charts 
(where information was not recorded on the chart, the pharmacy was contacted 
to obtain the information from the pharmacy database). 
3. Clinic return appointment date obtained (from either patient or clerk). 
Table 3.4 below provides a summary of the study procedures. 
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Table 3.4:  Study Procedure Outline 
 Baseline Month 1 Month 3 Month 6 










Case Report Form*  √ √ √ 
CES-D (caregiver) √ √ √ √ 
MOSSS (caregiver) √ √ √ √ 
Caregiver Self-reported 
adherence 
 √ √ √ 
Med measure/pill counts  √ √ √ 
CD4 counts & CD4% √   √ 
Viral Load √   √ 
Months 1 2 3 4 5 6 
Pharmacy Refill √ √ √ √ √ √ 
Clinic attendance √ √ √ √ √ √ 
* Form capturing any changes in circumstances including growth monitoring. 
Note: Pharmacy refill data and clinic attendance were captured from hospital records on a 
monthly basis. 
 
3.7.5.5. Study Instruments 
 
Consent Forms  
The consent form outlined the aim of the study and the approximate duration of the 
interviews.  Permission to access the child‟s patient folder for medical and virological 
data was requested.  The caregiver was informed of the possibility of being recruited 
into a focus group discussion and requested to indicate their willingness to participate 
in any future focus groups.
31
  Finally, they were informed of their right to refuse 
participation and should they agree to participate initially, they could withdraw at any 
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 It was envisaged that two focus groups would be convened viz. one with biological parents and one 
with non-biological parents to explore issues which may emerged from the data indicating differences 
in factors between these two groups.  It was hypothesized that there would be differences.  However, 
the majority of caregivers were found to be biological parents.  There was therefore no basis for 












stage without prejudice to the child‟s medical care.  The consent form was 
administered in the patient‟s first language and they were given a copy to take home. 
 
Enrolment Forms (Appendix 4) 
These were in two parts.  Part 1 consisted of information provided by the caregiver 
such as caregiver and child demographic details; ARV start date; history of clinic 
attendance at the IDC and referral route; the caregiver‟s opinion of the child‟s health 
condition prior to commencement of HAART; and child‟s ARV regimen.  
Information about the caregiver‟s perception of the reason for initiation of ARV and 
source of this information was solicited. 
 
In part 2, the medical information obtained from the patient folders was documented. 
This included the verification of the date of commencement of IDC clinic attendance, 
route of referral and HAART regimen. Other information such as  TB status at 
enrolment, PMTCT participation by mother, details of last hospitalization (prior to 
enrolment), medical reason for initiation of HAART, significant medical problems, 
clinical staging, other drugs prescribed, baseline weight, height, CD4 and viral load 
data. 
 
Baseline Questionnaire (Appendix 10) 
The design of this instrument was based on the literature regarding adherence which 
was predominantly related to adult populations since at the planning and initiation of 
this research, there was a paucity of data for the paediatric population. It was also 
hypothesis driven based on the evidence from the literature.
32
  Data was captured on 
this form at one point in time only. 
 
This questionnaire collected data across the following domains: (1) Child 
characteristics which included child-minding arrangements and other health and 
demographic factors.  (2) Caregiver characteristics (primary caregiver status, that is, 
relationship to child), demographic details: caregiver details such as age, educational, 
marital, and employment status; source of financial support; caregiver HIV status, 
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health status, history of compliance to TB treatment or ARVs, if applicable, fertility 
plans (applicable to biological mothers).  (3) Socio-economic characteristics such as  
type of housing, access to water and sanitation, HIV infection among household 
members; HIV treatment among other members of household excluding index child; 
Issues of disclosure, stigma and discrimination indicated by questions such as who 
knows the child‟s status, does the child know his/her status (not applicable in the case 
of children younger than 3 years) were explored.  Caregiver perceptions of when the 
„right time‟ for disclosure to the child was and who the best person for initiation of the 
process of disclosure was and solicitation of bad experiences related to disclosure of 
HIV status; (7)With regard to social support, the following  information was elicited: 
support group attendance by caregiver and perception of household, friends and 
family support.  One section dealt with how ARVs fit into the daily routine, who the 
responsible person for administration of the morning and evening doses were and the 
type of reminder tools used.  Specific information was obtained regarding the 
weekend routine; the ease of administration for each ARV and utensils used for 
administration (e.g. syringes, cups, spoons etc); means of coping when the child 
refused medicine. This information was obtained after the child had been on ARVs 
for at least 2 weeks.  Caregiver knowledge, attitude and practice regarding HIV and 
Treatment including the practice of consulting traditional healers were probed.  An 
open-ended section for general comments about ARVs or the child provided the 
caregiver with an opportunity to inform the interviewer of any additional information. 
 
Prospective Case Report Form (Appendix 6) 
The data were captured on this form at every follow-up visit.  The following data 
were captured: HAART Regimen (to allow for any changes), height and weight, TB 
treatment status, co-trimoxazole prescription
33
, co-administration of any other 
medication and the reasons, history of hospitalization since the last visit, caregiver 
complaints about the child‟s health, possible side-effects, appetite and household food 
security, changes in household routine or child-minding arrangements, since the last 
visit and any significant family events since last visit (e.g. funerals, hospitalizations of 
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other family/household members, illness of siblings/caregiver, retrenchments, house 
moves). 
 
The Centre for Epidemiologic Studies Depression Scale (CES-D)  
This instrument was administered to caregivers at baseline and at each subsequent 
follow-up visit (Months 1, 3 and 6). 
 
Description (see Appendix 11) 
The CES-D is one of the most widely used self-report depression screening 
instruments and has been translated into several different languages and administered 
to a wide range of populations.  In this study it was translated into Xhosa
34
 (see 
section on Translations).  It is commonly used in primary care practice (Schulberg et 
al. 1985).  Brandt (2007) found that thirteen of the studies reviewed on the 
psychological adjustment of HIV-infected women, employed the CES-D, including 
three longitudinal studies (Milan et al. 2005; Miles, Gillespie, & Holditch-Davis 
2001; Richardson et al. 2001) and two conducted in developing country settings 
(Thailand and Uganda) by  (Bennetts et al. 1999; Kaharuza et al. 2006).  In South 
Africa, two studies with HIV-infected populations have used the CES-D.  Forsyth et 
al (2005) conducted research with poor, HIV-infected pregnant women in Pretoria, 
while Brandt (2007) employed the CES-D to assess the mental health of poor HIV 
infected women as caregivers of children in Cape Town  
 
The CES-D is a self-report instrument developed to measure current levels of 
depressive symptoms in the general population, and as a first-stage screening device 
(as opposed to diagnostic) in clinical and research settings (Radloff 1977). The 20-
item checklist requires the person to rate the presence and frequency of symptoms 
experienced for the „past week‟ on a four-point scale ranging from “rarely or none of 
the time” (0) to “most or all of the time” (3) – that is 0,1,2,3 options. Total scores 
range from 0 to 60, with higher scores indicating higher levels of depressive 
symptoms. 
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 The English was translated into Xhosa by one person and back translated into English by another.  
The research also corroborated the translation with Brandt(2007) who had conducted a concurrent 













In the original study involving this instrument, a score of 16 was used as an arbitrary 
cut-off to compare the proportion of individuals in the general and clinical 
populations who scored at or above this point (21% and 70% respectively (Radloff 
1977). According to Radloff the instrument demonstrated high internal consistency 
among both the general population (  = .85) and the psychiatric population ( =.90). 
This finding has been verified by subsequent studies(Hann, Winter, & Jacobsen 1989; 
Lewinsohn et al. 1997; Measurement Excellence and Training Resource Information 
Center 2002; Myers & Weissman 1980)  
 
In her analysis, Brandt (2007) used a cut-off of 10 in addition to controlling for 5 
items in the scale indicating somatic symptoms (items 2, 5, 7, 11 and 20 (i.e. restless 
sleep, poor appetite, fatigue, lack of energy and poor concentration).  The criteria to 
determine an appropriate cut-off for the reduced scale was that suggested by (Radloff 
& Locke 1986), namely, “the cut-off is that score that identifies the upper 20% of the 
distribution”. Several studies do not employ a revised cut-off score when excluding 
somatic items (Milan et al. 2005 ; Simoni & Ng 2000).  
 
Another method used by some researchers is to weight the scores in order to retain the 
range of the original CES-D from 0 to 60 as well as the typical cut-off score 
(Schrimshaw 2003). The use of this cut-off by Schrimshaw did not change the results 
significantly.  The prevalence of depressive symptoms remained high within the HIV 
infected group in both instances compared to the HIV negative group of women.
 35
 
Validity of the instrument in resource-poor settings was established by Kaharuza et al 
(2006) in their study with HIV-infected adults in Uganda where they report construct 
validity of the CES-D was adequate.  In Brandt‟s (2007)study good internal 
consistency was found with a Cronbach‟s alpha of 0 .79. 
 
Medical Outcome Study Social Support Survey – Revised (MOSSSS) 
This instrument was administered to the caregivers at baseline and each subsequent 
visit (Months 1, 3 and 6). 
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Description (see Appendix 12) 
In its original form, the Medical Outcome Study Social Support Survey (MOSSSS) is 
a 19-item scale developed to assess various dimensions of functional social support 
received by persons with chronic conditions.  In addition to a question that elicits 
information regarding network size, respondents rate how frequently they perceive 
tangible support, affectionate support, positive social interaction and 
emotional/informational support to be available when they need it on a 5-point Likert 
scale. Responses ranged from 1 (“None of the time”) to 5 (“All of the time”), with 
higher scores indicating that support is more frequently available. This scale was first 
used to measure the social support of HIV-infected women (Sherbourne & Stewart 
1991).  
 
For the purpose of this study the adaptation by (Brandt 2007) who also conducted her 
study in Cape Town, was used. She had modified it in two ways, firstly, by the 
addition of an item regarding assistance with care giving responsibilities (“Someone 
to help you take care of your children when you can‟t”) in order to tap support related 
to child care. Secondly, questions pertaining to satisfaction with the four types of 
social support assessed by the scale were included.  The formulation of these 
questions was taken from the Social Support Questionnaire (Sarason et al. 1983). 
Respondents were asked to indicate their degree of satisfaction with a dichotomous 
choice of a smiling or an unhappy face.
36
  A flash card depicting the ratings and faces 
was made for the participant‟s ease of reference during the interview.  The rationale 
for this adaptation as reported by Brandt, is that in addition to perceived support, 
satisfaction with support was hypothesized to be more predictive of women‟s physical 
and psychological wellbeing than network size and received support (Brandt 2007).  
 
Psychometric properties 
Data for the development and validation of the MOSSSS was drawn from a sample of 
2 987 patients who participated in a larger study of health care systems in the US 
(Sherbourne & Stewart 1991). Based on this sample of ambulatory general medical 
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 Since Brandt and I were working with similar populations, we felt that utilizing the same instruments 













patients, mean scores for total support, as well as tangible support, positive social 
interaction and emotional-informational support were 70 (out of 100), with 
affectionate support scoring slightly higher at 74.  Results also confirmed that the 
MOS had good internal consistency (Cronbach alphas = .91-.97) and one-year test-
retest reliability (stability coefficients = .72-.78) (ibid).  
 
Brandt (2007) confirmed these reliability results.  Results from her study established 
that total scores and subscale scores had adequate reliability.  Cronbach‟s alphas for 
total support and total satisfaction scores ranged from .83-.92, while subscale scores 
for availability of support ranged from .75-.86 and for satisfaction with support from 
.54-.81.  Only satisfaction with affectionate support scored below .65, indicating 
moderate internal consistency.  
 
3.7.5.6. Translation of Instruments 
 
All questionnaires, tools and consent forms were translated into Xhosa by the first 
research assistant (graduate).  The back translation was conducted by an independent 
translator for verification.  The translated documents were tested among six Xhosa-
speaking lay counsellors for verification of meaning and vernacular and revised. For 
consistency of meaning and interpretation, both the English and Xhosa versions were 













3.8. Data Capture and Analysis 
 
The research questions outlined in Table 4 were developed to guide the analysis of the 
data. 
Table 3.5:  Research Questions 
Objective 1: 
1. What is the mean rate of adherence at 1, 3 & 6 months for each ARV amongst 
the cohort using the Medicine measure? 
2. What is the mean rate of adherence at 1, 3 &6 months as measured by self-
report method? 
3. What is the mean rate of adherence at 1, 3 & 6 months as measured by on-time 
pharmacy collection? 
4. What is the mean rate of adherence at 1, 3 &6 months as measured by on-time 
clinic attendance? 
5. What are the mean adherence rates for the follow-up period (6 months)? 
 
Objectives 2 & 3: 
1. What is the agreement between the four adherence measures and viral load at 6 
months after treatment initiation? 
2. How do each of the measures compare with each other? 
3. Which is the „best‟ method for measuring adherence in this study? 
 
Objective 4: 
1. Which child, caregiver, health and socio-economic characteristics impact on 
adherence to HAART? 
2. What is the prevalence of depression symptoms amongst caregivers?  
3. What is the level of perceived social support and satisfaction amongst 
caregivers? 
4. Does caregiver psychological factors such as depression and perceived social 












A database was designed using the Microsoft  Access programme. Raw data was 
captured from the questionnaires into Access
©
. All capturing was completed by the 
researcher.  
 
The database was exported to STATA  for Windows version 9 for data 
cleaning and analysis. A subset of 10% of the source documents was randomly chosen 
for verification of captured data to ensure quality control.  Verification of data was 
done manually by checking study data capture form in conjunction with patient 
folders and IDC CRFs to verify clinical outcomes and socio-demographic data. In 
addition, each record of the total cohort was checked manually according to the 
criteria on the „quality control sheet‟ at the end of the recruitment and follow-up 
period. Source documents included abstracted data on case report forms, 
questionnaires.  In the case of missing laboratory results, these were obtained from the 
hospital‟s computerized records.  
 
While cleaning data the researcher created variables not in the original data base in a 
format suitable for analysis.  This applied particularly to the variable names for the 
various measures of adherence.  Formal statistical analysis was preceded by 
appropriate exploratory analysis, both descriptive and bivariate.  Descriptive analysis 
included computing means, standard deviations and measures of skewness for 
continuous variables, and generating frequency distributions for categorical variables. 
Bivariate analysis included correlational analyses and Chi-squared tests. 
 
The main analysis was divided into three parts, namely: Part 1, described in Chapter 
4; Part 2, described in chapter 5 and Part 3, described in Chapter 6. 
 
3.8.1. Part 1: Characterization of cohort and adherence rates 
 
Descriptive statistics were employed for basic characterization of the cohort.  
Adherence rates were determined for each measure of adherence in the following 
manner: 
 
Caregiver self-report:  
Data collected at month 1, month 3 and month 6 using the Paediatric AIDS Clinical 












averaged to a cumulative adherence rate using a simple average. All observations with 
available data were included, that is, if a child, was transferred, died or defaulted 
during follow-up all data was included till the time of attrition and averaged.  
 
Cumulative Adherence Formula for caregiver self-report:  
Cumulative Adherence was calculated as  sum (yesterday+2 days +3 days)/sum 
(doses) for Month 1+Month 2+ Month 3/3, expressed as a percent. 
 
In addition, mean adherence rates were calculated for each ARV, averaged over the 
follow-up period.  Cumulative frequency of missed doses per ARV was calculated 
from caregiver self-report measures. 
 
Medicine Measure 
Data from monthly pharmacy collections were abstracted from patient medication 
charts or the pharmacy computer in the case of incomplete or missing data on the 
charts for amounts of syrup or capsules issued for each ARV, as well as dosing 
information.  This was noted on the medication follow-up assessment form (Appendix 
7) from which the return medication was deducted. 
 
Adherence formula for Medicine Measure: 
Total amount of medicine issued (mls) / capsules – amount of returned meds 
(mls)/capsules/ total expected dosing for preceding period of 1 month (mls/capsules) x 
100.   
 
[Note: An amount of medication carried over from previous month was added to the 
amount issued in subsequent month].  This was usually noted by the pharmacist to 
keep over prescription to a minimum. 
 
Pharmacy refill:  
Data on pharmacy refill dates and return dates were abstracted from the patient 
medication chart.  These were subsequently evaluated for „on-time‟ collection.  „On-
time‟ collection was defined as no more than 4 days around the appointment date but 













Adherence Formula for Pharmacy refill:  
The number of „on-time‟ collections divided by expected number of collections, 
multiplied by 100 
 
Clinic Visits 
Data on clinic attendance and appointment dates were abstracted from the patient 
folder and clinic register (where appointment dates were not noted in the folder). 
These were subsequently evaluated for „on-time‟ visits.  „On-time‟ visits were defined 
as no more than 4 days around the appointment date but no longer than 2 days beyond 
the appointment date.  This evaluation was conducted by programming the database to 
calculate (appointment date- visit date).  Where patients had called in to change the 
appointment date before hand, the new date was captured as the appointment date 
with notation to that effect.  This only occurred in one instance. 
 
Adherence Formula for Clinic visit:  
The number of „on-time‟ visits divided by expected number of appointments, 
multiplied by 100. 
 
3.8.2. Part 2:  Adherence Measures 
 
Estimation of agreement between measures explored the following research questions: 
(1) Do the four measures of adherence agree with each other?  
Data was skewed thus Spearman‟s correlation matrix was employed to determine 
agreement between measures because the assumption of normality was violated. 
 
(2) How does each measure agree with 6-month viral load? 
In the absence of a „gold standard‟ measure of adherence, viral load was chosen as the 
reference measure for adherence.  The reason for this choice is two-fold: (1) the data 
were available routinely, and (2) virological suppression is the desired outcome to 
determine treatment success.  This is possible in a treatment naïve population such as 
the participants of the present study.  Electronic measuring devices have been used as 












prospective studies with follow-up periods > 3 months, in the monitoring of syrups 
(Muller et al. 2007).  
 
The data for viral load at 6 months was skewed and was log transformed to the base 
10 (a 1 unit increase corresponds to a ten-fold increase in the response) which resulted 
in a normal distribution. 
 
Firstly, control variables were identified which were hypothesized to influence viral 
load at 6 months using box plots and Kruskal Wallis tests.   
 
Secondly, unadjusted and correlation analyses adjusted for disease severity were 
employed to determine the agreement between adherence measures and viral load at 6 
months.  
 
Thirdly, multivariate models were conducted to identify the strength of agreement of 
each measure with viral load in the presence of disease severity variables. 
 
(3) What is the best cut-off threshold for adherence? 
Using undetectable viral load (<400 copies per ml) as the reference measure, 
sensitivity and specificity analysis with Receiver Operator Curves (ROC) were 
conducted for each measure.  To further increase specificity values, analyses using a 
composite measure of adherence were conducted.  First, three measures were 
combined into a composite measure by averaging the three adherence scores; then two 
measures were combined in the same way.  The cut-off with the highest predictive 
value (correct classification) as well as most „evenly balanced‟ sensitivity and 
specificity values was deemed to indicate the best cut-off   threshold for the creation 
of a dichotomous adherence variable.  
 
3.8.3. Part 3: Factors influencing adherence 
 
Part 3 describes the factors associated with adherence.  The variables are arranged 












Table 3.6:  Definitions of variables used in analyses to identify factors associated with adherence.  
.  
Domain Variable Definition of  variable 
Child 
Characteristics 
Age (months) Child age expressed in months 
Gender (M) Male child 
Recent illness  Illness within one month prior to ARV initiation 
last hospitalization 
(days/ months) 
Hospitalization within one month prior to initiation of ARV. 
Calculated in days and months. 
Other drugs (Y) Prescription drugs for concomitant illness other than ARVs 
WHO stage 3&4 WHO disease staging criteria: stages 3-4 vs. stages 1&2 
IDC attend (Yes) 
Attendance of IDC for HIV management prior to initiation of 
ARVs 
Since (days/months) 
Refers to the duration of time attending IDC prior to initiation of 
ARVs (calculated in days and months) 
Current TB (Yes) TB disease at initiation of ARV treatment 
Health Problem (Yes) Caregiver report of child having a health problem at ARV initiation 
Caregiver 
Characteristics 




Biological mother‟s participation in PMTCT programme during 
pregnancy with index child 
age (20-30 yrs) vs. >31 20-30 age group vs. <20 and 31-50; 51-60; >60 
Education (Std 10) Caregivers who completed high school 
Post school education 
(Yes) 
Caregivers who pursued post school formal education 
 Unemployed (Yes) Not in full-time or part-time employment. 
Planning more children 
Caregivers reporting intentions to conceive more children than 
index child 
Day care (Bio mother) Biological mother is the child minder during the day 
Depression (>9 cut-off) Those with CES-D scores > 9 
Socio-economic 
Characteristics 
Housing (informal)  
Those living in mostly self-made informal dwellings (shacks) vs. 
brick built houses 
Sanitation (inside)  Inside water flush toilets vs. outside pit latrines / bucket toilets  
Water (outside)  
Those who do not have piped running water inside the home but 
use a communal tap outside. 
Housing density Number of adults and children in the home 
Any other infected (Yes) 
Having another person in the household HIV infected other than the 
index child 
Grants (Y) 
Receiving a social welfare grant from the state (e.g. child care, 
pension, disability grants) 
Significant Life events 
(Y) 
Experiencing significant life events defined as death in family, 
illness, hospitalization of any household member, retrenchment, 
employment (after unemployment), divorce/separation, new baby, 
moving house etc.  
Health service 
characteristics 
Access to ARV clinic 
(ward) 
Those who were referred to IDC via the inpatient wards at RXH vs. 
those who were referred by primary care clinics 
Counselled  
 
Those who received initial counselling regarding ARVs by 
counsellor vs. doctor or nurse 
Referred to IDC for 
ARVs  
Those referred specifically for ARVs to IDC (at a stage when they 
need it vs. those referred prior to requiring ARVs – for HIV 












Based on identifying the best predictor of viral load, the measure most highly 
correlated with virological outcomes was chosen as the most appropriate measure of 
adherence for use as the adherence measure in the analysis of associations with 
adherence.  
 
Several variables, indicating disease severity (see Table 3.7), were analyzed for 
association with viral load since these were hypothesized to potentially influence viral 
load outcome (see Appendix 8).  Bivariate analyses were conducted both for 
association with viral load and for tests of co-linearity between variables, using chi-
square tests.  Viral load data was skewed and thus log transformed to the base 10.  
Z-scores for anthropometric measures were calculated using EPI INFO (EPI NUT), 
Centre for Disease Control (CDC) version 2000.  
 
Table 3.7:  Proxy variables indicating disease severity 
Variable Definition 
Height-for-Age Z-score Indicating stunting 
Weight-for-Age Z-score Indicating wasting 
„Health problem‟  Caregiver report of child being ill at initiation of 
ARVs 
„Recent sickness‟ Acute illness within one month prior to 
commencement of ARV treatment 
„Recent hospitalization‟  hospitalization within one month prior to ARV 
initiation 
„Current TB‟  TB disease at ARV initiation 
WHO staging  stages 3 & 4 
„Other drugs‟  Taking other prescription drugs for concomitant 
health conditions at initiation of ARVs 
Baseline viral load measure The viral load measure taken prior to initiation 
of ARVs 
 
Bivariate analyses were conducted as follows: t tests were used to compare the 
adherent (>95% doses taken based on caregiver self-report) and non-adherent 
participants on continuous variables and chi square tests, generating odds ratios and p-
values with 95% confidence intervals, were used for dichotomous variables.  
Four approaches were used to analyze the CES-D scores.  (1) The use of the 
traditional cut-off of 16 to identify women at risk for depression; (2) The use of a cut 
off of 10 based upon findings of Brandt (2007);(3) The use of CES-D scores as 












vs.non-depressed.  (4) The identification of the cut-off for the present study as defined 
by Radloff (1977).  These results are described in chapter 4.   
 
Cumulative scores were calculated as follows: sum CES-D (score Month 1 + Month 
3+ Month 6) divided by 3; where data was missing the scores were divided by the 
number of completed months for which data was available. 
 
For the MOSSSS, the mean of total raw scores for perceived support and total 
satisfaction scores were calculated. In addition, mean scores were determined for each 
of the four sub-domains.  These scores were not dichotomized but were treated as 
continuous in the bivariate and multivariate analyses. 
 
Power calculations were conducted for each variable included in the regression 
analysis to determine whether the study had sufficient power to detect significance at 
the level of Alpha 0.05 if the hypothesized odds ratios were true (Table 6.4 in chapter 
6). 
 
The „repeated measures‟ analysis approach was not used despite measures at baseline 
and treatment months 1, 3 and 6, due to the fact that viral load outcome  was only 
available at one time point, namely, 6 months.  However, paired t-tests were 
conducted on selected variables, where changes over time were hypothesized to 
influence adherence such as the CES-D (depression), food security, MOSSSS, (social 
support) scores and significant life events, to determine whether changes in scores 
between month 1 and month 6 were statistically significant. 
 
Several logistic regression models were fitted using stepwise forward and backward 
analysis in order to test the strength of association of variables, identified in bivariate 
analysis as having an association with the measure of outcome (adherence).  These 
variables were grouped into the four domains (child, caregiver, socio-economic and 
health systems characteristics).  Adherence was dichotomized with 1= >95% (good 
adherence) and 0= <94% (poor adherence).  In this way the „best‟ model was chosen 
on the basis of the most plausible, clinical implication, guided by the odds ratios of 












3.9. Ethical Considerations 
 
Consent and Confidentiality 
Permission to conduct this research was obtained from the Provincial Department of 
Health, Western Cape and the Red Cross Children‟s War Memorial hospital. Written, 
informed consent was obtained from each respondent for participation in the study. 
 
Participation was voluntary and non-participation in the intervention by eligible 
patients did not compromise their access to treatment.  Only one caregiver refused to 
participate.  There were four patients who defaulted from the clinic and thus the study.  
Patients were considered defaulters in the study if they missed an appointment and 
could not be contacted within two months of the missed appointment.  A further two 
patients were very late for their appointments but returned within the 2 month period 
and were therefore not considered to be defaulters. 
 
All patient data were entered into the database using unique enrolment numbers to 
link the data.  Data capture sheets contained patient identifying information in order to 
link the laboratory results to the patient data.  All confidential information relating to 
the study was held in a lock up facility at the site and computerised data were 
managed by the Principal Investigator only.  No patient identifying details will be 
revealed in research reports or scientific publications.  
 
Benefits 
There were no direct benefits to the patients for participation in this study. 
Laboratory results were obtained from routine clinical screening results therefore no 
invasive procedures were required for this study. 
 
No funding was received for this study and there were no financial benefits to 
patients.  Participants were interviewed during their routine clinic appointment.  
Children were given a sweet by the research assistant and allowed to play with the 













Caregivers, who scored high on the depression scale, were asked whether they wanted 
a referral to the hospital social worker.  In all cases the caregivers were willing to 
speak to the counsellor about what they thought was causing their symptoms and only 
one participant required further management by the social work department.  This 
discussion usually took place after the interview, after the screening instrument was 
scored by the researcher.  However, the interviewer was trained to score the 
questionnaire and if it appeared that the score was high, he/she would score 
immediately and discuss with the caregiver directly after the interview. 
 
When poor adherence or incorrect dosing was noted by the researcher, the caregiver 
would firstly be informed and the details solicited.  Thereafter, the information would 
be noted on the patient folder and the patient would be referred for further 
management to members of the health care team. 
 
The Helsinki declaration 
This study was carried out according to the ethical principles set out in the World 
Medical Association‟s Declaration of Helsinki as amended in October 2000 (WMA 
General Assembly, 2000) and in compliance with the National Health Act (Act No. 61 
of 2003).  The researcher has certification in “Protection of Human Participants in 
Biomedical and Behavioural Research”, obtained on the 7 September 2001 at 
Columbia University‟s Health Sciences Division. 
 
Approval for this study was obtained from the Research Ethics Committee of the 
University of Cape Town as well as the Dissertation Committee (ref: 256/2004 dated 













RESULTS PART 1: COHORT DESCRIPTION 
 
4.1. General Overview of Results  
 
The results section is divided into three parts viz. Part 1: Description of the cohort, 
Part 2, Adherence measurement and Part 3: Factors influencing adherence.   
 
Part 1 deals with the first aim of the analysis to describe the cohort. Part 2, deals with 
the determination of which adherence measure best predicts the viral load outcome 
and how each measure agrees with the other.  The four measures of adherence used in 
this study were  pharmacy refill; clinic visits; caregiver self-reported adherence and 
medicine measure/pill counts.  Data were collected at Months 1, 3 and 6 of treatment.  
Part 3 deals with determination of which factors influence the adherence outcome. 
 
Data on pharmacy refill and clinic visits were available for 135 children, with the 
death of 7 children during the follow-up period.  Data on caregiver self-report were 
available for 135 caregivers at interval 1 (month 1) and 97 caregivers at intervals 2 
(month 3) and 3 (month 6).  Medicine measures/pill counts were available for 97 
children for intervals 1 to 3.  CD4 and viral load results at 6 months were available for 
116 of the 135 children (Figure 4.1).  Analysis of adherence measures was based on 
averaged cumulative rates, not repeated measures, because there was only one 
outcome measure, namely, viral load count at 6 months (see chapter 3 for details of 
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4.2. Descriptive Data on Cohort characteristics 
 
Demographic and other details were available for 135 children. A description of the 
cohort is preceded by the presentation of the cohort follow-up results.  Objective 1 is 
addressed at the end of this chapter with the description of adherence for the various 
measures.  
 
4.3. Follow-up Outcomes of children enrolled into the study 
 
One hundred and thirty five children on treatment were enrolled into the study during 
the period 1 October 2004 to 30 June 2006, followed up for 6 months respectively. 
Two of the children were siblings and therefore had the same caregiver. One sibling 
was initiated on treatment a month after the first one.  By the end of the follow-up 
period thirteen children were transferred from RXH to primary care clinics for 
antiretroviral treatment follow-up (viral load results were obtained from five of these 
children and form part of the analyses); seven children had died; four children had 
defaulted treatment and could not be traced.  Defaulters were defined as those 
children not returning for clinic follow-up after missing one clinic appointment and 
not being contactable after one month through telephonic and home visit follow-up by 
clinic staff (which meant they did not return for clinic appointments or medicine 
refills for 2 months).  The remaining one hundred and eleven children were attending 
the IDC clinic for antiretroviral treatment (see Table 4.1) at six months of treatment.  
 
Table 4. 1:  Status of cohort at the end of the follow-up period 
Outcome Frequency % 
Alive on HAART 111 82.22 
Defaulted 4 2.96 
Died 7 5.19 
Transferred Out 13 9.63 













4.4. Socio-economic characteristics  
 
4.4.1. Areas of Residence 
 
More than half of the cohort lived in the suburbs of Khayelitsha and Phillippi (67%). 
The largest proportion (36%) lived in Khayelitsha.  This is a peri- urban area 
approximately 35kms away from RXH, covering an area of approximately 15km
2
 and 
home to approximately ½ million people.  The many people living in Khayelitsha 
originate from the Eastern Cape Province and often travel between the Western Cape 
and Eastern Cape, throughout the year but particularly during the Christmas 
holidays.
37
  Phillippi, Nyanga and Gugulethu were the main areas where the rest of 
the cohort lived (see Figure 4.2).  These areas are of similar demographic profile as 
Khayelitsha with high rates of unemployment and informal dwellings.  
 
Figure 4.2:  Distribution of participants according to Residential Areas (N=135) 
 „Other‟ = Belthorn (1) Bloekombos (1) Delfdt (1) Driftsands (1)Du Noon(4) Langa (3)     
Muizenberg(1) Westlake (1) Woodstock (2) Rondebosch(1) Grassy Park(1) 
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 This information is relevant to service delivery. Often patients who have access to fridges in town 
need to have their medication changed when they go to the E.Cape for extended periods, especially 
























4.4.2. Housing and Sanitation 
 
Approximately 55% (74/135) of families lived in informal dwellings (self-made wood 
and iron structures) and approximately 53% having no piped water inside the 
dwelling. Only 33% (45) of families had an inside flush toilet despite 45% reporting 
that they lived in formal dwellings (brick dwellings).  The remaining number of 
respondents reported using outside pail toilets.   
 
4.4.3. Household Density  
 
Housing density ranged from 1-18 adults per dwelling and 1-10 children per dwelling.  
However, the mean housing density for adults was 3 and for children, 2. Thus, 
household density was a median of 4 (IQR 3-6) and a mean of 5 (sd: 2.59). 
 
4.4.4. HIV infection in the household 
 
In response to the question “Are any other household members HIV infected”, sixty 
nine (51.11%) affirmed that other household members, other than the index child 
were infected with HIV.  Sixty two (45.93%) said “No” while only four (2.96%) 
reported that they did not know the status of other household members.  
 
4.4.5. Disclosure of HIV status and Experience of Stigma 
 
Caregiver reported that none of the children in this cohort had been told that they were 
infected with HIV.  Disclosure to the child was not applicable to the majority of 
children (67.4%) in this cohort who were younger than three years of age (mean age 
27.08 months). 
 
For those older than three years, caregivers reported that they had difficulty in 
initiating the process of disclosure with their children and chose to focus on the 












Children between the ages of three and seven years in the cohort were given some of 
the following reasons for taking ARVs:   
“I tell him he has chest problems”[ caregiver of a 5 year old];  
“I tell him he is sick”[caregiver of a 4 year old]  
“I told her she has pneumonia”[caregiver of a 6 year old];  
“I tell him that he has TB”[caregiver of a 6 year old];  
“I told her it is for her ear problems”[caregiver of a 5 year old]. 
 
Several caregivers expressed the opinion that the child was too young (despite the fact 
that there were children >5yrs in this cohort) and didn‟t know anything about HIV and 
some reported that their children had not started asking any questions about it yet.   
Caregivers were more likely to disclose the child‟s HIV status to other family 
members (60.74%) than friends and neighbours (8%).  However, twenty nine 
(21.48%) respondents reported that only they and their partners (the biological parents 
of the child) were aware of the child‟s status while thirteen (9.63%) had not told 
anyone else, not even the biological father of the child.  
 
Only 8% reported that they had chosen to tell friends/neighbours including a foster 
parent who had told her pastor and all her family members about the child‟s HIV 
status.  Of those who had disclosed, only ten respondents (7.41%) reported that they 
experienced adverse reactions after disclosure.   
 
Some of the adverse reactions included the following stories:  
“…my cousin didn't want her child to play with mine. I left and went to live alone” 
(biological mother of a 21 month old child);  
 
“…the biological  mom abandoned child and father when she discovered their 
status,  we have never heard from her again” (stepmother of a 6 month old baby);   
 
“…after the death of my mother, the family would not take care of us anymore 
because we here HIV positive, we had to leave the house” (the mother of a 19 month 
old baby);  
 
“…when I told him [partner], he ran away from us at the time I felt like dying but 













4.4.6. Household Food security 
 
In response to the question, “In your opinion, has there been sufficient food to satisfy 
the child‟s appetite?” more than 80% reported that they thought there was sufficient 
food in the household over the follow-up period.  Table 4.3 illustrates that the 
response of those who answered at each interval suggested an increase in report food 
sufficiency over time.  However, the results of paired t-tests showed no statistical 
differences between the mean affirmative responses at the three points in time (Table 
4.2).  However, the frequency of responses regarding insufficient food supply 
decreased over the 6 month period from 12 in month 1, to 5 in month 6 (Table 4.3).  
 
Table 4.2:  Paired t test results:  Food security over time 




CI t Pr(T <t) 
Month 1 and Month 3 84 0.12 0.05 -.086     ;0.11 0.24 0.60 
Month 3 and Month 6 69 0.58 0.05 -0.15   ; 0.03 -1.27 0.10 
Month 1 and Month 6 75 -0.05 0.04 -0.14    ;0.03 -1.27 0.10 
 
4.4.7. Significant Life Events 
 
Significant life events were defined as events affecting the family such as funerals, 
hospitalizations, illness of primary caregiver, illness of a sibling of the index child, 
illness of other family members whom the caregiver had to look after and 
retrenchments.  “Other” responses specified by the respondents included; having a 
baby, moving house, separating from spouse/boyfriend and finding employment. 
Between 24% and 30% of respondents reported experiencing a significant life event 














Table 4.3:  Summary Food security and significant life events over time 
 Month 1 Month 3 Month 6 
Food security    
Observations 93 87 77 
Yes (enough) 81 (87%) 77 (88%) 72(94%) 
No (not enough) 12 (13%) 11 (12%) 5 (6%) 
    
Significant Life Events    
Observations 94 88 78 
Yes 23(24.5%) 24(27%) 23(30%) 
No 71(75.5%) 64(73%) 55(70%) 
 
4.5. Caregiver Characteristics  
 
4.5.1. Caregiver Relationship to the child 
 
One hundred and thirty four caregivers represented 135 children (two children were 
siblings).  Approximately eighty six percent of primary caregivers were biological 
mothers (N=115) the remainder being grandmothers (7.5%), aunts (4.5%) and foster 
parents (2.2%). Of the children not having a biological mother as primary caregiver, 
two (10.5%) were abandoned and 12 (63%) were orphaned.   
 
Four percent (N=6) of children had biological mothers living elsewhere (not involved 
as primary caregivers).  It should be noted that children living in residential care 





Caregivers were asked to categorize themselves into one of the following age 
categories:  Under 20; 20-30; 31-40; 41-50; 51-60 and >60 (Table 4.4).  Data were 




















Under 20 2 1.5 
20-30 82 61.2 
31-40 39 29.1 
41-50 5 3.7 
51-60 2 1.5 




The majority of caregivers reported that they went to high school.  One hundred 
(74.07%) caregivers reported completing senior high (standards 8-10/ Grades 10-12).  
Of these, forty (30%) reported passing the highest standard (standards 10/ Grade 12).  
Twelve (9%) reported no high school attendance while three (2%) reported absolutely 
no schooling.   
 
4.5.4. Marital Status 
 
Approximately 42% of caregivers were married/ living with a partner while 53% 
reported never being marri d.  The remaining number of caregivers reported that they 
were divorced (2%), separated (1.5%) or widowed (1.5%). 
 
4.5.5. Caregiver Employment status and Sources of Income 
 
The majority (75.6%) of caregivers reported that they were unemployed, while only 
13% reported having formal employment.  The rest of the sample reported casual 
employment (8%) and running a home-based small business/spaza shop (3%).  
 
Approximately 41% (N=54) of caregivers reported that their spouses/partners 
provided financial support to them and their child while 34% (N=45) reported to be 
the sole providers.  The remaining caregivers were supported by parents and other 












Sixty percent of caregivers reported receiving some form of social security grant.  The 
largest proportion of social security grants (86%) were childcare dependency grants.  
The rest were derived from old age pension grants (5%), disability grants (6%) and 
foster care grants (3%). 
 
4.5.6. Caregiver Health Status 
 
Regarding the caregiver‟s knowledge of their own HIV status, 81 % (N=109) reported 
that they knew their status and of these, 90% (N=98) were HIV-infected.  
Approximately 8% (N=10) caregivers were on antiretroviral treatment (for 
themselves).  A further 8% (N=11) reported that they suffered with chronic health 
problems other than HIV infection.  These included conditions such as arthritis, 
hypertension and asthma.  One caregiver reported being on tuberculosis (TB) 
treatment for the second time.  Twenty percent (N=27) reported that they had previous 
TB. 
 
4.5.7. Caregiver Mental Health and Social Support 
 
4.5.7.1. Depression  
 
In order to identify symptoms of depression among caregivers we used the Centre for 
Epidemiologic Studies for Depression (CES_D) depression screening tool.  Analysis 
of the cumulative CES-D scores for intervals 1, 2 and 3 for this cohort, resulted in a 
mean score of 5.2 with a range between 0 and 52 at interval 1.  CES-D scores declined 
over time with a mean of 4.45 at interval 2 and 3.5 at interval 3 with a corresponding 
decline in the maximum range from 52 at interval 1 to 33 at interval 3 (Table 4.5), 
indicating that depressive symptoms amongst caregivers declined as children‟s 
duration on ARV treatment increased between 1 and 6 months.  However, analysis 
using a matched pair t-test (Table 4.7) resulted in no statistically significant difference 
between the mean scores at months 1 and 6 (mean difference= 1.18; p=0.12). 
Similarly, the difference in means of CES-D scores between months 1 and 6 was 1.75 
but this was not statistically significant either (p=0.09).  The finding regarding lack of 












observation attrition from month1 to month 6.  On closer examination, the 16 missing 
observations at month 6 included observations with the highest CES-D scores at 
month 1(e.g. max. 52 at month 1, missing at month 3) which accounted for the higher 
mean at month 1. 
 
Table 4.5:  Mean CES-D scores at Treatment months 1, 3 and 6 
Variable N Mean Median Std. Dev. Min Max 
CES-D Month 1 92 5.24 1.5 9.06 0 52 
CES-D Month 3 85 4.46 1 7.77 0 38 
CESD Month 6 76 3.50 1 6.10 0 33 
 
To determine whether there was any significant difference in CES-D scores from 
month 1 to month 6, for the cohort who remained till 6 month follow-up, the mean 
scores for each interval were calculated.  The results are in Table 4.6. 
 
Table 4.6:  Mean CES-D scores at Treatment months 1, 3 and 6  
for caregivers remaining till 6 month follow-up 
Variable N Mean Median Std. Dev. Min Max 
CES-D Month 1 72 4.11 1 7.09 1 44 
CES-D Month 3 67 4.40 1 7.21 1 30 
CES-D Month 6 72 3.50 1 6.10 1 33 
 
The mean CES-D score at month 1 for those with missing values at month 6 (N=20), 
was 9.3 with a median score of 3 (SD= 13.51) in comparison to those (N=76) for 
whom data was not missing (mean =4.1 and median=1(SD= 7.09). 
There was 20% attrition between months 3 and 6 from those with scores at both 
intervals (Table 4.5).  The mean CES-D score at month 3 for those (N=18) who had 
missing data at month 6, was 4.6 (SE: 2.32; CI -.22; 9.5) compared to those who did 
not have missing data (N=76) and had a mean of 4.40 (SE: 0.88; CI: 2.6; 6.1).  
 
Evidence from paired t-tests indicate that there was a slight difference in mean scores 
between months 1 and 6 for those who had data at both intervals, however this 












Table 4.7:  Comparison of Mean CES-D scores: Results of Matched paired t-tests 
Variable Observations Mean Std Err 95% Confidence Interval 
CES-D month1 72 4.11 0.83 2.45; 5.77 
CES-D month 6 72 2.93 0.59 1.74; 4.11 
Difference in means 72 1.18 1.01 -0.84; 3.20 
Degrees of freedom= 71 ;      t = 1.16;   Pr(T > t) = 0.12 
 
CES-D Score thresholds indicating depressive symptoms 
As indicated in chapter 2, cut-off scores indicate severity of symptoms.  In this study 
four approaches were used.   
 
Scores >15, indicating caregivers with depressive symptoms, were found among 
9.78% (9/92) caregivers at month 1; 9.41% (8/85) at month 3 and 3.95% (3/76) at 
month 6. There was no statistically significant difference between groups at month 1 
and 6 (p=0.09).  Biological parent status was not significantly associated with 
depressive symptoms (using the >15 cut-off) at month 1 (Fisher‟s exact = 0.62; one-
sided Fisher‟s exact =0.41).   
 
Using a higher threshold with a score of >23 resulted in a prevalence of 4.35% (4/92), 
5.88% (5/85) and 2.63% (2/76) respectively.  There was no statistically significant 
difference between groups at intervals 1 and 3 (p= 0.28).  
Using the approach based on (Radloff 1977)‟s definition as outlined in Chapter 3,
38
 
the cut-off score for depressive symptoms in this cohort was >9, which was similar to 
Brandt‟s Cape Town study.  Indicating that amongst these cohorts, scores >9 
indicated depressive symptoms requiring referral or attention. In this study, the cut-off 
was identified using the cumulative CES-D scores, as opposed to (Brandt 2007)‟s 
study which was cross-sectional.  Graph 4.1 illustrates the frequency of depressive 
symptoms among caregivers in the sample at different thresholds. 
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No association was found between HIV positive status of the caregiver and depression 
(Pearson χ2
 =
 0.11; p= 0.74). 
 












Frequency of Depressive symptoms 






In the present study a Cronbach‟s Alpha of 0.82 was established, indicating good 
internal consistency. 
 
Social Support   
Using the Medical Outcomes Survey of Social Support tool perceived availability of 
social support among caregivers was determined.  The tool considers four domains of 
social support, namely: tangible support, affectionate support, positive social 
interaction and emotional/ informational support and scores can vary from zero to 
100.  In this study, the cumulative mean scores across the four domains were very 
high (see Table 4.8).  
 
Perceived social support and satisfaction did not relate to the size of the respondents 
network (the number of people specified by the respondent as providing the support), 
but rather to the quality of perceived support from those from whom the support was 












was derived was 2 (S.D 3.35; IQR 2-3) ranging from 0 to 34
39
 close friends or family 
included.  The difference between mean scores at baseline and at 6 months (-3.45; 
N=60) were statistically significant (Pr (T< t) = 0.001), indicating increased 
perception of social support at 6 months.  
 
The mean month 1 score for the 20 respondents with missing data at month 6, was 
92.45 (SE: 3.74) vs. 96.74 (SE: 1.22) when compared with the 60 respondents for 
whom data were available at months 1 and 6.  These results indicate that those who 
were not available for follow-up at 6 months had lower perceived social support at 
month 1 than those who were available for follow-up.  
 
One hundred and ten (81.48%) respondents perceived the members of their household 
as supportive and helpful.  Seventy eight (52.1%) had family living close by who 
were supportive and helpful while seventy three (54.48%) also had friends living 
close by who were supportive and helpful.  Forty-four percent (N=60) of the sample 
attended support groups on a regular basis. 
 






















Mean* 95.89 95.41 96.05 95.36 96.14 
Median (IQR) 99 (93-100) 100(92-100) 100(100- 100) 100(95-100) 100(92.5 – 100) 
Std. Deviation 9.28 10.2 10.10 10.39 8.93 
Minimum 24.5 20 20 22.5 30 
Maximum 100 100 100 100 100 
 * These are cumulative scores 
Table 4.9 below illustrates the depression and perceived social support indicators over 
time.  The data show a steady decline in the mean depression scores over time but no 
statistical significant difference in means between baseline and month 6 were found (t 
= 1.12 ; p=0.26).  In contrast, perceived social support scores increased over time and 
the change from baseline to 6 months was found to be significant (t= -3.45; p=0.001). 
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 This number was verified by the researcher – the respondent stuck by her response that this was the 













Table 4.9:  Depression and Social Support indicators over time 
 Baseline Month 1 Month 3 Month 6 
Depression*          
                 Yes 14 15 10 8 
   No 66 77 75 68 
Observations 80 92 85 76 
Mean (SE) 5.40 (0.87) 5.24 (0.94) 4.46 (0.84) 3.5 (0.70) 
Difference in 
Means baseline & 6 
months? 
t = 1.12 (N=63)      (pr| T> t| =0.26)   
Perceived Social support   
Observations 78 80 85 75 
Mean (SE) 93.73(1.33) 95.41 (1.31) 96.74 (1.13) 98.84 (0.52) 
Difference in means 
baseline and 6 
months? 
t = -3.45  (N=60)    (pr |T>t|)=0.001   
*Depression indicated by > 9 score 
 
4.5.8. Fertility Plans and participation in PMTCT programme 
 
The majority (62.96, N=85) of caregivers reported that they had no plans to have any 
more children in the future while approximately 23% (N=31) said that they would like 
to have more children. 
 
Approximately 36% (N=48) of the biological mothers reported that they participated 
in the PMTCT intervention for the birth of the index child. Two (1.5%) were not sure 
whether they had received any intervention while the majority (49%, N= 66) reported 
that they did not.  Of note is that approximately 16% (N=19) of those planning to 
have more children did not participate in the PMTCT intervention for the index child, 
including those who were not sure whether they had received any intervention. 
However, there was no statistically significant association between PMTCT 
participation and planning to have more children (Pearson Χ
2
 (1df) =0.3941; p =0.53) 
4.5.9. Caregiver perception of reason for ARV treatment initiation 
 
Most caregivers (78.5%) responded that the child was sick and therefore doctors 
recommended that the child start treatment.  However, one (0.74%) caregiver reported 












that they didn‟t think that their child was sick but the doctors said the child should 
start treatment.  Six (4.4%) reported that they had asked the doctors to initiate 
treatment. 
 
4.5.10. Caregiver knowledge and attitude to ARVs  
 
While most of the respondents understood the basic facts about ARV treatment (Table 
4.10) and few reported that their child had experienced side effects during the first 
month of treatment, only 26% were familiar with the names and doses of the child‟s 
ARV regimen by 1 month.  The amount of respondents (96.7%) who believed that the 
benefits of ARVs outweighed the risks did not match those with a belief in a good 
prognosis for their children.  Seventy-two (57.6%) expressed the concern that their 













Table 4.10:  Knowledge and Attitudes towards ARV treatment  
Questionnaire response Number of respondents  N= 125 (%) 
Believe it is good to give child a break from ARV 
treatment 
3 (2.4%) 
Take child to traditional healer regularly 3 (2.4%) 
Always give ARVs exactly the same time each 
day 
123 (98.4%) 
Believe that all three ARVs should always be 
given and none left out. 
124 (99.2%) 
Know all the names and doses of child‟s regimen 32 (25.8%) 
Believe treatment should not be stopped when 
child gets better 
123 (98.4%) 
Believe that ARV treatment can cure HIV 12 (10%) 
Believe that ARV treatment is lifelong 125 (100%) 
Believe the benefits of ARVs far outweigh the 
risks 
120 (96.7%) 
Believe child will get sick/ medicine will stop 
working/ viral load will increase if more than 3 
doses are missed a week. 
124 (99.2%) 
Concerned about the child living long enough to 
complete school 
72 (57.6%) 
Child experienced side-effects  38 (30.65%) 
 
4.5.11. Medication administration 
 
The primary caregivers reported that they were mainly responsible for giving the 
medication and sixty one (45.2%) reported that they had no one else to rely on to give 
the medication.  Nineteen (14%) relied on the child‟s father, twenty-three (17%) 
relied on a grandmother while ten (7.4%) relied on the child‟s sibling to assist with 
medication administration.  The remainder relied on friends (3), a nanny, nurses
40
 (8) 
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and aunts/uncles (9).  In one case, the grandmother considered herself the primary 
caregiver because the biological mother was still at school but the biological mother 
lived in the home and would assist with administration.   
 
Table 4.11 illustrates that grandmothers who were the primary caregivers of the 
children, were more likely to rely on someone else to assist with medication 
administration than biological mothers, foster parents or aunts.  In other words, the 
grandmother brought the child to the clinic, took care of the child during the day and 
lived with the child but would rely on another member of the household, notably, her 
own daughter (sibling of the child‟s biological mother who died) to give the child the 
medication. 
 









Grandmother Mother Other Total 
Aunt 6 0 0 0 0 0 6 
Foster Parent 0 0 3 0 0 0 3 
Grandmother 9 0 0 0 0 1 10 
Mother 0 1 0 1 114 0 115 
Total 15 1 3 1 114 1 135 
 
4.5.12. Reminder Tools 
 
Participants were asked about their medication administration practices during the 
week (mornings and evenings) and at weekends (morning and evening) including 
specifying routines on Saturdays and Sundays. 
 
During weekday mornings most caregivers (54%, N=67/125) reported that they 
relied on cell phone (36%) and clock alarms (18%) to remind them to give 
medication. Other reminder tools included radio (2.4%, 3/125) and TV (3.2%, 4/125). 
Approximately 34% (N=42/125) relied on „routine‟
41
 or other people to remind them 
(7.2%, 9/125). 
 
                                                 
41
 This term „routine‟ was explained as the fact that they just remember to take tablets because it fits 













There are slight changes in the pattern of use of reminder tools during weekday 
evenings compared to weekday mornings.  Fewer (N=125) reported reliance on cell 
phones and clock alarms at night (44% vs. 53%) and more relied on TV programmes 
(17% vs. 3.2%).  Only two reported using the radio, two relied on someone else to 
remind them; and 36% vs. 34% reported reliance on „routine‟.   
 




Sixty-two (45.9%) children had no siblings.  The median number of siblings was 1 
(IQR 0-1) with a range of 0 to 7.  Only 4.4% (N=6/135) of the children had a sibling 
who was also HIV infected. 
 
4.6.2. Care giving Arrangements 
 
Eighty five (62.96%) children were looked after by their mothers during the day. 
Twenty-two (16.2%) attended school (N=10/135) or crèche (12/135) while the 
remainder were cared for by an aunt (5.93%), nanny (2.96%) or a grandparent 
(9.63%).  Only two children (1.48) did not have a consistent day care arrangement and 
one child was in respite care (Temba Care) for several weeks during the follow-up 
period. 
 
Only 5 (3.7%) children slept over at another home during the week or at weekends. 
The majority (92.6%) of caregivers reported that their child never sleeps away from 
home while four (2.96%) children “sometimes” slept away from home. 
 
4.6.3. Age and gender 
 
The mean age of children in this cohort was 27.1 months, ranging from 3.2 to 86.0 
months.  The median age was 17.7 months (IQR:  9.3 - 37.6).  Seventy-four (54.8%) 













4.6.4. WHO Staging Criteria 
 
At baseline, the majority (58.5%) were categorized with stage 3 and thirty-eight 
(28.2%) with stage 2 disease according to WHO staging criteria.  Only eighteen 




Baseline growth characteristics 
Baseline weight for the cohort ranged from 2.41kg to 22.6kg with a mean of 9.08kg 
and a standard deviation of 4.39.  Baseline height ranged from 49.4cm to 118.6 with a 
mean height of 75.4cm (sd: 15.79).  On average, children in this cohort were 2 to 3 
standard deviations below the norm on their anthropometric scores, indicating 
relatively poor nutritional status at ARV initiation (Table 4.12). 
 









In Africa ** 
(std.dev) 
Weight –for-age z-scores -2.53 1.47 -6.32 - 1.97 -1.02 (1.42) 
Height –for-age z-scores -2.99 1.67 -9.46 – 1.6 -1.64 (1.74) 
Weight-for-height z-scores -0.81 1.34 -3.65 – 4.48 -0.07 (1.44) 
**source: (World Health Organization 2007) 
 
4.6.6. Immunological and virological Features 
 
Baseline viral load results were available for 130 children (Table 4.13).  The median 
log baseline viral load for the cohort was 5.58 copies per ml with a range of 2.68 to 
6.86.   Viral load results at 6 months were available for 116 children.  The median log 













Baseline CD4 data were available for 135 children.  The median baseline CD4 % for 
the cohort was 13%.  The median absolute CD4 count was 502.  Six-month CD4 data 
was available for 117 children, with a median CD4percentage of 23% and median 
absolute value of 1100.  These results indicate that there was a good immunological 
response to treatment within the first 6 months. 
 




Median IQR Mean (Std. Dev) 
Baseline Measures 
Baseline CD4 % 135 13.0% (8.0 – 18.0) 14.5 (10.96) 
Baseline CD4 
absolute count 
133 502 (247 -886) 647.4 (561.9764) 
Baseline viral load 130 500000 (130 000-1400000) 994028 (1197560) 
Baseline Log viral 
load 
130 5.69 5.1 - 6.1 5.6 (.76) 
6 month Measures 
CD4 % @ 6 months 117 23.1% (16.4 – 28.9) 22.90 (8.48) 
CD4 absolute @ 6 
months 
117 1100 (673 – 1434) 1146.154 (627.3248) 
Viral load @ 6 
months* 
116 50 (LDL) (50 – 430) 61033.5 (348596.5) 
Log viral load @ 6 
months 
116 1.7 1.7 - 2.6 2.4 (1.2) 
*Maximum viral load @ 6 months = 2 900 000 copies per ml 
Abbreviation: LDL= Lower than detectable levels 
 
 4.6.7. ARV Regimens and concomitant medication at initiation of 
treatment 
 
HAART was provided by giving three separate ARV medications to each child.  In 
the case of children on TB treatment, a fourth ARV was added to the regimen for the 
duration of TB treatment
42
 for some children in the study only. 
 
All children in this study were on first line regimens since they were all initiated on 
treatment at entry into the study.  The regimens typically consisted of two Nucleoside 
Reverse Transcriptase Inhibitors (NRTI‟s) and one Non-nucleoside Reverse 
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 This practice was introduced during the study period.  Not all children on TB treatment in this study 












Transcriptase Inhibitor (NNRTI) or a Protease Inhibitor (PI).  The drug regimens
43
 are 
denoted as ARV 1, ARV 2, ARV 3 and ARV 4 in the results and are described in 
Table 4.14.  Thirty-nine (28.89%) children were on TB treatment at initiation of 
therapy.  One hundred and thirty one children (97.4%) were taking cotrimoxazole at 
initiation of ARV treatment.  Only five of the thirty-nine (12.82%) children who were 
on TB treatment
44




Table 4.14:  Frequency table for ARV Regimens utilized amongst the cohort 
Drug Name 
(abbreviation) 
Type Dosing Frequency Frequency (%) 
ARV 1    
Zidovudine (AZT) NRTI Twice daily 46 (34.07) 
Stavudine (D4T) NRTI Twice daily 89 (65.93) 
ARV 2    
Lamivudine (3TC) NRTI Twice daily 134 (99.26%) 
Didanosine (DdI) NRTI Twice daily 1 (0.74%) 
ARV 3    
Efavirenz (EFV) NNRTI Once daily 44 (32.59%) 
Kaletra
46
 (KLT) PI Twice daily 47 (34.81%) 
Nevirapine (NVP) NNRTI Twice daily 19 (14.07%) 
Ritonivir (RTV) PI Twice daily 25 (18.52%) 
ARV  4
47
    
Kaletra PI Twice daily 3 (2.22%) 
Ritonivir PI Twice daily 2 (1.48%) 
 
In addition to the twice daily dosing with ARVs, seventy-one children (54.6%) were 
taking additional medications including antibiotics, medication for asthma and 
epilepsy and a range of infections but excluding TB. 
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 These regimens were implemented during the period of the study which was 2004 to 2006. This was 
a period during which provincial policies regarding guidelines for treatment and drug procurement 
were being developed along with the implementation of the National ARV roll-out programme. It 
should be noted that a policy on first and second line paediatric ARV treatment was adapted in 2007 
being “age” and “history of exposure to perinatal NVP”, dependent.   
44
 This information was obtained from the patient folder. 
45
 The management guidelines for children on HAART receiving TB treatment was implemented to 
boost the ritonivir since TB medication is known to cause an interaction with Ritonivir (Rifampicin 
induces cytochrome p450 activity thereby reducing levels of Ritonivir in the body). 
46
 Kaletra consists of Lopinivir and Ritonivir (Ritonivir is not active merely to boost the Lopinivir 
levels).  
47
 ARV4 was only given to children on concurrent TB treatment and is no different to ARV 3 – it is 












4.6.7.1. Palatability of ARVs 
 
Most caregivers (93.5%) reported that ARV1 (AZT, D4T) was taken easily.  Nearly 
all (98.4%) reported that 3TC was taken easily (only one child was on Didanosine). 
Children found the NRTI‟s (AZT, D4T, 3TC, ddI) more palatable than either the 
NNRTIs (EFV, NVP) or the PIs (Ritonivir, Kaletra) with the PIs being the least 
palatable (Table 4.15). 
 
Table 4.15:  Frequency of ARV type and Palatability 
Drug Name (abbreviation) Class of Drug Frequency (%) Taken easily? (Yes) 
ARV 1   93.5% (N=116/124) 
Zidovudine (AZT) NRTI 46 (34.07)  
Stavudine (D4T) NRTI 89 (65.93)  
ARV 2   98.4% (N=122/124) 
Lamivudine (3TC) NRTI 134 (99.26%)  
Didanosine (DdI) NRTI 1 (0.74%)  
ARV 3   59% (N=73/124) 
Efavirenz (EFV) NNRTI 44 (32.59%)  
Kaletra (KLT) PI 47 (34.81%)  
Nevirapine (NVP) NNRTI 19 (14.07%)  
Ritonivir (RTV) PI 25 (18.52%)  
 
4.6.7.2. ARV Drug Formulations 
 
The ARV formulations for this cohort consisted primarily of syrups except for 
Efavirenz which is only available in capsule form but was opened by the caregiver 
and administered as a solution for children too young to swallow capsules (which 
were the majority in this cohort), (Table 4.16). 
 
Table 4.16:  Frequency distribution of ARV formulation 
Drug Name (abbreviation) Formulation 
 Syrups Capsules 
ARV 1 (N=125) 99 (79.2%) 26 (20.8%) 
ARV 2 (N=124) 122 (97.6%) 3 (2.4%) 
ARV 3 (N=124) 80   (64.5%) 44  (35.5%) 













4.6.8. Hospitalization over time and recent illness prior to ARV initiation  
 
At baseline, 124 children (95.4%) were reported ever being hospitalized prior to 
treatment but thirty-six, (27.7%) were hospitalized in the month before ARV 
initiation.  Caregivers reported „recent illness‟, defined as illness one month prior to 
ARV initiation, for 40 children (30.8%). 
 
By month 1 of treatment 20% of children were reportedly admitted to hospital since 
starting ARVs with only one child having two admissions during this period (Table 
4.17).  The mean duration of hospital stay was 7 days with a range of 1 to 18 days.  
By month 6 of treatment, five children (6%) were hospitalized in the period between 
month 3 and 6 with only one child having three admissions during this period.  The 
duration of hospitalization ranged from 2 to 93 days with a mean of 23 days.  Only six 
(6.25%) children had more than one hospital admission during the 6-month follow-up 
period (a maximum of 2 hospitalizations).  The data pr sented in Table 4.17 shows a 
decline in hospitalization as well as duration over the 6-month follow-up period.  
 
No association was found between baseline viral load and hospital admission during 
the 6 month follow-up period by month 1(Pearson Χ
2 
(70) = 68.1; p= 0.54); by month 
3 Pearson Χ
2
 (68) = 72.0; p= 0.35; and by month 6 Pearson Χ
2
 (61) = 68.8; p= 0.23). 
Table 4.17 provides data on hospitalization and duration of hospital stay at each time 
point.  One of the children hospitalized by Month 1 was also hospitalized by Month 6 
and 5 children hospitalized by Month 1 were hospitalized by Month 3 as well.  While 
the frequency of hospitalizations among the cohort declined from month 1 to month 6, 
the few children who were hospitalized by month 6 spent more days in hospital 
indicating that these were the sickest children with one child having 3 hospital 
admissions between month 3 and month 6.  The number of person days in hospital 
declined between month 1 and month 6 indicating that duration of hospital stay 













Table 4.17:  Hospitalization and Side effects over time 
 Month 1 Month 3 Month 6 
Hospitalization in the preceding interval    
Observations 94 88 78 
Yes 19 (20%) 17(19%) 5 (6%) 
No 75(80%) 72 (81%) 73 (94%) 
Mean duration(days) (SE) 10.16 (1.78) 6.94 (1.48) 23.2 (17.56) 
No. of Person (child)  days in hospital 193 59 39 
Range of no. of admissions per patient 1-2 1-2 1-3 
    
Side effects in the preceding interval**    
Observations 94 88 78 
 Yes 65 (70%) 49 (56%) 39 (50%) 
  No 28 (30%) 39 (44%) 39(50%) 
**Reported by caregiver. 
 
4.7. Health Service Factors 
 
4.7.1. Access to treatment 
 
The majority (74.8%) of children initiated on antiretroviral treatment had a history of 
attendance at the IDC and only a quarter of the children gained access to treatment 
through referral from clinics or as in-patients at the hospital. 
 
The original access route to the IDC clinic by this cohort was primary care clinics 
(34.8%), in-patient referral (54.8%) and self-referral (10.4%).  The hospital‟s in-
patient wards form the bulk of the referrals to the IDC clinic. 
 
4.7.2. Counselling for initiation of antiretroviral treatment 
 
More than half (52.6%) of the respondents reported that they were given information 
about ARVs by a lay counsellor.  Fifty one (37.8%) reported that a doctor had 
counselled them while a nurse informed 5%.  Six respondents (4%) could not 












4.8. Adherence Rates 
 
 
Objective 1: To determine the rate of adherence to HAART among the cohort. 
 
 
Table 4.18 presents a summary of the rates at intervals 1, 2 and 3 according to the four 
measures.  More details about agreement between measures of adherence and the best 
predictor of viral load are provided in Part 2 of this thesis. 
 
Table 4.18:  Summary of Adherence rates by measures per interval 
Type of 
Measure 
Month 1 Month 3 Month 6 Cumulative 
Mean 
 N Cohort 
Mean 
% (SE) 
N Cohort Mean 
% (SE) 
N Cohort Mean 
% (SE) 
Sample size; % 
(SE) 
CGSR* 122 96.7 (1.2) 85 95.9 (1.8) 75 97.2 (1.22) N=130; 97% 
(SE: 8.4); 
Pharm* 135 89.8 (1.7) 130 80.2 (2.7) 124 84.7 (2.28) N=135; 85% 
(SE:17.2). 
Clin* 135 93.7 (1.3) 131 85.1 (2.7) 126 87.2 (2.22) N=135; 89% 
(SE: 16.4) 
Med* 95 107.0 (3.3) 77 102.9 (4.9) 70 100.0 (2.78) N=96; 103% 
(SE:2.05) 
Note: Medicine measure/pill count rates are consistently 100% and greater which may be an indication 
of wastage due to the difficulty of administering syrups (spillage and vomiting of the child), rather than 
adherence. 
*Abbreviations: CGSR= Caregiver self-report; Pharm = Pharmacy refill ; Clin = Clinic visits; Med= 
Medicine measure/pill counts 
 
4.8.1. Caregiver self-report  
 
The mean cumulative rate of adherence according to caregiver self-report for the 6 
month period was 97% (SE: 8.4; N=130).  
 
In response to a specific question “Have you ever missed any doses?” results show 
that 88% (SE: 0.02) of caregivers reported that their child had never missed any 
doses.  
Twenty six percent of caregivers reported problems with administration.  Some of the 
common reasons for missing doses or problems with medicine administration were:  












daily routine‟ (1%); „child refused to take medicine‟(2%); “I‟m not always with 
him/her at the right time‟ (5 %); „I was busy with other things (3%) and „I was ill‟ 
(1%). 
 
4.8.2. Pharmacy Refill  
 
The mean cumulative adherence rate for pharmacy refill was 85% (SE: 17.22; 
N=135).  Ninety three percent of children had „on time‟ pharmacy collections. Only 
7% had late pharmacy visits for the period of follow-up.  The mean number of days 
late was 1 day (SE: 6.07) with a range of 0-31 days.
48
  Table 4.18 provides the details 
of mean adherence rates for pharmacy refill for Months 1, 3 and 6. 
 
4.8.3. Clinic Visits 
 
The mean cumulative adherence rate for clinic visits was 89% (SE: 16.38; N=135).  
The proportion of children with „on-time‟ clinic visits for the intervals 1, 2 and 3 were 
90%, 79% and 77% respectively (Table 4.18). 
 
4.8.4. Medicine Measure  
 
The mean cumulative adherence rate for medicine measure was 103% (SE: 2.05;N 
=96).  Syrup formulations were more frequently prescribed for this cohort which 
accounted for „over use‟ due to possible re-administration or spillage.  For example, 
for ARV 1: syrup vs. capsules was 79% vs. 21%, respectively.  See Table 4.18 for 
details of cohort mean adherence rates for medicine measure at months 1, 3 and 6. 
 
This measure was the most difficult measure on which to obtain consistent data due to 
caregivers not consistently returning medicines for measurement or leaving some 
bottles at home.  Table 4.19 below illustrates the adherence rates per ARV for the 
cumulative period.  It should be noted that the „bad tasting‟ medicine such as Kaletra 
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 On-time collections were defined as between 2 days before and up to 2 days after the appointment 
date.  Collections were considered „early‟ if collected more than 2 days before the appointment date as 












and Ritonivir had higher rates of adherence (over 100%).  The highest adherence rate 
was for DDI but only one child was receiving this in his regimen.  These results 
demonstrate the challenge of using medicine measure to calculate adherence in a 
paediatric population using syrup formulations.  Forty one percent of the cohort 
reported that they had difficulty administering the third ARV of their regimen.
49
  
Except for EFV (a capsule), the cohort all received ARV3 in syrup formulation.  
 
Table 4.19:  Mean adherence rates per ARV (based on Medicine measure) 
ARV No. Observations 
Cohort Mean 
% 
Std Error 95% Confidence Interval 
AZT 77 104  5.32 93.62 114.80 
D4T 156 95.05 1.82 91.45 98.66 
3TC 230 105.07 3.42 98.33 111.83 
ddI 3 142.18 20.72 53.02 231.34 
Klt 74 119.08 5.81 107.49 130.68 
Rtv 37 116.63 9.00 98.367 134.90 
EFV 84 96.56 2.71 91.17 101.95 
NVP 43 98.35 3.65 90.99 105.71 
 
Table 4.20. illustrates the frequency of missed doses per ARV by caregiver self-
report.  The mean adherence rates for Ritonivir and Kaletra were in excess of 115 % 
respectively, as measured by medicine measure and interestingly, these were also the 
drugs for which doses were most frequently missed, as measured by caregiver self-
report.  The other drugs with adherence rates in excess of 100% such AZT, 3TC and 
DDI did not follow a similar trend as measured by caregiver self-report.   
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Table 4.20:  Frequency of Missed doses per ARV by Caregiver Self-report 
ARV N Frequency % 
Lamivudine 274 6 2.19 
Stavudine 190 5 2.63 
Efavirenz 100 3 3 
Kaletra 97 9 9.28 
Zidovudine 96 3 3.13 
Nevirapine 47 2 4.26 
Ritonivir 44 8 18.2 
Didanosine 4 0 0.0 
Abacavir 1 0 0 
 
Finally, Figure 4.3: illustrates the comparison of means by the four different 
measures, indicating that medicine measure produces the most „outliers‟ in the data 
and among this study population (children), rates tend to be in excess of 100%. 
 
Figure 4.3:  Mean Medication adherence by four measures 
 
Abbreviations: Pharm= Pharmacy refill; Med=Medicine measure/pill counts; clin= clinic visits; 
sradh= caregiver self-report 
 
In summary, two of the adherence measures (pharmacy refill and clinic visits) 
measure attendance, while the other two (caregiver self-report and medicine 
measure/pill counts, measure doses.  Determining adherence rates using medicine 
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problematic since higher adherence rates tend to indicate administration problems 
rather than adherence per se as is evident when one compares the rates of adherence 
according to medicine measure (Table 4.19) and the frequency of missed doses per 
ARV according to caregiver self-report (Table 4.20).  For the syrup formulations, the 
highest adherence rates did not necessarily mean true adherence as is evident by the 
example of high adherence rates for Kaletra and Ritonivir according to medicine 















RESULTS PART 2: MEASURES OF ADHERENCE 
 
 
Objective 2: To determine agreement between the four measures of adherence. 
Objective 3: To determine agreement of the four measures with virological outcome 





This chapter reports the results of the analysis of the measures of adherence, 
addressing objectives 2 and 3 (see box above).  In this chapter the following research 
questions are answered, namely, (1) how do the four different measures of adherence 
agree with each other?  (2) How do the measures agree with viral load at 6 months?  
In addressing the second question, factors hypothesized to influence viral load were 
analyzed in order to adjust for covariates in determining the correlation of measures 
with 6-month viral load. 
 
The four measures of adherence used in this study were pharmacy refill; clinic visits; 
caregiver self-reported adherence and medicine measure/pill counts. 
 
5.2. How do the four different measures of adherence correlate with 
each other? 
 
Figure 5.1 below illustrates a matrix of scatter plots of the various adherence 
measures plotted against each other.  If they tended to agree, one would expect a 













Figure 5.1:  Correlation Matrix of scatter plots for four measures of adherence 
Note:  Cumulative rates are plotted for each measure for each observation. 
Abbreviations used in Fig 5.1:  pharm= pharmacy refill; med= medicine measure; clin=clinic visits; 
sradh= caregiver self-report. 
 
It is clear from these plots as well as from the matrix below (Figure 5.1 and Table 5.1 
below) that these different measures do not exhibit a high degree of agreement. 
However, these comments must be viewed in light of the fact that there was not much 
variability in these measures.  The clustering of straight lines in the plot indicates the 
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Using Spearman‟s correlation matrix (data was skewed, thus the assumption of 
normality is violated), the measures in agreement were pharmacy refill (pharm) and 
clinic visits (clin) (r=0.35; p=0.000).  One would expect this result since patients 
attend clinic on the day that they collect their ARVs from the pharmacy, especially 
during the first 6 months after initiation of ARVs, thereafter, clinic visits would be 
scheduled more infrequently than pharmacy refill visits.  Clinic visits was 
significantly yet negatively correlated with Medicine measure/pill counts (r= -0.21; 
p=0.04) indicating that those with higher adherence rates by clinic visit had lower 
adherence rates by medicine measure.  There was no association between caregiver 
self-reported adherence and any other measure.  Even for the correlations found, the 
sizes of the correlations are small. 
 
5.3. How do the measures correlate with viral load at 6 months?   
 
Since there is no „gold standard‟ adherence measure, virological outcome was used to 
determine the validity of the four measures as explained in chapter 3.  Justification for 
use of viral load as the reference measure was that this was a treatment naïve 
population followed up from initiation of ARV therapy for 6 months.  No children 
exposed to NVP during PMTCT had NVP in their treatment regimens.  Thus, 
lowering the possibility that virological failure would result from resistance, rather 













5.3.1. Unadjusted Correlations of measures with Viral load 
 
Firstly, unadjusted correlation analyses of measures with 6 month viral load were 
conducted.  The results of these analyses are in Table 5.2 below: 
 
Table 5.2:  Correlations of 6 month viral load with adherence measures 
Variable Log viral load 6 
(Prob > F; p value) 
Logvl 6 1.0000 
Pharmacy refill -0.17 
(0.07; p=0.16) 
Medicine meas. 0.04 
(0.69; p= 0.69) 
Clinic visits -0.15 
(0.19; p= 0.20) 
Caregiver Self-report -0.21 
(0.16; p=0.16) 
 
The measure with the strongest inverse association with 6 month viral load was 
caregiver self-reported adherence (r=-0.21), followed by pharmacy refill measure (r=-
0.17) and clinic visits (r=-0.15).  H wever, regression analyses conducted to 
determine the significance of these unadjusted associations showed that none of the 
measures had significant associations with viral load at 6 months (Table 5.2). 
 
5.3.2. Correlations of measures with 6 month viral load (Adjusted for 
baseline viral load) 
 
There was an inverse association between baseline viral load and pharmacy refill  
(r=-0.17) and a positive association with medicine measure (r=0.12).  However, these 
associations were weak.  Baseline viral load was therefore used as the covariate in 
subsequent analyses. 
 
Analyses, adjusted for baseline viral load, were conducted to determine correlation of 
measures with 6-month viral load (see Table 5.3).  To test association with log viral 












with logged viral load at baseline plus each of the adherence measures were fitted. 
Logged baseline viral load was significant in all these models (p<0.001).  
 
Table 5.3:  Spearman‟s Correlation of measures with 6 month viral load 
Variable 
Log vload (6) 
(Prob > F; pvalue) 
Log viral load (6 months) 1.000 
Log baseline viral load 0.35 
P < 0.001 
Pharmacy refill -0.17 
(0.000; p=0.18) 
Medicine measure 0.04 
(0.005; p=0.76) 
Clinic visits -0.15 
(0.000; p=0.23) 
Caregiver Self-report -0.21 
(0.000; p=0.12) 
  *adjusted for baseline viral load 
For the adherence measures, there was no difference in values between adjusted (for 
baseline viral load) and unadjusted models in respect of correlation with 6 month viral 
load.  None of these associations were statistically significant. 
 
5.4. Exploring associations between VL outcome and potential 
confounders 
 
Because disease severity may confound a relationship between adherence and viral 
load outcome, the variables indicating disease severity, hypothesized to influence 
viral load (Table 5.4) were tested for association before a more extensive model was 













Table 5.4:  Potential confounding variables for Viral Load outcome 
Variable Hypothesis Statement 
Recent sickness Illness may result in higher viral loads 
due to immune suppression. 
Health problem  As above 
Current TB disease As above 
WHO staging Those in stages 3 and 4 may have severe 
immune suppression and therefore higher 
viral loads. 
Recent Hospitalization As for “sickness”, “health problems”; 
“TB” and “WHO Staging” above 
“other drugs” These drugs may include drugs for 
chronic conditions which may influence 
immune strength and thus viral load. 
Baseline viral load A higher viral load at baseline may 
influence the viral load outcome at 6 
months i.e. if it is very high; the decline 
at 6 months may be dramatically reduced 
but not undetectable. 
Baseline height-for-weight z-score  Lower z-scores may indicate severe 
immune suppression thus higher viral 
loads 
Baseline weight-for-age z-score (WAZ) As above 
Baseline height-for-age z-score  (HAZ)  As above 
 
A series of chi-square tests were used to explore the relationships between the 
categorical potential confounders (Table 5.5).  The objective was to identify which 
confounders to include in a multivariate analysis taking account of co-linearity of 
confounders.  As expected, there was a strong association found between recent 
sickness and recent hospitalization (p<0.000), between recent sickness and other 
drugs (p=0.03), and between recent sickness and WHO staging of HIV disease 
(p=0.03).   
 
A strong association was found between recent hospitalization and health problems 
(p=0.001), between recent hospitalization and other drugs (p<0.001), and between 
recent hospitalization and WHO stage (p=0.004).  Lastly, significant associations 
were also detected between current TB and other drugs (p<0.000) and WAZ and 













Table 5.5:  χ
2






Recent Sickness Health Problem 3.27  0.07 
Recent Sickness TB 0.27  0.63 
Recent Sickness WHO stage 8.96 0.03 ** 
Recent Sickness Recent hospitalization 40.60 0.000 ** 
Recent Sickness Other drugs 5.07 0.03 ** 
Health Problem TB  1.52 0.22 
Health Problem WHO stage 3.52 0.06 
Health Problem Recent hospitalization 11.78 0.001 ** 
Health Problem Other drugs 0.91 0.34 
TB  WHO stage 0.82 0.36 
TB Recent hospitalization 1.08 0.30 
TB Other drugs 31.57 0.000 ** 
WHO stage Recent Hospitalization 9.47 0.002 ** 
WHO stage Other drugs 0.35 0.55 
Recent hospitalization Other drugs 8.25 0.004 ** 
Weight-for-age z-score(WAZ) Health Problem 5.73 0.02** 
Height-for-age z-score(HAZ) Health Problem 2.11 0.15 
Weight-for-height z-score(WHZ) Health Problem 2.17 0.14 
All with 1 degree of freedom except for those tests involving WHO stage* that had 2 df‟ 
(*dichotomized into 1&2 | 3&4) 
** indicating statistically significant association 
 
The relationship between each of the potential confounder variables were tested for 
association with baseline viral load using box plots and Kruskal Wallis tests and none 
were found to be significantly associated (Appendix 14).  These results allowed the 
use of baseline viral load as a control without concern about co-linearity.  However, 
since several of the severities of illness variables were associated with each other, 
caution was exercised in subsequent modelling.  „Recent sickness‟ was not used in the 
same model as „recent hospitalization‟, „other drugs‟, „current TB‟ or „WHO staging‟.  
„Other drugs‟ was not used in a model with „recent hospitalization‟, nor was „recent 
hospitalization‟ used in the same model as „WHO staging‟.  „Health problem‟ was not 













5.4.1. Association between potential confounders and 6 month viral load 
 
The relationship between categorical potential confounder variables and viral load at 6 
months were examined using box plots (Appendix 14) and Kruskal Wallis tests. 
Kruskal Wallis tests found evidence of a difference in median logged viral load by 
„health problems‟ (p=0.003; χ
2
 = 8.49 with 1 degree of freedom).  Thus, children 
whose caregivers reported that they were experiencing a health problem at initiation 
of ARVs, differed in their log median viral load at 6 months from those who did not.   
 
Baseline height-for-age (HAZ), weight-for-age (WAZ) z-scores and reporting a health 
problem at ARV initiation, were significantly associated with viral load outcome 
(p=0.02, 0.02, 0.03, respectively).  Those reporting a health problem were 0.39 as 
likely as those who did not, of achieving virological suppression, thereby confirming 
the results of the Kruskal Wallis tests reported in the paragraph above (Table 5.6). 
 
Table 5.6:  Disease Severity Variables – Association with viral load suppression 
Disease Severity Variable Odds Ratio SE Z P > |Z| 95% CI 
WHZ 1.29    .21      1.55    0.12      0.94   ;1.77 
HAZ 1.34   .17      2.33    0.02      1.05   ;1.72 
WAZ 1.43    .21     2.42    0.02      1.07   ;1.90 
Health problem 0.39    .17     -2.18    0.03      0.17   ;0.91 
Recent sick 0.88   .39     -0.29    0.77      0.37   ;2.09 
Recent hospitalization 0.87   .39    -0.32    0.75     0.36   ;2.11 
Current TB 1.01    .47      0.02    0.98      0.41   ;2.50 
WHO staging (3&4) 0.94   .43    -0.14    0.89      0.38   ;2.31 
 
5.5. Correlation of measures with viral load adjusted for disease severity 
 
In order to test the strength of association between adherence measures and 6 month 
log viral load, proxies for severity of illness found to be significantly associated with 
viral load were added to the model, starting with „health problems‟.  Regression 
analysis resulted in significant association between viral load at 6 months and HAZ 













Each adherence measure was fitted in a model that included log baseline viral load 
and „health problems‟ as predictors of viral load outcome.  A significant association 
between caregiver self-report and 6 month viral load outcome was established in this 
model (p=0.03), illustrated in Table 5.7.  Thus, results indicate that a high adherence 
score using caregiver self-report is likely to result in a low viral load.  This was the 
only significant association between adherence measure and viral load at 6 months 
adjusted for disease severity (indicated by „health problem‟).  Including more than 
two control variables did not improve the models and thus the adjusted model in 
Table 5.7 was chosen to best illustrate the association between log viral load and the 
adherence measures.  
 
Table 5.7:  Association of measures with viral load suppression (adjusted model 1) 












Caregiver self-report -2.37 1.05 -2.26 0.03 -4.46 -0.29 
Pharmacy refill -1.00 0.65 -1.54 0.13 -2.28 0.29 
Clinic visits -0.81 0.62 -1.31 0.19 -2.04 0.42 
Medicine measure   0.01 0.57 0.01 0.99 -1.13 1.14 
*This model includes log baseline viral load and „health problems‟ as control variables. 
 
To further illustrate the ability of each measure to predict virological outcome, the 
proportion of adherent patients with virological suppression was calculated for each 
measure, using a >95% cut off to indicate good adherence (Table 5.8) 
 
Table 5.8:  Proportion adherent among those with undetectable Viral Load 
Measure N 
Frequency with 
undetectable viral load 
<400 copies per ml 
Proportion adherent* among 
those with undetectable 6 m viral 
load 
Caregiver self-report 113 70 (61.95%) 65/70 (92.85% ) 
Pharmacy refill 116 73 (62.93%) 44/73 (60.27%) 
Clinic visits 116 73 (62.93%) 54/73 (73.97%) 
Medicine measure 87 55 (63.21%) 43/55 (87.27%) 
* using >95% cut-off for each adherence measure 
 
The majority (93%) of those with undetectable viral loads had >95% adherence 
according to caregiver self-reported adherence measure.  However, pharmacy refill 
measures and clinic visits measures did not yield this high percentage of adherent 












87% of those with undetectable viral loads at >95% adherence.  However, half of the 
medicine measures were over 100% adherence with a mean adherence rate of 115% 
for those with more than 100% adherence according to medicine measure.  This 
implies that medicine measure would have low sensitivity (section 5.6). 
 
There was a lack of variance in the data amongst the four adherence measures.  On 
closer examination of the data, residuals were approximately normal and there did not 
appear to be non-constant variance.  Examining the large residuals showed that these 
were mostly cases for which the model underestimated the viral load i.e. the model 
did not have sufficient information to explain why those people had such high viral 
load outcomes.  The discernable line in the plot of fitted values vs. residuals 
corresponds to a group of patients who all had a value for 6 month viral load of 50 
(number used in data for undetectable viral load).  The model consistently over 
predicts 6-month viral load values for this group.  Note that most of these patients also 
had a value of one (100%) for their caregiver self reports and there was little 
variability to differentiate between cases in a meaningful way.  Thus, the 
interpretation of this data is that those with undetectable viral loads (<50 copies per 
ml, in this instance), were those who also had 100% adherence according to caregiver 
self-report. 
 
In conclusion, using logistic regression modelling, the best agreement was between 
caregiver self-report and viral load at 6 months when adjusted for baseline viral load 
and disease severity. 
 
5.6. Sensitivity & Specificity of Adherence Measures  
 
Sensitivity and specificity analyses further tested the ability of the adherence 
measures to identify the „true‟ adherent and non-adherent patients given various 
thresholds in reference to viral load.  Receiver Operator Curves (ROC) were used to 
illustrate of the „best‟ measure‟.  In this instance, viral load at 6 months was 
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*Analysis using undetectable (< 400 copies per ml) 6 month viral load as reference. 
 
Figure 5.2 illustrates that caregiver self-report (sradh) is a slightly better method for 
identifying the adherent patients wi h the most values to the top left of the curve (area 
under the curve = 0.68 vs. pharmacy refill (0.65) and medicine measure (0.43).  
Medicine measure differed significantly from the other measures (χ
2
= 6.66 with 1 
degree of freedom; p= 0.01).  There was only a 0.01 difference in values of the area 
under the curve, between caregiver self-report and clinic visits (0.68 vs. 0.69) 
however; the shape of the curve indicates better sensitivity for caregiver self-report 













Table 5.9:  Sensitivity and Specificity of adherence measures at 95% threshold 


















0.55   ;0.77 
 Specificity 53.33 
Medicine Measure 
Sensitivity 24.62 
32.18 0.43 0.27   ;0.58 
Specificity 54.55 
 
The generally accepted threshold for adherence to HAART is 95%.  Table 5.9 
illustrates the sensitivity and specificity of each adherence measure at the 95% 
threshold.  Caregiver self-report has the highest sensitivity and highest predictive 
value (77%), to detect adherence but has the lowest specificity (to detect the true non-
adherence) compared with pharmacy refill, clinic visits and medicine measure.  Clinic 
visits had the second highest sensitivity value with the second highest predictive value 
to detect adherence and higher specificity than caregiver self-report did.   
 
5.7. A composite measure of adherence? 
 
A composite measure of adherence was modelled by combining caregiver self-report 
and clinic visit due to these two measures having the best predictive ability amongst 
the four measures (Figure 5.3).  This composite measure resulted in a larger value for 
the area under the curve (0.71) than either caregiver self-report (0.63) or clinic visits 
(0.66).  This composite measure was significantly associated (p <0.000) with viral 
load (OR=5.22 CI: 2.12; 12.8)  
However, this composite measure did not increase sensitivity, specificity or the 
predictive value more than any of the individual measures, though it increased 
specificity substantially more than caregiver self-report on its own; but the sensitivity, 
specificity and predictive values were similar to those for pharmacy refill, namely, 
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Using logistic regression modelling, the odds of virological suppression given 
adherence was analyzed for each measure including three different disease severity 
variables in the three models in combination with baseline viral load (Table 5.10).  
Adherence, as measured by caregiver self-report and clinic visits were more likely to 
predict virological suppression.  These findings were significant for models 1, 2 and 3 
(for caregiver self-report p= 0.002, 0.003 and 0.001, respectively) and for clinic visits 












Table 5. 10:  Odds of virological suppression given adherence (>95%) for four measures  
Model 1 (baseline viral load, health problem and HAZ) 
 Odds Ratio SE z P>|z| 95% CI 
Caregiver self 
report 
6.03    3.45      3.14    0.002      1.97 ;18.48 
Pharmacy refill 1.83   
 
0.85      1.30    0.19      0.74  ;4.56 
Clinic visits 3.22    
 
1.48      2.54    0.01      1.30  ;7.94 
Medicine 
Measures 
1.55 0.83      0.83    0.41      .55  ;4.41 
      
Model 2 (baseline viral load, health problem and WAZ) 
 Odds Ratio SE z P>|z| 95% CI 
Caregiver self 
report 
5.67 3.27      3.01    0.003      1.83 ;17.57 
Pharmacy refill 1.93      0.89   1.41    0.16      .78  ;4.78 
Clinic visits 3.18  
 
1.46      2.52    0.01      1.29 ;7.82 
Medicine 
Measures 
1.60      
 
0.86 0.87    0.38      0.56  ;4.59 
      
Model 3 (baseline viral load and health problem) 
 Odds Ratio SE z P>|z| 95% CI 
Caregiver self 
report 
6.52 3.81      3.20   0.001      2.10 ;20.53 
Pharmacy 
refill 
2.44    1.16      1.88    0.06      0.96  ;6.19 
Clinic visits 3.04   
 
1.38      2.44    0.02      1.25  ;7.40 
Medicine 
Measures 
1.28   0.67      0.47    0.64      0.46  ;3.55 
 
In conclusion, caregivers self-report is associated with virological suppression when 
controlling for disease severity and baseline viral load.  However, adherence (>95%) 
measured by caregiver self-report and clinic visits, provide the most significant odds 
of virological suppression.  Implementing these measures in a routine clinic setting is 
feasible.  Since caregiver self-report is significantly associated with viral load 
outcome at six months it was used as the adherence measure in subsequent analyses to 


















Exploratory analysis was conducted to determine the effect of several variables on 
adherence. 
 
Caregiver self report was used as the measure of adherence in the analysis of factors 
influencing adherence since this method of adherence measurement was more closely 
associated with virological success than any other measures (see Chapter 5).  
 
A conceptual framework based on the hypotheses of the possible relationships 
between risk factors and adherence was developed.  The conceptual framework 
included four domains, namely, child characteristics, caregiver characteristics, Socio-
economic characteristics and health system characteristics (Appendix 8).  This 
framework guided the choice of variables entered into the models.  
 
It should be borne in mind that the mean cumulative rate of adherence according to 
caregiver self-report was 85.38%.  This means that the majority of the cohort were 
adherent.  This resulted in extremely little variability in the data and thus the ability to 
detect significant differences between the adherent and non-adherent groups was 
unlikely, given the sample size. 
 
Exploratory data analysis was conducted using bivariate and stepwise regression 
modelling.  The stepwise models provided different results indicating that the models 
were unstable and that the study was possibly underpowered to due to a lack of 
variance in the data.  Despite these limitations, the results indicated a trend in data that 












6.2. Characterization of cohort by adherence status 
 
The variables which characterized the cohort were analyzed in relation to adherence 
status, based on caregiver self-reported adherence with >95% used as the cut-off for 
adherence (see Table 6.1).  The mean adherence rate amongst the non-adherent 
patients was 81, 5% vs. 100% for the adherent.  
 
A logistic regression model was fitted for each of the hypothesized variables in 
relation to adherence.  These marginal models revealed that four variables, namely,  
„Any other‟, „grants‟, „counsel‟
50
 and depression were  significant risk factors for 
adherence.  First, caregivers who reported to have received counselling by counsellors 
at initiation of their child‟s ARVs, were 3.2 times more likely to be adherent (OR= 
3.2, P=0.03) than those counselled by a doctor or a nurse.  ; Second, having another 
person in the household, other than the index child, infected with HIV (OR = 0.34, 
p=0.05) resulted in these caregivers being 0.34 times l ss likely to be adherent than 
those who did not report any other HIV infected individual in the household (p=0.05).  
These two variables were highly significantly associated with each other (p=0.004) 
where a person with another infected family member was less likely to be counselled 
by a counsellor (70% vs. 45%).  
 
Third, those who received grants were 2.71 times more likely to be adherent than 
those who did not.  Fourth, children who had caregivers with scores indicating 
depression at baseline were 0.07 times less likely to be adherent than those who did 
not (p=0.01).  “Counsel” and “depression” were significantly associated with each 
other, where a person who was depressed at baseline, was 0.28 times less likely to 
have been counselled by a counsellor for initiation of ARVs (p=0.001). 
  
An interesting observation is that a higher proportion of non-adherent patients 
reported undergoing significant life events compared to the adherent group, though 
these results were not statistically significant.  These „significant life events‟ were 
defined as funerals, illness of primary caregiver, illness of another household member 
other than the index patient, illness of sibling, hospitalizations and retrenchments.  An 
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open-ended section to the question solicited „other‟ events not specified.  These were 
reported as „moving house‟ and „having another baby‟.  
 
The results regarding PMTCT participation deserves comment despite results not 
being statistically significant.  Fewer children in the adherent group belonged to 
mothers who participated in the PMTCT programme.  On closer examination, results 
showed that 67% of children whose caregivers did not participate in PMTCT were 
younger than 13 months of age with a mean age of 7.5 months.  The unadjusted odds 
ratio for age less than 13 months and participation in PMTCT was 1.73 but this was 
not significant (p=0.17).  Closer examination of the data, using Kruskal Wallis tests, 
indicated that the ages of children whose biological parents participated in the 
PMTCT programme differed from those who did not.  This difference was statistically 
significant with younger (<27 months of age) children‟s biological mothers more 
likely to have participated in the PMTCT programme than older children (χ
2
=8.02; 
p=0.0046).  It should be borne in mind that the PMTCT programme commenced in 
May 2004 and study enrolment commenced in October 2004, thus non-participation 
may have been due to a lack of access to services rather than conscious choices on the 
























OR (95% CI) 
p-value 
(0.05) 
 Mean (SE) Mean (SE)   
Age (months) 26.78 (2.26) 25.45 (4.75) 1.00 (0.98;1.02) 0.81 
Gender (M) 0.54 (0.05) 0.68 (0.11) 0.54(0.19;1.53) 0.25 
Recent illness  0.37 (0.05) 0.21 (0.10) 2.19 (0.68; 7.06) 0.19 
last hospitalization 
(months) 
6.20 (1.32) 4.72 (1.65) 1.01 (0.96 ;1.06) 0.64 
Otherdrugs (Y) 0.54 (0.05) 0.58 (0.12) 0.85 (0.31 ;2.28) 0.75 
WHO stage 3&4 0.71 (0.04) 0.74 (0.10) 0.88 (0.29 ;2.60) 0.82 
IDC attend (Yes) 0.76 (0.04) 0.74 (0.10) .99 (0.99 ; 1.00) 0.19 
Since (months) 8.88 (1.33) 13.65 (3.95) 0.98 (0.96; 1.01) 0.20 
Current TB (Yes) 0.27 (0.04) 0.37 (0.11) 0.63 (0.22 ;1.76) 0.38 
Health Problem (Yes) 0.42 (0.05) 0.42 (0.12) 1.01 (0.37 ; 2.70) 0.98 
Caregiver 
Characteristics 
Biological Parent (Y) 0.85 (0.03) 0.89 (0.07) 0.65 (0.13 ; 3.07) 0.58 
PMTCT (Yes)
2
 0.36 (0.05) 0.53 (0.12) 0.51 (0.19 ;1.35) 0.17 
age (20-30yrs) 0.60 (0.05) 0.68 (0.11) 0.70(0.24 ;1.98) 0.51 
Education (Std 10) 0.29 (0.04) 0.37 (0.11) 0.69 (0.25 ;1.92) 0.48 
Post school educ (Yes) 0.16 (0.04) 0.21 (0.10) 0.72 (0.21 ;2.44) 0.60 
Unemployed (Yes) 0.77 (0.04) 0.63 (0.11) 1.91 (0.68 ;5.34) 0.22 
Planning more children 0.22 (0.04) 0.32 (0.11) 0.60 (0.20 ;1.74) 0.34 
Day care (Bio mother) 0.86 (0.03) 0.07 (0.32) 0.70 (0.14 ;3.31) 0.65 
Depression 0.55 (0.05) 0.95 (0.05) 0.07 (0.01; 0.53) 0.01* 
Socio-economic 
Characteristics 
Housing (informal) 0.52 (0.05) 0.68 (0.11) 0.50 (0.18 ;1.42) 0.19 
Sanitation (inside) 0.34 (0.05) 0.26 (0.10) 1.45 (0.48 ; 4.35) 0.50 
Water (outside) 0.58 (0.05) 0.68 (0.11) 0.62 (0.22 ;1.17) 0.38 
Housing density 4.89 (0.25) 4.21 (0.53) 1.13 (0.89 ;1.42) 0.29 
Any other infected (Yes) 0.49 (0.05) 0.74 (0.10) 0.34 (0.11 ;1.00) 0.05* 
Grants (Y) 0.61(0.05) 0.37 (0.11) 2.71 (0.99; 7.42) 0.05* 
Significant Life events 
(Y) 
0.45 (0.06) 0.63 (0.11) 0.49 (0.17; 1.37) 0.17 
Health service 
characteristics 
Access to ARV clinic 
(ward) 
0.56 (0.05) 0.47 (0.12) 1.41 (0.53 ;3.73) 0.49 
Counselled (by counsellor) 0.59 (0.05) 0.32 (0.11) 3.17 (1.12 ; 8.98) 0.03* 
Referred to IDC for ARVs 
(Yes) 
0.25 (0.04) 0.26 (0.10) 0.94 (0.31 ; 2.85) 0.92 
1. The N values are true for 111 and 19 respectively, except where otherwise indicated in the table. 
2. The Provincial PMTCT programme commenced in May 2004, prior to this only the Khayelitsha 














6.2.1. Characterization of those with missing adherence data 
 
The characteristics of those for whom adherence data
51
  was missing (N=5), differed 
for mean age (40.09 months) with a range of 9.97 to 67.43 months.  There was a slight 
difference in means for the following variables:  
(1) There was a mean of 53.20 days since the last hospitalization, compared to 141.74 
for non-adherent patients and 186.01 for adherent patients.  
(2) The mean number of household members was 5 compared to 4.21 and 4.89 for 
non-adherent and adherent patients, respectively.  
(3) The mean was .40 for caregivers in the age group 20-30 years compared to 0.68 
and 0.60 for non-adherent and adherent patients, respectively.  
(4) These patients were more likely to have been referred from the wards (0.60) 
compared to 0.47 and 0.56 for non-adherent and adherent patients, respectively.  
(5) Caregivers with standard 10 (Grade 12) education accounted for a mean of 0.20 
among this group, compared with 0.37 and 0.29 for the non-adherent and adherent 
patients, respectively.  
(6) The mean for having another person in the household infected with HIV apart 
from the index child was 0.20 among this group compared to 0.74 and 0.49 for non-
adherent and adherent patients, respectively.   
(7) Only one caregiver had access to a social welfare grant.   
 
Since this group constitutes a very small sample, the impact of this missing data is not 
anticipated to be significant enough to have changed the results of the study 
significantly, had the data not been missing. 
 
6.3. Multivariate Logistic regression models 
 
In an effort to evaluate whether there were any other variables (other than those 
identified in the bivariate analyses) which were significant, multivariate analysis was 
conducted using forward and backward stepwise models (see Appendix 15).  This 
approach was used to deal with any possible confounding.  Models tested included 22 
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to 27 variables.  The „best‟ model was one, which included 25 variables (see caption 
below table 6.2).   
 
In this model (Table 6.2) attendance at the IDC clinic prior to ARV initiation was 
statistically significantly associated with adherence (p=0.002) with those who 
attended prior to ARV initiation for HIV management being 59.34 times more likely 
to be adherent than those who were referred directly for ARVs, however the 
confidence interval was very wide (4.61;763.53).  Except for „planmore‟ which 
entered the model at p=0.07; nine variables entered the model at p<0.05.  Those who 
reported sickness within one month prior to ARV initiation (recent sick), were 18.54 
times more likely to be adherent than those who did not (p=0.01).  Those counselled 
by counsellors were 6.24 times more likely to be adherent than those counselled by 
doctors and nurses at ARV initiation.  An interesting result related to fertility plans 
with those planning to have more children being less likely to be adherent (OR=0.20) 
than those who were not. Furthermore, those with TB at ARV initiation, living in 
informal housing and caregivers with depression were less likely to be adherent (OR= 
0.09; 0.12 and 0.03, respectively).   
 
On the other hand, a forward stepwise model (Table 6.3)  run with (pe 0.1) resulted in 
the variables indicating being counselled by a counsellor (Counsel) and having 
another person in the household infected with HIV (Any other) entering the models at 
marginally significant levels (p=0.07 and 0.10, respectively).  The different results 
from the various models indicate data instability due possibility to the lack of power 













Table 6.2:  Results of Backwards Stepwise Regression model  
Adherence Odds Ratio Std.Err P>|z| 95% Confidence 
interval 
Grants 4.89 3.77 0.04 1.08; 22.10 
Recent sick 18.54 21.38 0.01 1.93; 177.82 
Planmore 0.20 0.18 0.07 0.03; 1.14 
Counsel 6.24 5.46 0.04 1.12; 34.66 
Since 0.99 0.00 0.02 1.00; 1.00 
Health problem 0.11 0.09 0.01 0.02; 0.63 
ID attend 59.34 77.34 0.002 4.61; 763.53 
Current TB 0.09 -0.08 0.01 0.01; 0.57 
Housing (informal) 0.12 0.11 0.02 0.02; 0.73 
Depressed 0.03 0.05 0.03 0.00; 0.74 
Variables included in the above model (pr=0.1): agemo recentsick dayslasthosp Otherdrugs since 
housedensity Stage Reltochild PMTCT  GiverAge Educ Employment Planmore Anyother Counsel 
Access PostSchool Housing Gender HealthProb IDattend CurrentTB SigLE Grants depressd (see 
chapter 3 Table 3.5 for description of variables). 25 variables entered into this model (N=86) 
 
Table 6.3:  Results of Forwards stepwise regression model 
Adherence Odds Ratio Std.Err P>|z| 95% CI 
Counsel 2.70 1.48 0.07 0.92;7.91 
Anyother 0.39 0.22 0.10 0.13; 1.18 
Variables included in the above model: (N=119) agemo recentsick dayslasthosp Otherdrugs since 
housedensity Stage Reltochild PMTCT GiverAge Educ Employment Planmore Anyother Counsel 
Access PostSchool Housing Gender HealthProb IDattend CurrentTB, pe (0.1) 
 
 6.4. Power Analysis 
 
A power analysis for the predictor variables was conducted to determine what level of 
power was in the study for each of the variables entered into the models.  The results 
outlined in Table 6.4 indicate that in general, the study was underpowered and thus 
Type 11 errors
52
 were likely to occur in the results.  Power ranged from as low as 3% 
for „duration of time between hospitalization and ARV initiation (last hospitalization) 
to 88% for IDC attendance prior to ARV initiation. 
 
Also note that while the sample size varied slightly in the study data, consistent values 
of N=100 were used to calculate Power.  Table 6.4 illustrates the probability of 
detecting significance if the hypothesized OR was true.  It should be noted that the 
„hypothetical‟ odds ratios in Table 6.4 are approximated from the odds ratios found in 
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 A type 11 error occurs when the data is unable to find a difference that exists as opposed to a Type 1 












this study.  The table illustrates that adequate power (>80%) was present to detect 
significant differences for three variables, namely, IDC attendance prior to ARV 
initiation, sanitation (inside flush toilets) and access to grants, if the hypothesized 
odds ratios were true. 
 
The results indicated that if the hypothesized odds ratios were true, the power was 
substantially weak to determine significant differences between the two groups 
(adherent and non-adherent).  Variables such as „recent sickness‟ prior to ARV 
initiation (3%); no. of days since last hospitalization (3%); duration of IDC attendance 
prior to ARV initiation, „since‟ (4%); access to ARV treatment via the wards (9%); 
marital status (11%); age (13%); depression and knowing the names of the ARVs 













Table 6.4:  Power Calculations with Alpha set at 0.05 if the OR was true 
Group 
 
Variable Odds Ratio   Power 
Child Characteristics 
Age  1.29 13% 
Gender (M)  0.55 45% 
recentsick (Y)  1.03 3% 
HealthProb (Y)  0.01 37% 
IDattend (Y)  2.50 88% 
Since/idc duration 
(DAYS/months) 
 0.01 4% 
CurrentTB (Y)  0.66 30% 
WHO Stage (3&4) 0.59 39% 
Last hospitalization (months)  0.96 3% 
Otherdrugs (Y) 0.40 62% 
Caregiver 
Characteristics 
Reltochild (Bio) 0.57 38% 
PMTCT (Y) 0.40 72% 
GiverAge (20-30)  0.83 10% 
Educ (Std10)  0.66 30% 
PostSchool (Y)  0.07 23% 
Employment (unemployed) 1.81 62% 
Planmore (Y)  0.57 46% 
Day care (Biological mom) 0.64 29% 
Depression (>9) (Y) 1.36 17% 
Know names of ARVs 1.36 17% 
Marital status 1.20 11% 
Socio-economic Factors 
Housing (Informal) 0.44 63% 
Water (Outside)  0.44 63% 
Sanitation (Inside) 2.33 81% 
Housedensity  2.5 74% 
Anyother (Y)  0.63 32% 
Grants (Y) 2.55 88% 
Significant Life Events (Y) 0.55 45% 
Health System 
Characteristics 
Counsel (Counsellor)  1.89 64% 
Access (Ward) 0.83 9% 




















This chapter provides a synthesis of the main, including important though not 
significant findings of the study presented in chapters 4 to 6 situated in the context of 
previous research, where possible.  An attempt was made to focus on those studies 
that are most comparable in terms of study population and methods used, where 
possible.  Finally, limitations of the study will be discussed. 
 
The purpose of this study was three-fold: first, to identify the adherence rate amongst 
a paediatric population younger than 7 years of age; second, to identify an adherence 
measure (amongst four) best suited to routine clinic practice within a resource-limited 
setting and third, to identify correlates of adherence within this setting.  No other 
study on adherence to HAART has previously focussed exclusively on the age group 
targeted in this study, namely <7 years.  The mean age of the cohort was 27 months.  
The cohort was characterized with severe immune suppression (mean CD4percentage 
<15%) from households where 76% of caregivers were unemployed and more than 
half were living in informal dwellings (self-made „shacks‟).  The majority of 
caregivers were the biological mothers of the children.  
 
7.2. Adherence Rates and virological suppression amongst the cohort 
 
Paediatric adherence is challenging as is evident from the review in chapter 2.  It is 
estimated that paediatric adherence in general (not HAART specific), is not very high, 
namely 58% vs. 75% in adults (van Rossum, Fraaij, & de Groot 2002).  In contrast, 
among the cohort of paediatric patients in the present study, 85% had >95% 
adherence as measured by caregiver self-report with 88% of adherent caregivers 
reporting no missed doses.  This relatively high cohort adherence rate is comparable 
to other paediatric HAART adherence studies using caregiver self-report measures 
conducted in resource-limited settings.  These include countries such as Uganda, 












(Hansudewechakul et al. 2006; Reddi et al. 2007; Mukhtar-Yola et al. 2006)  
reporting 89%, 90%, 89% and 80% cohort adherence, respectively. 
 
Seventy-four percent of those for whom six month viral load results were available 
(N=116), had virological suppression.  This finding is markedly better than the results 
of a paediatric HAART adherence study in Thailand where only 53% of patients were 
suppressed at 6 months only reaching 76% at 12months (Puthanakit et al. 2005a).  It 
should be noted that the present study was conducted among a treatment naïve 
population and the follow-up was relatively short (6 months).  These factors would 
mostly preclude treatment resistance
53
 from being a major factor in virological failure 
and thus inferring high adherence from virological suppression would be justified.  
The fact that virological failure occurred amongst 26% of this treatment naïve cohort 
should alert our attention.  There may be several reasons, as previously alluded to, for 
virological failure some of which may result from non-adherence and others from 
pharmacokinetic dynamics.  A study conducted at two sites in South Africa (RXH and 
Baragwaneth Hospital), involving therapeutic drug monitoring of Efavirenz, found 
that children receiving doses according to the current treatment guidelines were not 
receiving adequate exposure to the drug (Ren et al. 2007).  According to the authors, 
low Efavirenz concentrations result in rapid emergence of efavirenz-resistant 
mutations of HIV causing treatment failure.  One third of the study cohort had an 
Efavirenz–based regimen.  Efavirenz capsules needed to be opened and dispersed in 
water for administration in this very young cohort.  This practice in itself could lead to 
under dosing if all the medication is not dissolved and given to the child.  However, 
there is insufficient data in this study to determine the cause of virological failure 
amongst this group. 
 
Baseline viral load was highly correlated with viral load outcome at six months.  
Higher baseline values resulted in higher values at six months.  This confirmed the 
hypothesis that if the baseline viral load was very high, the decline after six months 
may be significant, though detectable.  This finding is similar to results of  a study 
among adults on HAART, which found that baseline viral load values were 
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significantly associated with virological outcome measured at six months of initiation 
of treatment
54
 (Mathews et al. 2002). 
 
An a priori hypothesis in the present study was that disease severity influences 
virological outcome.  Several indicators for disease severity were used and the 
indicator which was consistently associated with viral load outcome at 6 months was 
the variable indicating that the caregiver had reported that the child had a health 
problem at ARV initiation (“health problem‟).  Those whose caregivers reported a 
health problem at ARV initiation were more likely to have virological suppression 
than those who did not.  In a resource-limited setting, this could be a very simple 
predictor of adherence.  The result supports previous findings (cited in chapter 2) that 
severity of illness and in this case, the caregiver‟s perception of severity of illness, 
impacts positively on treatment success as indicated by virological suppression, at 
least in the short term.  Some may argue that the caregiver report of a health problem 
at ARV initiation is not an objective measure of disease severity but according to the 
data of the present study, it was a good proxy. 
 
7.3. Adherence Monitoring: Comparing the four Measures 
 
In 1998 Flexner noted that it was impossible to measure adherence in an outpatient 
setting with absolute accuracy and precision and we still face this dilemma in 2008 
(Flexner 1998).  This study was an attempt to find the „least flawed method‟ amongst 
the „flawed‟, which is suitable for ambulatory patients in a resource-poor setting. 
 
The adherence measures displayed high sensitivity (to detect adherence) but not high 
specificity (to detect non-adherence).  The use of composite measures such as 
combining caregiver self-report and clinic visits were tested to increase specificity. In 
the present study a composite measure of caregiver self-report and clinic visits yielded 
higher specificity  than either caregiver self-report or clinic visits but caregiver self-
report had the highest sensitivity at the >95% threshold.  In the absence of a gold 
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to find evidence in a comparable paediatric HAART adherence study in resource-limited settings in the 












standard measure of adherence, viral load suppression was used as the reference 
measure with acknowledgement of its limitations as outlined in chapter 2. 
 
Among the four measures, the medicine measure/pill count was the most challenging 
measure to implement.  All children in this study had syrup formulations in their 
regimens (due to their young age).  There were large volumes issued and caregivers 
often neglected to return the bottles for measurement.  There were incidences reported 
of spillage, vomiting and even broken bottles, which led to overestimation of 
adherence with a mean of 115% adherence for those with over 100% adherence.  
Those with more than 100% adherence comprised 50% of the group measured by 
medicine measure.  The overuse of medication from the container may not translate 
into absorption by the child since not even the caregivers were clear about „how much 
the child actually got in‟ after a vomiting or spitting episode.  Caregivers try to repeat 
doses in an attempt to give the „correct‟ dose.  Amongst very young children (< 1yr) 
this may be easier than with older children who may fuss and refuse repeat dosing.  
This measure was not correlated with virological outcome.  The adherence data 
according to medicine measure, clearly illustrates the difficulties in paediatric ARV 
treatment administration using unpalatable formulations or adapting adult capsules, 
like opening and dissolving Stavudine and Efavirenz capsules.  In addition, three 
separate formulations have to be administered which triples the problem for the 
caregiver and the child.  These facts indicate that this measure is not practical as an 
adherence measure in a paediatric population.  Davies et al (2007) had similar 
findings with regard to the adherence rates in excess of 100% as well as finding no 
association between medicine measure and viral load.   
 
No measures were significantly correlated with virological outcome in unadjusted 
associations. On the other hand, caregivers self-report was significantly correlated 
with virological outcome when adjusted for disease severity in this study (p=0.001).   
However, the odds of virological suppression given adherence, using clinic visits as 
the measure of adherence, was significant and half that of caregiver self-report 
(OR=3.2; p=0.02 vs. OR=6.0)  
 
Caregivers self-report, pharmacy refill and clinic visits, as measures of adherence, 












methods have the added value of alerting the clinician to a problem at the first sign of 
non-adherence such as missing doses (in the case of caregiver self-report) or missing 
an appointment such as a pharmacy refill date or a clinic appointment. 
 
Several paediatric studies have found correlations between caregiver self-report and 
viral load and some were in resource-poor settings, namely, Cotê d‟ Ivoire and 
Thailand (Gibb et al 2003; Arrivé et.al 2005; Hammami et al, 2004; Marhefka et al. 
2006; Puthanakit et al. 2005a). 
 
Possible reasons for the „good performance‟ of this measure may be: first, for the 
duration of the study, doctors and nurses generally did not speak the patient‟s first 
language which is predominantly Xhosa, while the research assistant who 
administered the caregiver self-report questionnaire in this study belonged to the same 
cultural and language group of the patients.  It is hypothesized that the patients were 
therefore more willing to declare non-adherent behaviour to the research assistant than 
they would to a doctor or nurse because they were able to communicate comfortably.  
Farley et al. (2003)  suggested that the caregiver self-report performs „better‟ when it 
is administered by someone with whom the patient „feels comfortable‟.  In this study, 
the interviewer was not directly responsible for providing the clinical care and this 
may have made caregivers feel more willing to declare their adherence problems 
without fear that it would impact on their child‟s quality of care.  Second, the standard 
PACTG questionnaire provided a tool for phrasing questions in a non-judgmental way 
and asking for specific information which has been proven to  provide a better picture 
of how the patient is managing adherence (Chesney et al. 2000b).  Finally, this 
hypothesis is further  supported by research which found that using face-to-face 
interviews for patients‟ reports and the way in which questions are asked, plays a role 
in the quality of information received (Ickovics & Meisler 1997). 
 
The lack of high specificity for the adherence measure is not unique to this study.  
One other study that employed multiple measures in a paediatric adherence study 
using caregiver self-report, pharmacy refill, clinic appointments, physician adherence 
assessment and MEMS-monitored medication adherence found that “the highest 
specificity was attained when both MEMS and pharmacy refill were used in 












correlation between viral load at 6 months and clinic appointments as well as 
physician-assessed adherence, no correlation between caregiver self-report and viral 
load outcome was found. 
 
The finding that caregiver self-reported adherence was correlated with viral load 
outcome in this setting is encouraging since it is a „relatively‟ low-cost method.  
Despite the lack of significant agreement between viral load suppression and 
pharmacy refill and clinic visits, these „relatively‟ low cost methods have value in this 
setting.  It may be used to alert the clinician to potential adherence problems at the 
earliest sign, thereby facilitating timely intervention as opposed to waiting for viral 
load results which may become available 4 to 6 months later, after the adherence 
problem has potentially been exacerbated. 
 
The development of improved adherence monitoring techniques, such as the 
„Simpill™
55
‟ technology emerging on the market
56
 (a variation on the MEMSCap) 
may not be appropriate for paediatric adherence monitoring for the reasons outlined in 
this dissertation regarding syrup formulations as well as costs being prohibitive for 
routine use among children in resource-poor settings. 
   
7.4. Factors impacting on adherence 
 
This study is one of the few paediatric adherence studies in which associations 
between factors and adherence were statistically derived (Nabukeera-Barungi et al. 
2007; Giacomet et al. 2003; Mellins et al. 2004). According to a review of the 
paediatric adherence literature conducted by (Simoni et al. 2007: 1375): 
 
“Lists of factors presented are more likely to be derived from clinical 
experience or surveys in selected areas such as “mental health and coping”; 
than from theory-driven research or studies in which the associations were 
examined statistically.” 
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This study was exploratory due to the paucity of data regarding paediatric adherence 
in resource-limited settings at the time of the conceptualization and implementation of 
the study.  As a result, instruments were designed to capture many aspects of the 
complex dimensions of paediatric adherence based on hypothesis and evidence from 
paediatric studies primarily in resource-rich settings and the data based on adult HIV 
infected patients.   
 
7.4.1. Child Characteristics 
 
Age of the child was not significantly associated with adherence.  This may be due to 
a unique aspect of the study population which was the young ages of children with 
access to HAART in a resource-poor setting, with a confined range (<7 years) and the 
youngest being 3 months old.  Published literature generally reported mean ages of 
between 4 and 12 years with age ranges between 2 and 21 years (3Cs4kids 2008; 
Nabukeera-Barungi et al. 2007; Mukhtar-Yola et al. 2006; Puthanakit et al. 2005b). 
 
All children in this cohort were of non-school going age and generally all dependent 
on caregivers to administer their medication.  The higher rate of adherence amongst 
the cohort (85%) may therefore support the findings of studies which report that 
adherence is higher among younger children (Martin et al. 2007; van Rossum et al. 
2002; Arrivé et al. 2005). 
 
No children in this study were told their HIV status because caregivers perceived 
them to be “too young to know”.  Thus, the effect of the child‟s knowledge of their 
HIV status on their adherence could not be determined. 
 
In bivariate analysis, no child characteristics were associated with viral load.  
However, in multivariate analyses, children who were ill (p=0.01) and those who had 
TB (p=0.01) were more likely to be adherent than those who differed on these 
variables.  Attendance and duration of attendance of the IDC outpatient clinic 
influenced adherence in a contrasting manner.  Attendance of IDC prior to initiation 
of ARVs was significantly associated with adherence in a positive direction 












inversely associated with adherence with those in the non-adherent group having a 
mean of >13 months attendance prior to ARV initiation compared to the adherent 
group with a mean of <9 months attendance.  
 
A possible explanation for these apparently conflicting results regarding IDC 
attendance is offered.  Caregivers of those who were attending the IDC for a longer 
time prior to ARV initiation may not have perceived their children as being very ill 
and the data showed that those who reported „recent sickness‟ were more likely to be 
adherent than those who did not.  Clinicians or counsellors may not have provided the 
same intensity of preparation prior to treatment as those who were referred 
specifically for ARVs on the assumption that they had sufficient HIV-related 
knowledge and health care workers may have assumed that these caregivers were 
comfortable with administering the treatment.   
 
In contrast, children identified and brought into HIV care prior to the initiation of 
ARV treatment may be at an advantage regarding regular medication administration. 
Pneumocystis jirovecii pneumonia (PJP) prophylaxis (cotrimoxazole) and 
multivitamin syrups are standard of care at the IDC.  This may create a smoother 
transition for both caregiver and child, from the administration of these medications to 
ARVs.  However, this is pure speculation and the study was not designed to test these 
hypotheses. 
 
The health status of the children was associated with adherence.  The data showed that 
children for whom illness episodes during the month prior to initiation of ARVs were 
reported, as well as children who suffered a „health problem‟ at initiation of ARV 
treatment, were more likely to be adherent than those who did not (p=0.01 each).  The 
younger ages of the cohort and the fact that the study was conducted at the outpatient 
clinic of a paediatric specialist hospital, indicates that the children were all possibly 
vertically infected and severely immune compromised.   
 
The mean CD4percentage of <15% and mean log baseline viral load of 5.6 is 
indicative of the level of severity of illness in this cohort.  This statement is supported 
by the fact that the majority (78.5%) of caregivers perceived the reason for ARV 












treatment” and in-patient referral made up 55% of the referrals to the IDC clinic.  
Similarly, a study in Uganda which found that children who have had at least one 
hospitalization episode prior to ARV initiation have better adherence and in another 
study, the PENTA study group found that children with more severe disease have 
better adherence (Nabukeera-Barungi et al. 2007; Gibb et al. 2003).  Thus, the health 
status of the cohort in general may explain, in part, the relatively high rate of 
adherence amongst this cohort. 
 
7.4.2. Caregiver Characteristics 
 
A high proportion of caregivers were biological mothers (85%) with 61% in the age 
group 20-30 years.  This high rate of biological mothers as primary caregivers of HIV 
infected children is comparable to a study conducted in Nigeria where 80% of 
children had a biological mother as their primary caregiver (Mukhtar-Yola et al. 
2006).  The relatively high rate of adherence amongst this group is in line with an 
adherence study in India (among non-HIV infected children).  This study found that 
children with biological parents were more adherent (Natu & Daga 2007).  Contrary 
to these findings, a study in Italy found that HIV-infected children in foster care did 
better (Giacomet et al. 2003).  
 
In bivariate analysis, depression was the only variable which had a statistically 
significant effect (p=0.01) on adherence with those with depressive symptoms (score 
>9) less likely to be adherent than those who did not have any symptoms (OR 0.07).  
The prevalence of depressive symptoms amongst the cohort of caregivers was 
approximately 18%.  A study conducted amongst depressed adult patients on HAART 
showed that treating depression with anti-depressant medication, improved adherence 
to HAART (Horberg et al. 2008).  This has implications for identification of caregiver 
symptoms of depression in paediatric ARV treatment programmes if it is inferred that 
depression treated in the caregiver would impact positively on adherence of the child.   
 
However, this may mean a restructuring of the „vertical‟ manner in which ARV 
services are currently managed in some health care settings in South Africa.  To 












that the caregiver will need to be referred to another facility to obtain access to further 
management and treatment.  This may involve spending another day at another 
facility and may involve further transport costs as well as possibly child-minding 
arrangements if the mother usually takes care of the child during the day.  The 
evidence from studies show that the caregiver may be more likely to forgo her own (in 
the case of female caregivers) health care if it impacts on her caring role of the child 
(Wrubel et al. 2005).  
 
Therefore, while further studies are needed to explore the impact of these caregiver 
characteristics in a resource-poor setting, the available evidence suggests an 
appropriate adherence enhancing intervention would involve a family centred model 
of care.  Furthermore, data from the meta-analysis of seven perinatal trials conducted 
in East, West and South Africa shows that children whose mothers have died have a 
3.5-fold higher risk of dying independent of the child‟s HIV status (Newell, Coovadia, 
& Cortico-Borja 2004).  It is therefore imperative that mother-child dyads be kept 
intact to ensure adherence and the survival of the children.  
 
There was a trend towards lower mean scores, indicating less depressive or no 
depressive symptoms, amongst caregivers as treatment duration amongst children 
increased.  Notwithstanding the myriad of factors which impact on caregiver 
psychological well-being (poverty being a major contributing factor (Brandt 2007)), 
these results indicate that having a sick child adds to depressive symptoms in 
caregivers and as children become established on HAART and their health improves, 
depressive symptoms decrease.  This decrease between month 1 and month 6 was not 
found to be statistically significant in this data but this was probably due to the lack of 
power to detect a difference on this variable (approximately 17% power in the study
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and the fact that those with the highest scores at month 1 had missing data at month 
6).  Depression and stress have been found to impact negatively on adherence among 
adult patients on treatment (Chesney 2000; Gordilloet al. 1999; Holzemer et.al 1999; 
Murphy et al. 2001; Patterson et al. 2000).  These findings have been confirmed in 
paediatric adherence studies with higher levels of baseline parenting stress and 
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experiences of negative stressful life events associated with worse adherence as 
measured by clinic attendance rates (Mellins et al. 2004).   
In multivariate analysis (with alpha set at p=0.1) both depression and fertility plans 
were significantly associated with adherence.  Once again those caregivers with 
depressive symptoms were less likely to be adherent (p=0.03) as well as those 
caregivers who were planning to have another child (p=0.07).  Caregivers who were 
planning to have another child were 0.2 times as likely to be adherent as those who 
were not planning to have another child.  This finding may be related to the amount of 
confidence the caregiver had in the child‟s prognosis.   
 
An interesting finding relates to the knowledge and attitudes of caregivers to ARV 
treatment in the present study.  While the majority expressed the belief that the 
benefits of ARVs far outweigh the risks, this belief did not translate into hope for a 
good prognosis.  More than half (58%) expressed concern that their child may not live 
long enough to complete their schooling because of their infection.  It should be borne 
in mind that in the absence of antiretroviral treatment children with HIV-infection are 
not expected to live beyond their 2
nd
 birthday in resource-poor settings (Newell et al. 
2004).  It will probably take time for people in this setting to trust that ARVs can 
increase the life span of children.  
 
 It is not known what long-term impact this „lack of faith‟ in the ability of ARVs to 
provide a long life may have on the child‟s level of adherence.  A qualitative study of 
caregiver perspectives of paediatric adherence found that adherence was affected 
negatively by children adopting their mother‟s attitude towards medication (Wrubel et 
al. 2005).  
 
7.4.3. Socio-economic Characteristics 
 
In bivariate analysis, two variables were significantly associated with adherence 
namely, having another person infected with HIV in the household, other than the 













Those with another person infected with HIV in the household, other than the index 
child, were less likely to adhere (0R=0.34) than those without.  This factor relates to 
adherence in several ways.   
First, the majority of infected household members (other than infected biological 
mothers) were fathers, aunts and siblings.  This may indicate that children in 
households where other family members are in need of care and attention are more 
vulnerable to non-adherence.  Often the primary caregiver of the child has multiple 
care-giving roles, for example, other children (siblings of the index child) who may 
also be infected as well as partners or other family members.  This places an 
additional burden of care on someone who is also possibly HIV-infected and subject 
to health constraints.   
 
Second, in the present study very few (10%) caregivers were taking antiretroviral 
treatment for themselves.  The study did not determine how many caregivers were 
actively seeking health care on a regular basis and thus in need of treatment but not 
accessing it.  Though the implications for caregiver health care appears self-evident, 
there is a paucity of empirical data to support the assumption that providing a „family-
centred‟ model of health care will impact positively on the health of the HIV-infected 
child in particular, as well as the affected child.  The results from this study may 
provide the basis for further research into this factor.  
 
The strong association of access to social welfare in the present study supports the 
link between adherence and the family context.  At the start of this study, the IDC 
clinic was providing health care and antiretroviral treatment for the caregivers of 
children on HAART but this programme was halted within three months of the 
commencement of the study due to health service policy (see Chapter 3). 
 
Social Welfare support was found to impact significantly on adherence with those 
accessing monthly government grants, almost three times more likely to be adherent 
as those who did not.  This finding should be considered in the context that 76% of 
caregivers were unemployed and 60% reported receiving some form of social welfare 
grant.  Most (86%) of the grants were childcare dependency grants which was valued 
at R160 per month during the period of the study.  On the surface, the impact of this 












explained by the findings from the study by Brandt (2007).  Her study among women 
found that HIV infection and experiencing irregular household income were 
predictors of depression to an equal extent.  She therefore suggested that: 
“…in the case of poverty, the absolute value of household income was less 
significant than how stable and regular household income was and therefore  
whether women experienced their households‟ financial security as 
predictable.” (Brandt 2007: 234) 
 
Thus the impact of grants on adherence may be related to the fact that the majority of 
the unemployed caregivers had access to at least some form of regular income which 
ameliorated the depressive symptoms which have been shown to impact on adherence 
(Chesney 2000). As mentioned above the results of the present study indicate that 
those caregivers with depressive symptoms were less likely to be
58
 adherent than 
those who did not have depressive symptoms.  Similarly, a study among South 
African AIDS orphans found that AIDS orphans were less likely to have 
psychological ill health if they lived in a household with access to social security 
grants, food security and at least one member in employment, suggesting that efforts 
to alleviate poverty could mitigate the psychological problems manifesting as 
depression and delinquency in AIDS orphans (Cluver, Gardner, & Operario 2007). 
This study further illustrates the link between social welfare grants and psychological 
well-being which was found to influence adherence in the present study 
 
An important though not significant finding, (P=0.17), was that those experiencing 
“significant life events” were less likely to be adherent (OR=0.49) than those who did 
not.  Experiencing significant life events may be stressful and can cause disruption in 
daily routine.  Furthermore, research indicates that general life stress impacted more 
profoundly on HIV-infected women (Boland, Moore, & Schuman 1999; Catalan & 
Burgess 1996; Catz et al. 2000).  
 
 In the present study, the most caregivers were biological mothers who were also 
HIV-infected.  There may be several reasons for the association between experiencing 
a significant life event and non-adherence.  For example, attending funerals in this 
setting often meant that caregivers had to travel long distances to another Province to 
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attend the funeral and often the proceedings would last a number of days causing 
disruption to daily routine as well as extended periods away from home.  One of the 
reasons often cited for non-adherence in the literature, is „being away from home‟ 
(Chesney 2000).  The primary caregiver may leave the young child in the care of 
someone else for the duration of their travels without disclosing the child‟s HIV status 
and thus the importance of administering the medication.  Disclosure of the child‟s 
HIV status to another person is more important in paediatric ARV treatment than 
amongst adults.  A young child needs someone to act as a secondary caregiver for 
medication administration in the event that the primary caregiver is unavailable for 
any reason.  In the paediatric context, disclosure of the child‟s status to others has 
been linked to adherence to medication (Byrne et al. 2002; Nabukeera-Barungi et al. 
2007). On the other hand, the medication may not be easy to administer to a young 
child by someone who has not been „taught‟ how to do it.  Syringes are often used in 
this setting by caregivers to administer the ARV syrups to the young child.  The use of 
syringes to administer medicine may be a „foreign‟ concept to those who relate 
syringes with injections. 
 
While funerals or death in the family was one of the most likely significant life event 
reported, illness and hospitalizations were often cited as well.  
 
In the multivariate analyses, both the variables „grants‟ and „housing‟ emerged as 
statistically significant (p=0.04 and 0.02, respectively).  In multivariate analyses, the 
strength of association between access to grants and adherence became stronger with 
the odds of adherence being almost 5 times that of those who did not have access to 
grants. 
 
With regard to „housing‟, those in informal housing were less likely (OR=0.12) to be 
adherent than those who lived in formal (brick built) houses.
59
  This finding should be 
interpreted with caution since the majority of the cohort lived in informal dwellings 
(76%) and the level of adherence was relatively high for the cohort (85%). 
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7.4.4. Health Service Characteristics 
 
The factors explored within this domain related to counselling and access to ARV 
treatment and service.  In bivariate analyses those counselled by a counsellor were 3 
times more likely to be adherent (p=0.03).  The reason for this finding probably lies in 
the explanation previously described regarding language and cultural barriers between 
clinical staff and patients while counsellors (like the research assistant) provide the 
bridge to close the gap in communication.  The lay counsellors employed at the 
hospital are themselves HIV infected, some of whom are on treatment and others who 
have children who are on treatment.  The counsellors conduct support groups on clinic 
and as a result are known by the patients and trusted.  This improved communication 
leads to better understanding of the information regarding HIV and antiretroviral 
treatment as well as dosing instructions in a manner that is culturally sensitive.  The 
counsellor understands the cultural constraints impacting on caregivers‟ decisions to 
initiate antiretroviral treatment. 
 
For example, during the first few months of the study, there were patients who did not 
understand the instructions given by either the doctors or the pharmacist regarding 
dosing of ARVs and even identification of ARVs from amongst the large volume of 
medications issued.  They would seek out the research assistant (Xhosa speaking) to 
clarify information.  This was during the period when most counsellors were primarily 
focussing on pre and post HIV test counselling of caregivers with no formal training 
in paediatric ARV treatment literacy, except as „experienced‟ caregivers, though they 
had received training in adult treatment literacy.
60
  Those counsellors who had 
children on treatment were in a better position to counsel caregivers whose children 
were about to start treatment. 
 
In the multivariate analyses, adjusted for disease severity, only „counsel‟ remained 
statistically significant in this domain with the strength of association between 
adherence and „counsel‟ increasing to the odds of those counselled by a counsellor 
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being 6 times more likely to be adherent than those counselled by either a doctor or a 
nurse (p=0.04).  Thus, the important role of this cadre of „lay healthcare workers‟ in 
this setting, has been demonstrated in this study on paediatric adherence to HAART. 
A meta-analysis of 36-controlled studies in chronic disease looking at adherence and 
long-term health outcomes, found that behaviourally-oriented programs with special 
attention to patient environments and context, were consistently more successful at 
improving the clinical course of chronic disease (Mazzuca 1982). Although this 
research was conducted during the pre-AIDS era these conclusions may still hold true 
for adherence to HAART.  Authors of another study which was a randomized 
controlled study looking at the efficacy of an adherence enhancing intervention 
concluded that:  
“Limited evidence suggests that interventions to enhance adherence to 
antiretroviral therapy in people with HIV are most likely to be successful 
when they are comprehensive, longitudinal, and tailored to the person” (Tuldra 
et al. 2000: S154)  
 
While studies cited above involved adult patients on HAART, these are considered 
relevant in the context of paediatric adherence since adult caregivers are responsible 
for adherence of their children or children in their care.  In the context of paediatric 
HAART adherence, the data may be interpreted to mean that it is important to prepare 
caregivers of children about to initiate ARV treatment with the relevant knowledge 
and skills to ensure good adherence.  A strategy to support them throughout the 
process to cope with the various developmental stages of the child when they will be 
presented with new challenges to adherence should be in place.  One such 
intervention has been developed and implemented at the IDC (study site) subsequent 
to the present study (Michaels & Nuttall 2006c). 
 
While the data from the study lacked sufficient variance to clearly „explain‟ the 
reasons for non-adherence amongst the 15% non-adherent patients, given the non-
significant findings on the majority socio-demographic variables employed by the 
study, the following evidence from an intervention study may shed light on this 
matter.  A study using the information, motivation behavioural skills model (IMB) of 












95% adherence was related to lower levels of behavioural skills, which include self-
efficacy, for example, to overcome side-effects and incorporate medication into daily 
living.  Lower behavioural skills were more likely when adherence-related 
information and motivation were low.  Mental health, for example, depression, as well 
as unstable living conditions and poor access to healthcare all impacted on motivation 
(Starace et al. 2006).  In the present study, depression in the caregiver was more likely 
to impact negatively on a child‟s adherence to HAART.  Caregivers‟ levels of self-
efficacy and motivation were not determined in this study. 
 
7.5. Study Limitations 
 
This study has several potential limitations.  First, the study lacked sufficient power to 
detect significant differences between the adherent and non-adherent groups on most 
of the variables (see power calculations in Chapter 6: Table 6.4) due in part to the lack 
of variability in adherence data (high rate of adherence).  Several variables, such as 
the variables used as proxies to indicate disease severity, included due to the 
exploratory nature of this study, overlapped with each other.  Due to the small sample 
size, many variables available in the database could not be added to the analysis and a 
hypothesis driven approach was used for variable reduction to approximately 25 
variables, which may be considered too many for the small sample.  The striking 
difference between the models in the multivariate analysis illustrated in (chapter 6) 
suggests data instability.  This may be due in part to the lack of variance in adherence, 
the lack of power related to the sample size to show significant differences for the 
small effect size as well as missing data on certain variables which caused models to 
reduce the number of observations to the lowest denominator.   
 
Despite these limitations, the results of the study on factors impacting on adherence 
indicate a trend in the data which is mostly intuitive including the encouraging finding 
of the effect of being counselled for ARV initiation by a lay counsellor.  The result is 
considered encouraging because the South African ARV programme is relying 
increasingly on this cadre of worker in the health care team to facilitate HIV specific 













Second, this study was implemented in a routine clinic setting without additional 
resources (except an interviewer and the researcher) to create a „controlled‟ study 
environment.  This resulted in a higher rate of attrition of subjects than anticipated due 
to patients being transferred out to other clinics during the study follow-up period and 
research staff missing patients for interviews and data collection due to return clinic 
appointments being changed without changes being communicated to research staff, 
resulting in more missing data than was expected.  However, this limitation 
(conducting a study under „normal‟ clinic conditions) can also be seen as strength.  
The recommendations arising out of the study in a sense have been piloted in the „real 
world‟. 
 
Third, the study was conducted at a paediatric specialist hospital and though patients 
were recruited from the outpatient clinic, more than half the patients attending the 
IDC are referred from the wards.  This may have led to the sample being biased 
towards ill children and as described in the literature and cited above, adherence has 
been shown to be greater among children who were very ill or hospitalized.  However, 
the study population described in the study is drawn from the same population 
attending primary care clinics in the Greater Cape Town area.   
 
Fourth, random sampling could not be employed and all eligible patients were 
approached for consent to participate in the study.  While it may be argued that those 
who agreed may be different to those who declined, this did not affect this study since 
there was only one refusal.  While the results cannot be generalized to all caregivers 
or all HIV infected children on treatment in South Africa, the socio-demographic 
characteristics of the sample renders them typical of caregivers and children living in 
urban based resource-limited settings.  
 
Fifth, while there is a need for paediatric adherence longitudinal studies and this study 
has fulfilled this need to a certain extent, the follow-up period of this study was 
relatively short, namely, 6 months.  Studies have shown that adherence declines over 














Sixth, the exploratory nature of the study resulted in the inclusion of perhaps too 
many variables for the small sample size.  However, this could also be seen as 
strength, thereby providing „pilot data‟ for future studies which explore factors 
impacting on adherence in resource-limited settings. 
 
Seventh, the use of virological outcome as a reference measure (gold standard) may 
be a contributing factor to the lack of adequate sensitivity and specificity at the 
various cut-offs of adherence using the various adherence measures.  As noted above, 
several factors impact on virological suppression and for this reason it should not be 
considered a gold standard measurement.  However, in defence of its use, amongst 
this treatment naïve study population, it appeared sufficiently robust as a „gold 
standard‟ measure with those considered adherent according caregiver self-report 
having a 93% virological suppression rate.  Though it should be borne in mind that 
neither adherence measures, nor virological suppression are perfect measures of 
adherence and therefore discrepancies between adherence classification and treatment 
success is expected. 
 
Finally, several variables collected at the three time points during the 6 month follow-
up, were analyzed in relation to its impact on adherence but not correlated with 
virological suppression due to the fact that viral load outcome was only available at 
one time point (month 6).  The hypothesis that certain changes overtime impact on 
adherence was not be fully explored.  The reduction in observations over time led to 














CONCLUSIONS AND RECOMMENDATIONS 
 
8.1. Introduction  
 
To summarize, the research questions posed by the present study and elaborated on in 
chapter 3 were as follows: first, what is the adherence rate amongst the cohort?  
Second, is there agreement between the four adherence measures and viral load?  
Third, what is the „best‟ method of adherence in a routine clinic setting? Fourth, 
which factors, impacting on adherence?  These factors were conceptualized within 
four domains, namely, child, caregiver, socio-economic and health characteristics 
  
8.2. Adherence Rates and utilization of Measures in a routine clinic 
setting 
 
The first question pertaining to adherence rates was answered in the following 
manner: First, rates of adherence according to each measure were calculated.  Second, 
the „best‟ measure according to its correlation with viral load was identified through a 
series of regression analyses.  As a result, caregiver self-reported adherence measure 
was identified as the best measure and used to determine the cohort adherence rate of 
85%. 
 
The researcher‟s experience of administering the four measures was discussed in 
chapter 7 in order to highlight the ease or difficulty of implementing each measure in 
a routine clinic setting.  It was determined that pharmacy refill and clinic visit 
measures were the easiest to obtain and monitor and these correlated with each other 
as expected since both measured „attendance‟.  These measures may be useful in 
alerting the clinician to potential adherence problems indicated by the first missed 
pharmacy or clinic appointment and early interventions could be instituted. 
 
On the other hand, caregivers self-report was shown to be predictive of virological 












several factors: first, it should be administered by another person and not given to the 
caregiver to complete and return; second, the interviewer should conduct the 
interview in the caregiver‟s first language; third, the interviewer should not be the 
same person responsible for the clinical care of the child. 
 
8.3. Factors influencing Adherence 
 
The evidence from this study shows that amongst all the factors in the four sub-
domains socio-economic and health service characteristics have the most significant 
impact on adherence.  Characteristics situated a priori in the child characteristics 
domain and impacting significantly on adherence were de facto linked to health 
service characteristics (such as IDC attendance prior to ARV initiation and duration of 
attendance). 
 
The implications of these findings for service and further research will be discussed in 




8.4.1. Adherence Monitoring: Implications for service delivery 
 
Caregivers self-report, pharmacy refill and clinic visit adherence measures are useful 
to alert the clinician to the first signs of potential adherence problems.  These methods 
provide a relatively easy means of monitoring adherent behaviour throughout the 
patient‟s course of treatment (life long) not only at initiation of treatment.  
 
8.4.1.1. Recommendation 1: A Multi-pronged approach to adherence monitoring 
 
It is recommended that the health care service institute mechanisms to monitor patient 
adherence on an ongoing basis.  This monitoring should occur on a micro level, that 
is, at the level of the interface between clinician and patient as well as on the macro 
level, that is, at the level of health service management to monitor adherence on a 












adherence has public health implications regarding potential resistance and its impact 
on the utilization of ARV drugs.  This recommendation is accompanied by a proposal 
for implementation, namely, the „Algorithm for adherence monitoring in a resource-
limited setting‟ (Figure 8.1). 
 
The proposed approach is plausible in the South African setting for the following 
reasons:  Firstly, in South Africa, the HIV/AIDS programme relies on „lay 
counsellors‟ to provide counselling and support to HIV infected patients.  These „lay 
counsellors‟ often identify themselves with the same language and cultural groups of 
the patients and may themselves be HIV infected and on ARV treatment.  This allows 
them to build an empathetic and trusting relationship with the patients.  In this 
context, the health care workers could effectively administer a caregiver self-reported 
adherence measure based on the premise that if you want to know how the patient is 
doing, ask them, and then allow them to tell you without judgment!  Secondly, 
antiretroviral drugs are scheduled drugs and have to be issued by a pharmacist, thus 
providing an opportunity for the involvement of the pharmacy
61
.  Thirdly, the 
clinician or nurse has an ongoing clinical monitoring role with the patient and 
combining adherence monitoring will improve the realization of the goal of attaining 
treatment success. 
 
Algorithm for adherence monitoring using a multi-pronged approach 
It is recommended that a multi-pronged approach to monitoring adherence be used in 
resource-limited settings utilizing three of the measures tested in the present study, 
namely, caregiver self-report, pharmacy refill and clinic visits.  Figure 8.1 illustrates 
the mechanism of this adherence monitoring system.  Several members of the health 
care team can participate in the monitoring of adherence at various points within the 
health system.   
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The cadre of workers known by several designations such as, “lay counsellors” or 
“patient advocates” or “expert patients”, can play an important role in bridging the 
communication between clinicians and patients if they are language and culturally 
sensitive to the needs of patients.  They could be instrumental in administering the 
caregiver self-report
62
.  It is recommended that the prescribed instrument not be 
administered every month to avoid „response fatigue‟ but that key questions are asked 
at every visit, for example, (1a) “have you had any difficulty giving medicines in this 
past month?  (1b) if the answer to the previous question is “yes”, and then ask, “What 
was the difficulty”?  (1c) did this cause you to miss any doses?   
 
The information obtained by the lay counsellor must be communicated to the clinician 
or nurse.  Counsellors can play a role in facilitating self-efficacy skills by exploring 
with the caregiver how they can overcome similar problems or barriers in future. 
 
Pharmacy Refill 
Pharmacists have been playing an increasing role in monitoring patient adherence in 
the era of HAART.  Increasing volumes of medication stored by patients due to repeat 
scripts being filled without taking into account how much is left from the previous 
script, could lead to patients not returning for „on-time‟ collection to refill 
prescriptions.  It is important that the pharmacist monitors on-time collections and 
establishes the reasons for „late collections‟.  If patients report that they had sufficient 
medicine and didn‟t see the need to come on the appointed date, this could indicate 
that either too much medicine is being prescribed (not taking into account the amounts 
left at the end of each month, or patients are not being strictly adherent and thus not 
using the required amounts.  Either way, pharmacy monitoring of refill collection 
dates provides an opportunity to correct either a potential problem within the health 
system or a problem experienced by the patient.  This information should be 
communicated to the clinician or nurse. 
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Since clinic visits are necessary for repeat prescription as well as clinical, 
immunological and virological monitoring, regular attendance is necessary even if the 
patient is feeling well.  Thus monitoring on-time clinic visits is another way of 
identifying potential barriers to adherence.  If the patient does not attend on-time, the 
results of the pharmacy collection and previous caregiver reports should be evaluated 
to identify whether there may be a problem which is also impacting on the child‟s 
adherence.  It is therefore important that this monitoring be on-going and that data 
across the three measures are combined into one reporting system (namely, the patient 
folder) to provide easy access to all concerned with the patient‟s care. 
 
At the level of health management, it is suggested that the rates of „on-time‟ clinic 
visits be used as an indicator of adherence (at clinic, district and provincial level) by 
health managers.  This data provides information for health service planning which 
includes the identification of staffing and resource needs in an ongoing manner.  At 
present data on the number of patients on ARVs per month, including information on 
patient attrition is collected in the Western Cape Province, for example.  The proposed 
system of monitoring will add another dimension to the existing data collection by 
establishing patterns of clinic attendance by those remaining on treatment.  The 
current system of defaulter tracking relies on clinic visit records.  However, the lost 
opportunity for timeous intervention caused by the broad definition of „defaulter‟
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renders this system ineffective to deal with potential adherence problems and renders 
this system merely as a „policing‟ tool to find errant patients. 
Thus, the multi-pronged approach outlined above, if implemented synergistically 
within the system will help to identify potential adherence problems before treatment 
failure or „defaulting‟.  
 
It is further recommended that this proposed system of adherence monitoring be 
implemented and evaluated to test this hypothesis. The system requires piloting to 
determine acceptability amongst health care workers and the development of the 
structure of the counselling interventions. Subsequent to the pilot study, a randomized 
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 There is currently no standard definition of a „defaulter‟ in South Africa.  Definitions range from 
patients who missed the clinic visit for more than one week to „someone who has missed the clinic 












controlled trial should be conducted to evaluate the impact of the intervention on 
adherence. 
 
What is the role of viral load measurement in adherence monitoring? 
The above-mentioned proposal does not exclude virological monitoring which has a 
place in monitoring treatment success and alerting the clinician to treatment failure 
which may result from resistance.  However, it should be used as an adjunct to 




























8.4.2. Adherence enhancing interventions 
 
A review of the literature outlined in chapter 2 indicated that the few empirically test 
adherence enhancing interventions were generally very intensive and required at times 
a huge investment in resources, especially human resources, without the 
corresponding magnitude of success expected from such investment.  It is against this 
background that the following recommendations are made based on the evidence from 
the present study as well as other relevant studies. 
 
8.4.2.1. Recommendation 2: Paediatric-specific treatment literacy training  
 
It is recommended that an evidenced based generic paediatric treatment literacy 
guide and concomitant training initiatives be developed aimed at educating caregivers 
and health care workers on paediatric specific HIV treatment in South Africa.  At 
present, there is no co-ordinated strategy to address the lack of education and 
awareness around paediatric ARV treatment in South Africa.  
 
The main finding in this study, regarding the impact of counselling by a counsellor 
prior to ARV initiation on adherence, highlights the importance of clear 
communication between caregivers and health care providers regarding the 
implications and scope of ARV treatment in children.  There is a paucity of data to 
support a standardized approach to paediatric treatment literacy.  However, the 
increasing number of HIV infected children in Sub-Saharan Africa demands a change 
in the status quo.  It is important that clear and consistent messages relating to 
paediatric HIV management and treatment be articulated.  No one can dispute the 
value of providing information and ensuring that the patient has sufficient knowledge 
about his/her (or the child‟s) condition and therapy. 
 
8.4.2.2. Recommendation 3: A Family-centred Model of Care 
 
Evidence from this study showed that children who had other members of the 













It is recommended that a „one-stop‟ clinic visit which ensures that at the minimum, 
the caregiver is included in the clinical consultation with the child as an important 
proactive intervention which can impact positively on adherence.  The ideal situation 
is to have all members of the family encouraged to seek HIV testing and health care 
monitoring, especially siblings of the index child. 
 
Health care delivery at the primary care level using the „general practitioner‟ approach 
where all members of the family could receive health care at the same visit, would 
facilitate such a family-centred model of care.  This should include uninfected 
caregivers and siblings of children on treatment.  For example, grandmothers who are 
primary caregivers may not be HIV-infected but may suffer with chronic diseases 
such as hypertension, diabetes and rheumatism which will impact on their quality of 
life and care-giving roles.  The health system should be able to support the clinician‟s 
ability to enquire after the health of the caregiver and do something about any 
problem identified, including depressive symptoms in the caregiver.  
 
8.4.2.3. Recommendation 4: Training Health care workers  
 
It is recommended that the transfer of knowledge and skills to health care workers, 
especially nurses at the primary level be scaled up
64
 in South Africa in order to 
increase the capacity of the health system to render family-centred care at primary 
care level which includes paediatric HIV management and treatment 
 
As discussed in chapter 2, there is a „fear‟ amongst many clinicians and nurses in 
South Africa regarding paediatric HIV management and treatment.  Demystifying 
paediatric HIV management and treatment will be the first step in the process of 
setting up a family-centred model of care at primary care level.  These 
recommendations are made despite the knowledge that South Africa and many Sub-
Sahara African countries are facing a health care worker crisis but the current vertical 
and specialist approach to paediatric management and treatment is not sustainable.  It 
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is acknowledged that a certain amount of specialist expertise (and therefore specialist 
patient care) is necessary within the ever-changing field of HIV and AIDS. 
 
8.4.2.4. Recommendation 5: Early identification of HIV- infected children 
 
Children in this study cohort were relatively young, some as young as 3 months old.  
The data further showed that attendance at the IDC outpatient clinic prior to initiation 
of ARV treatment impacted positively on adherence.  It is therefore imperative to 
identify HIV-infected children very early in order to bring them into care and 
commence the practice of administering life saving drugs, initially with PJP 
prophylaxis, treatment of opportunistic infections and later with antiretrovirals
65
.   
 
8.4.2.5. Early identification of HIV- infected children 
 
It is recommended that the early identification of HIV infected children is 




Clearly a successful PMTCT programme will go a long way to facilitating this by 
identifying and tracking HIV-exposed children.  Should PMTCT programmes fail to 
follow-up HIV exposed children, these children should not be allowed to be „lost in 
the system‟ and opportunities during immunization visits should be utilized to do 
routine HIV screening of infants.  A further opportunity for identifying HIV-infected 
children is to „trace‟ any off-spring of adults testing HIV positive at voluntary 
counselling testing services
67
. In this way, initiating ARV treatment may not have to 
be dealt with as an „emergency‟ as it often is in this setting due to children being 
identified when they are severely immune-compromised.  
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 Currently HIV-exposed infants in South Africa are offered co-trimoxazole for Pneumocystis Carinii 
pneumonia (PCP) prophylaxis started at four to six weeks of age, free formula for six months if 
requested by the mother and diagnostic Polymerase CHAIN reaction (PCR) HIV testing beginning at 
six weeks of age. ARV therapy is offered to HIV-infected children with prolonged or recurrent 
hospitalization, those children classified with WHO clinical stage 3 or 4 disease, or those with CD4 cell 
percentages below 20 percent if younger than 18 months of age.(see www.doh.gov.za/docs/index.html )  
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 This recommendation is given with the proviso that caregiver education is provided and public 
awareness is created regarding paediatric HIV management and treatment (especially in the light of the 
implications of the  CHER study recommendations, as commented on in Chapter 2 section 2.12.1).  
67
 Adults testing HIV positive should be asked whether they have any children (even if they are male!). 












8.5. Recommendations for future research  
 
Firstly, the support for the proposal to introduce an explicit discipline within 
biopharmaceutics called pharmionics,
68
  is reiterated here.  This recommendation is 
made on the premise that this will encourage financial support for quality research 
regarding adherence in the broadest sense but especially with regard to paediatric 
antiretroviral treatment adherence especially in resource-poor settings. 
 
It is therefore imperative that first, studies are carried out using larger sample sizes
69
  
to further investigate measurement and correlates of adherence among children in 
resource-limited settings.  If the relatively high rates of adherence as demonstrated in 
the present study and other studies emerging from resource-limited settings are true, 
then large sample sizes are required to detect an effect.  Factors which emerged as 
statistically significant or marginally significant in this study should be further 
explored.  There is a need for further quantitative data to determine the impact of 
various barriers to non-adherence, especially within the health system and within the 
socio –economic domain.  Large-scale government and health service interventions 
can have a direct impact by removing barriers which may be out of the control of 
individual patients to effect change in these domains. 
 
Second, defined age cohorts should be studied since results cannot be generalized 
across various age groups, a problem which was identified through the literature 
review and discussed in chapter 2.  
 
Third, study designs should be longitudinal with a minimum of 6 months follow-up.  
It has been found that levels of adherence decline over time.  For this reason, barriers 
identified during the first few months of treatment may be different to barriers which 
impact on long-term adherence.  We have sufficient data to prove that cross-sectional 
adherence studies are no longer viable for exploring the complexities of adherence 
related behaviours and influences. 
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 The proposal by Vrijens (2005) was described in Chapter 2 (2.13). 
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Fourth, choices of adherence measures and „gold standard‟ measures used in 
paediatric adherence studies should be carefully considered in the context of resource 
limited settings.  Further research into the validation and development of „user-
friendly‟ adherence measurement tools such as those tested in the present study, with 
adaptations to increase specificity.  
 
Finally, research into the development and evaluation of adherence interventions in 
the context of resource-limited settings are required to maintain these present 
relatively high levels of adherence to HAART reported in these settings.  These 
include research into health systems factors which may impact on adherence as 
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Appendix 3:  Consent Form (English) 
 
I understand that I have been asked to take part in this study because my child has been started on 
antiretroviral treatment for HIV infection.  The researcher has explained to me that this study is aimed 
at understanding what factors affect children‟s ability to take the antiretroviral medication.   
 
The researchers have explained that I will be completing two administered questionnaires which will 
last approximately 45 minutes to an hour approximately one month after my child started the treatment. 
Subsequent questionnaires regarding the medication will be administered at the 3month and 6 month 
visits. 
 
I understand that my child‟s clinic records will be used to obtain information about their clinical and 
virological status. 
 
I understand that the specific answers I give will not be given to the doctors or the health staff that 
provide me with the treatment and there will be no change with regard to the treatment I receive.   
 
I understand that I may be invited to participate in a focus group discussion with other parents to 
discuss issues relating to children on antiretroviral treatment. 
 
The researchers have explained that I am not obliged to take part in this study and if I refuse to take 
part, it will not affect the service I receive at the hospital.  
 


























Appendix 4 :  Enrolment Form 
 
Enrolment Number: __/__/__ Date of Enrolment: __/__/____Completed by: _____________ 
Patient Folder No: ____________________                             ARV Start date: __/__/____
  
Name & Surname of Child: ____________________________ 
D.OB: __/__/____ (dd/mm/yyyy)       Gender:   M   /  F  (circle) 
Caregiver Contact Details: 
Name and Surname: _____________________________ [Print]  
Relationship to the Child: ___________  
Address: ___________________________ 
               ___________________________ 
Tel No:   __________________ (h)   Cell: _ _ _ _ _ _ _ _ _ _ No telephone/s  
Ask Caregiver: 
1. Has the child attended the ID clinic prior to ARV treatment?  Yes__No_ 
(Ingaba umntwana uhambe lekliniki phambi kokuba aqalise unyango lwentsholongwane) 
2. If yes, since when (mm/yyyy)? (Ukuba ewe, uqale nini) ______ 
3. How did you get access to this ID clinic at the hospital?  
(Ingaba wangena njani kule kliniki ilapha esibedlele) 
1= referred by community clinic 
(Ndathunyelwa yikliniki yase kuhlaleni) 
2= referred by hospital after child was hospitalised 
(Ndathunyelwa sisibhedlele emva kokuba umntwana wayelalisiwe) 
3= Other [specify] (Enye – chaza)_________ 
4. When was the last time this child was sick?  (days/ weeks or months) ________ 
(Ugqibele nini umntwana ukugula) 
5. What was wrong with the child? _____________________________________ 
(Yayi yintoni ingxaki yomntwana) 
6. Does the child have any health problems today?  Yes __ No__  [If no, skip to 8] 
(Ingaba umntwana unengxa ngokwempilo namhlanje) 
7. If yes, what is wrong? ______________________________________________ 
(Ukuba ewe, yintoni ingxaki) 
8. Is the child currently being given any other medication?  Yes__No___ 
(Ingaba umntwana unikwa amanye amayeza angamanye) 
9. If yes, specify (condition & medication) ________________________________ 
(Ukuiba ewe, chaza – imeko namayeza) 
___________________________________________________________________________ 












(Yintoni, ngokokwakho, isizathu sokuba umntwana aqalise olunyango lukaGawulayo) 
___________________________________________________________________________
From whom did you get information about the ARV treatment? 
(Ingaba walufumana phi ulwazi malunga nalamachiza entsholongwane kaGawulayo) 
1= counsellor (Umcebisi) 
2= nurse (Umongikazi) 
3= doctor (uGqirha) 
4= social worker (UnoNtlalo-Ntle) 
5= 1,2 + 3 
9= Don‟t remember (Andikhumbuli) 
11. What do you remember about what they told you about the treatment for the child?  
(Yintoni oyikhumbulayo malunga nowakuxelelwayo ngolunyango lomntwana) 
_______________________________________________________________
_______________________________________________________________ 
For Office Use Only 
 
Medical History 
Information to be obtained from patient folder] 
13. Has the child attended the ID clinic prior to ARV treatment? Yes__No__   
14. If yes, since when (mm/yyyy)?  ______ 
15. If not, was the child referred for ARVs?    Yes __ No__ N/A___ 
16. If yes, who referred (institution/clinic)? ____________ 
17. Is the child currently on TB treatment?    Yes __ No__ 
18. If yes, since when? ________ 
19. Is the child currently on Cotrimoxazole/Bactrim?   Yes __ No ___ 
20. Was the child exposed to ARVs through PMTCT programme?   Yes ___ No ___ 
21. If yes, (specify)           1= AZT 
2=  NVP 
3= Combination therapy   
9=Don‟t Know 
22. Last hospitalization date: __/____ (mm/yyyy) 
23. Reason for hospitalization: ______________________________ 
24. Date of Completion of screening questionnaire:__/__/____ (dd/mm/yyyy) 
 
25. Medical Reason for commencing treatment (as noted on screening questionnaire) 
________________________________________________________________________
____________________________________________________________ 
26. Other significant medical problems 
a. HIV related:______________________________________________ 
b. Non HIV related:_________________________________________ 















CD4 Count / %  



















Enrolment Procedure Checklist 
1. Obtain Consent  ……………….……………..  
2. Complete Enrolment log………………….…..  













Appendix 5:  Standard Operating Procedures 
 
Objective of the Study 
 
This is a prospective cohort study to determine how four different measures of 
adherence approximates immunological and virological markers and explore factors 




All children under 6 years of age initiating HAART between the period October 2004 
and October 2005 are eligible for enrolment into the study. 
(Note: All children  
 
Exclusion criteria 
Children who are in long term residential care, at a children‟s home are not eligible.  
 
Study Procedures  
 
This study will be conducted along side the routine ARV service provided at the Red 
Cross Children‟s War Memorial Hospital.  No additional phlebotomy procedures will 
be conducted for the purposes of this study.  Immunological and virological results 




Patients will be identified at the Tuesday and Friday Infectious Diseases outpatient 
clinics.   
 
Tuesday Morning Clinic 
 
Tuesday clinics are held in S20 and the sisters-in-charge are Brenda Joshua (for 
PAWC) and Desireé Jansen (for research).   
 
The designated person for the Adherence study will identify patients by perusing 
patient folders in the record clerk‟s office.  The inclusion of a „screening 
questionnaire‟ form in the patient folder indicates a candidate for ARVs or a patient 
on ARVs.  Patients who are indicated to commence ARVs or who are making their 
two week visit appointment will be identified at this stage for enrolment. 
 
Patients at 2 week post ARV initiation visit. 
These patients will be identified and approached by the researcher for consent to 
participate in the study.  
Patients indicated for work up to initiate ARVs can only be confirmed after 
consultation with the doctors. The appointment dates of the next visit of these patients 












Friday morning Clinic 
 
Friday clinics are held in S19 and the research nurse co-ordinator is Sr Patricia 
Appolles. 
The names of eligible patients for recruitment at this clinic will be obtained prior to 
the clinic being held on a Friday.  Attendance of these patients will be confirmed on 




(To be conducted within 2-3 weeks of initiation on HAART) 
 
1. The researcher will explain the purpose of the study and the procedures to be 
followed during the follow-up. 
2. Consent will be obtained.  The patient will sign a consent form and they will be 
given a copy of the consent form. 
3. Once consent has been signed, an enrolment form will be completed.   
4. Should the patient have been in consultation with the doctor already, their next 
clinic appointment date will be obtained directly from he patient (recorded on 
the appointment card).  Should the patient still require seeing the doctor the next 
appointment date will be obtained after the clinic session from the sister-in-
charge who will access the appointment book for this information. 
5. All clinical information to be recorded on the enrolment form will be obtained 
from the patient folder subsequent to the clinic. (Note: the folder may not be 
retained by the researcher thereby hampering the patient‟s flow in the referral 
system – pharmacy etc.).  The folder will be requested from records via Srs P. 
Appolles or D. Jansen if necessary. 
 
Document Checklist for this visit: 
 
1. Consent Form…………………………. __ 
2. Complete Enrolment Log details……… __ 
3. Enrolment Form……………………….. __ 
 
Visit 1 after enrolment (1 month after initiating ARVs) 
 
Socio-demographic and treatment Baseline Data Collection  
 (To be conducted within 4-6 weeks after initiation on HAART) 
 
The following documents/procedures to be completed during patient visit. 
4. Baseline questionnaire (not to be conducted by the same person doing the self-
reported adherence questionnaire). 
5. Prospective Study case report form. 
6. Self –Report Adherence Questionnaire 
7. Pill Count/ Medication measure.  
8. Record whether the patient‟s appointment visit is on time or not. (Note: An „on-
time appointment is defined as „on time‟ 7 days around the given date but no 













The following procedures to be completed by researcher subsequent to visit. 
1. Check patient pharmacy refill computerised record for quantities and dates of 
prescriptions filled.  
2. Note whether pharmacy prescriptions were collected „on-time‟  
 
Document Checklist for this visit: 
 
1. Baseline questionnaire ………………………… __ 
2. Self-reported adherence questionnaire ………..   __ 
3. Pill count/medicine measure results …………..   __ 
4. Follow-up visit Case Report Form ….…………  __  
5. Appointment schedule noted ………………….   __ 
 
Visit at 3 months 
 
The following documents/procedures to be completed during patient visit. 
1. Prospective Study case report form. 
2. Self –Report Adherence Questionnaire 
3. Pill Count/ Medication measure.  
4. Record whether the patient‟s appointment visit is on time or not. (Note: An 
„on-time appointment is defined as „on time‟ 7 days around the given date but 
no longer than 3 days after the given date.) 
 
The following procedures to be completed by researcher subsequent to visit. 
1. Check patient pharmacy refill (computerised record or prescription chart in 
patient folder) for quantities and dates of prescriptions filled.  
2. Note whether pharmacy prescriptions were collected „on-time‟ based on 
appointment and collection dates. 
3. Enter information on data capture form  
 
Document Checklist for this visit: 
 
1. Prospective enrolment form……………………  __ 
2. Self-reported adherence questionnaire ………..   __ 
3. Pill count/medicine measure results …………..   __ 
4. Follow-up visit Case Report Form ….…………  __   
5. Appointment schedule noted ………………….   __ 
 
Visit at 6 months 
 
 Repeat all procedures as for visit at 3 months.   
 
The following procedures to be completed by researcher subsequent to visit. 
1. Check patient pharmacy refill (computerised record or prescription chart in 
patient folder) for quantities and dates of prescriptions filled.  
2. Note whether pharmacy prescriptions were collected „on-time‟ based on 
appointment and collection dates. 
3. Obtain viral load results for 6 month visit 













Document Checklist for this visit: 
 
1. Prospective enrolment form……………………  __ 
2. Self-reported adherence questionnaire ………..   __ 
3. Pill count/medicine measure results …………..   __ 
4. Follow-up visit Case Report Form ….…………  __   
5. Appointment schedule noted ………………….   __ 
 
Procedures for quality control 
 
1. Complete the Quality control sheet to identify missing data is captured. 
2. Request patient folders through sister-in-charge to obtain any missing 
data. 
3. Prepare folders and data capture sheets for researcher to abstract 














Appendix 6:  Case Report Form 
 
Enrol No:_/_/_    
Visit No. ____ 
Gender:   M   /  F  (circle) 
ARV Start date: __/__/____         
Visit Date:  __/__/___ 













1.  Returned unused medicines    
2.  Kept appointment as scheduled    
3.  Primary caregiver accompanied child    
4.Self-reported adherence questionnaire 
completed          (1, 3,6,) 
   
5. Pill Count/meds measurement done 
     (1,3,6,) 
   
 
6. Pharmacy refill record checked 
    (1,3,6 months) 




Obtain information from folder 
7. Height: _________    8. Weight: __________ 
9. TB Rx?   Yes __ No__   10. Bactrim?   Yes __ No ___ 
11. Other drugs?  Yes__ No___ 
12. If yes, give reason for prescription______________________________________ 
Ask Caregiver: 
13.  Has the child been in hospital since the last visit?    Yes___  No___  
(Ingaba umntwana wakhe walaliswa esibhedlele emva kotyelelo olugqithileyo) 
14. If yes, No. of admissions? 
Ukaba ewe, ulwamkelo? 
15. Total duration of all hospital admissions (in days) _________  
( (Ixesha elingakanani)_________ 
16. Does the caregiver have specific complaints about the child‟s health? Yes _No__ 
(Ingaba umongi unezikhalazo anazo malunga nemplilo yomntwana) 
 Baseline 6 mths 12mths 18mths 
CD4     












17.  If yes, specify 
(Ukuba ewe, chaza) 
___________________________________________________________________________ 
 
18. Has the child experienced any of the following since the last visit?Yes_ No__N/S__ 
(Ingaba umntwana wakhe wanenye yezingxaki zilandelayo emva kotyelelo lokugqibela) 
1= headaches (Intloko) 
2= vomiting after taking medicine (Ukugaba emva kokuthatha amayeza) 
3= Rash (Amaqhakuva amaninzi  amacinci emzimbeni) 
4= abdominal pain (Intluku zamanqa) 
5=fever [in opinion of caregiver] (Umkhuhlane) 
6= diarrhoea (Ukuhambisa) 
7= listlessness [having no energy, sleeping a lot] (Ukungabi namdla) 
9=Other [specify] (Enye- Chaza) 
________________________________________________ 
 
Appetite and Food security 
 
19.Have there been any changes in the child‟s appetite (increase or decrease ); 
does the  
(Ingaba kukhe kwakho umahluko emntwanani malunga nomdla wokutya [ 
unyukile okanye uhlile]: inagaba umntwana utya ukutya kwesiqhelo/ kakhulu 
okanye kancinci kunesiqgelo) 
child eat regular meals / more or less than usual? 
________________________________________________________________________
________________________________________________________________________
20. In your opinion, has there been sufficient food to satisfy the child‟s appetite?   
(What does the child eat mostly?)  Is there sufficient food for the household? 
(Ngokwezimvo zakho, ingaba bekukho ukutya okwaneleyo ukwanelisa umdla 
womntwana? utya ntoni umntwana ixesha elininzi? Ingaba kukho ukutya 






21.  Any changes in the household routine or child-minding arrangements since the last visit?      
Yes ____ No___ 
(Ingaba akukho tshintsho kwizicwangciso zekhaya okanye ukucinga komntwana ukususela 
kutyelelo lokugqibela) 














22.  Any significant family events occur since the last visit?      
(Ingaba akukho ziganeko zekhaya zibablulekileyo ezithe zenzeka emva kondwendwelo 
lokugqibela) 
   1= funerals, (Umncwabo) 
   2=hospitalizations, (Ulalo esibhedlele) 
   3=illness of primary caregiver, (Ukugula kukamongi) 
  4=illness of sibling (Ukugula kwenzala) 
  5=illness of other family member whom caregiver had to look after 
       (Ukugula kwelinye ilungu lekhaya ebeliphantsi komongi) 
  6=retrenchments  (Ukuphelelwa ngumsebenzi) 
  7= No change in circumstances (Akukho zinguqu) 
  8= refused to answer (Walile ukuphendula) 
  9=Other [specify] (Enye – chaza) 
       ________________________________________________________________ 
        ________________________________________________________________ 
 


















Appendix 7:  Medication Measure Assessment Form 
 
Enrolment No: ____    ARV Start Date:____ 
 
Dispensing Record 
 Medicine Dose Times/day Date Commenced Date Stopped/changed 
1.      
2      
3.      
4.      
5.      
Adherence Record: 
Drug 1(AZT,d4T or ABC) 
Medicine Adherence Month 0 Month 1 Month 3 Month 6 
 Assessment Date 
(dd/mm/yyyy) 
    
 Assessed by:[Print]     
 Dispensed (ml or 
tabs) 
    
Returned Meds     
Expected usage:     
Actual usage     
%Adherence     
Drug 2 (3TC of ddI) 
Medicine Adherence Month 0 Month 1 Month 3 Month 6 
 Assessment Date 
(dd/mm/yyyy) 
    
 Assessed by:[Print]     
 Dispensed (ml or 
tabs) 
    
Returned Meds     
Expected usage:     
Actual usage     
%Adherence     
Drug 3(NVP,EFV,RTV,KLT) 
Medicine Adherence Month 0 Month 1 Month 3 Month 6 
 Assessment Date 
(dd/mm/yyyy) 
    
 Assessed by:[Print]     
 Dispensed (ml or 
tabs) 
    
Returned Meds     
Expected usage:     
Actual usage     


















Coding A priori Hypothesis 
Child Characteristics    
Age (in months) Agemo 
(continuous) 
 Inverse correlation between  
adherence and age  
gender Gender 
(Categorical) 
Male Boys more likely to be adherent 
(Boys are more valued than girls) if 
dependent on caregiver (perceived 
as more sick? Or are more valued) 




Those reporting sickness within one 
month of arv start are more likely to 
be adherent 






Yes / No Those reporting a health problem at 
enrolment are more likely to be 
adherent 




Y/N Those reporting “Yes” were more 
likely to be adherent 
Period between first visit to 





and  “idsince”  
Those with the longest interval 
between “arvstart” and “idsince” are 
more likely to be adherent  
TB Rx at enrolment Currenttbrx 
 
Y/N Those who do not report having TB 
at enrolment are more likely to be 
adherent 
WHO clinical staging Staging 
Categorical 
1,2 & 3,4, Those in stages 3 and 4 are more 
likely to be adherent than those in 
stages 1,2 
Period between last 




Days / Months Those with the shortest 
interval[within 1 month] between 
“arvstart” and “lasthosp” date are 
more likely to be adherent 
Otherdrugs other than 







transform to Yes/No 
Those who do not report „any other 





Those with poor nutritional 
indicators, more likely to be more 
sick, thus more adherent. 
Caregiver Characteristics    













Biological parents more likely to be 
adherent. 





*combine “N” and 








Those who report not going through 
PMTCT are more likely to be 
adherent (those who respond yes – 
more likely to be in denial, thus less 
adherent) 




















60 and over 
more likely to be biological parents 








Those with a senior high education 



















Those in the categories 
4“unemployed” and 








Those in categories Yes (1) and Not 
sure (4) are more likely to be 
adherent 
Depression CED-D scores  1.Categorize >15 
(convention) and or 
2.Establish threshold 
for cohort 
Those who are depressed are more 
likely to have non-adherent children. 
Know the names of ARVs Knownames Y /N Those familiar with ARV names 
after 1 month, more likely to be 
adherent. 










6= Partner died 
Those married or living with 















Those with “inside tap” are more 






Those with “inside toilet are more 
likely to be adherent 






Increased number of children and 
adults in household impacts 
negatively on adherence. 
Any other household 




Yes/No/ Don‟t know Those in households with known 
HIV infected members are more 















Coding A priori Hypothesis 
Grants Grants  (Y/N) Those receiving grants more likely 
to be adherent. 
Significant Life events  LE 1=funerals 
2=hospitalizations 
3=illness of primary 
caregiver 
4=illness of sibling 




8=refused to answer 
9=Other 
Those experiencing significant life 
events during follow-up, less likely 
to be adherent  
Health Service 
Characteristics 
   












Those counseled by counsellors 
were more likely to be adherent. 





Those who gain access via hospital 
ward are more likely to be adherent 
Referred for ARVs only Referred 
(Binary) 
Y/ N+N/A Those who were not specifically 
referred for ARVs (N+N/A) are 













Appendix 9:  Power and Sample Size Calculations 
 
Effect size conventions:  small = .20   medium = .50   large = .80 
 
Effect size Alpha Power Sample size Actual Power 
0.2 0.05 .80 788 0.8006 
0.2 0.05 .70 620 0.7006 
0.2 0.05 .60 492 0.6002 
0.2 0.05 .50 388 0.5020 
0.2 0.05 .40 294 0.4010 
0.2 0.05 .30 208 0.3003 
 
Effect size Alpha Power Sample size Actual Power 
0.4 0.05 .80 200 0.8036 
0.4 0.05 .70 158 0.7049 
0.4 0.05 .60 126 0.6055 
0.4 0.05 .50 98 0.5001 
 
 
Effect size Alpha Power Sample size Actual Power 
0.5 0.05 .80 128 0.8015 
0.5 0.05 .70 102 0.7056 
0.5 0.05 .67 96 0.6788 
0.5 0.05 .60 82 0.6090 
0.5 0.05 .50 64 0.5036 
 
Effect size Alpha Power Sample size Actual Power 
0.8 0.05 .95 128 0.8015 
0.8 0.05 .90 56 0.9050 
0.8 0.05 .80 42 0.7056 
0.8 0.05 .60 82 0.6090 
0.8 0.05 .50 28 0.5312 












Appendix 10:  Baseline Questionnaire:  
 
This questionnaire must be administered within 2- 4wks of the patient  
starting ARV therapy. 
 
PROCEDURE CHECKLIST: 
1. Complete Case Report Form for Visit 1  ………………..      
2. Complete this questionnaire.         ………………     
3. Remind Caregiver to bring all medicine containers (medicine bottles and 
capsule pkts) at the next visit (1 month after starting ARV) …….    
 
Interviewer Name:___________________ 
Date of Interview:_________________  Patient Folder number: ______________  
Patient Enrolment Number:__/__/__ 
Name of child:___________________ 
Date of birth (dd/mm/yyyy) __/__/______ [NB. Only 6 yrs or younger] 
Gender:  boy   □  girl    □ 
ARV start date:______________ 
 
NOTE: 
A.1. Who is the primary caregiver of this child?[relationship] _______________ 
(Ngubani oyena omelene nokunika umntwana amayeza) 
A.2. Who is mainly responsible for giving the medication?______________________ 
[If not the person being interviewed, stop interview and make arrangements to see 
the responsible person at a later stage] 
 
Interview completed?    Yes□   No□   
If No, specify reason ________________________________________________ 
Interviewee:  [Relationship to Child]_________________________________ 
 
B.1. Who responded to this questionnaire? [circle appropriate number below] 
(Ngubani ophendula lemibuzo) 
1=Both biological parents (ngabazali bobabini…[skip to C] 
2=biological mother (ngumama) …………………...[skip to C] 
3=biological father (ngutata)      ……………………[skip to C] 
4=grandmother (ngumakhulu) 
5= Aunt (ngu-anti) 
6= Foster parent (ngumzali owonyuliweyo) 
9= Other [specify](enye – chaza)_________________ 
B.2.  If not the biological parent, is the caregiver a legal guardian?      Yes□   No□ 













B.3. If not the biological parent, where are the parents?  
(Ukuba ayingobazali, baphi abazali) 
1=mother deceased 
2=father deceased 
3=mother living elsewhere (specify)______________ 
4=Other 
5= not applicable [in the case of adoptive, foster parents] 
9= don‟t know [abandoned child] 
 






C1. How old are you? 
(Mingaphi iminyaka yakho) 
Under 20 □ 20-30 □ 31-40 □ 41-50    □ 51-60 60 and over □ 
C.2.. What was the highest standard passed at school? __________________ 
(Liliphi elona banga liphezulu oliphumeleleyo) 
C.3.  Do you have any post-school qualifications?   Yes □   No□   If no, go to C.5. 
(Unayo imfundo ephakamileyo)  
C.4  If yes, specify_________________________ 
C.5.  Marital Status (Isimo ngokomtshato):  
1=single (awutshatanga)  
2=widowed (umyeni watshaba)  
3= divorced (nohlukana)  
4=Married (utshatile)  
5=living with partner (uhlala neqabane)  
6= partner died (iqabane latshaba) 
 
C.6.  Employment status (Isimo ngokomsebenzi):   
1= Formal employment (umsebenzi osisigxina) 
[specify  occupation:_________________] 
2=Unemployed (wausebenzi) 
3=Casual employment (umsebenzi wamaxesha) 
4=home business (ishishini lasekhaya)[specify:eg. spaza shop_____________ 
 
C.7.Who provides financial support in the home [relationship 
tchild]?___________________ 





5= Other (specify:__________________) 













C.8. Do you receive any grants?            Yes  □   No□     If No, go to D. 
(Ingaba kukho imali kaRhulumente oyifumanayo) 
C.9. Specify type of grant? 
(Chaza uhlobo lwale mali) 
1= child care dependency grant (imali yokonga abantwana) 
2= Old age pension (Inkam-nkam) 
3= disability grant (Imali yokukhobozeka) 
4= child maintenance support [from father] (Imali yokonga umntwana evela 
kutata) 




D.1 Type of housing (Uhlobo lwendlu): informal dwelling       □   
      formal brick dwelling □  
D.2 Access to water (Ufikelelo emanzini):                    outside tap only □ inside taps □ 
D.3 Inside Flush Toilet (Indlu yangasese engaphakathi etsalwayo) □   Outside toilet 
(engaphandle) □ 
D.4 How many people live in the home? (specify: ______adults _______children) 
(Bangaphi abantu abadala nabantwana abahlala endlini) 
D.5 How many siblings does [child‟s name] have? _________ 
(Bangaphi abantakwabo anabo) 
D.6. How many siblings are HIV infected? ______ 
(Bangaphi abantakwabo abosuleleke yile ntsholongwane kaGawulayo) 
D.7. Are you planning to have any more children?    Yes □  No □ Not applicable □  
 
D.8. If Yes, When do you plan to have more children?  
___________________________________________________ 
D.9 Are any other household members HIV infected?  Yes □  No  □ 
(Ingaba bakhona abanye abantu ekhaya abosuleleke yintsholongwane kagawulayo) 
D.10 If Yes who?[relationship to child]_____________ 
(Ukuba ewe, ngubani) 
D.11. Is anyone else, other than the child, on ARV treatment?  Yes □  No □ 
(Ingaba ukho omnye umntu ngaphandle komntwana okunyango lukaGawulayo) 
D.12. If yes, specify Ukuba ewe, 
chaza)______________________________________ 
[If interviewee‟s status mentioned, skip to 16] 
D.13. Do you know your HIV status?           Yes  □   No□   [if no, go to D.18.] 
(Ingaba uyasazi isimo sakho malunga nentsholongwane kaGawulayo) 
D.14. Are you HIV positive?                         Yes □   No□    [if no, go to D.18.] 
(Ingaba unayo letsholongwane) 
D.15. Are you on antiretroviral treatments?   Yes  □   No□   [if no, go to D.18.] 
(Ingaba ukunyango lwamachiza entsholongwane kaGawulayo) 
D.16. When did you start treatment? (mm/yyyy) ___/_________ 
(Uluqale nini olunyango) 
D.17. Have you skipped any doses of your medication in the last 3 days?  
(Ukhe waphosa ukusela ipilisi zakho kwezintsuku zintathu zidlulileyo) Yes □ No□   













  (Ingaba unengxa ebalaseleyo ngokwempilo) 
D19.  If yes, specify health problems _________________________ 
 (Ukuba ewe, chaza ingxaki) 
D.20.  Have you ever had TB?         Yes  □   No□   [if no, go to D.24.] 
(Ingaba wakhe wanesifo sephepha – iTB) 
D.21. When did you last have TB? (mm/yyyy)___________________ 
 (Ugqibele nini ukuba neTB) 
D.22.  Did you complete treatment? (Walugqiba unyango)Yes  □   No□    
[if yes, go to D.24] 
D.23. What is the reason for not completing TB treatment?  
(Yintoni eyabangela ungalugqibi unyango lwe TB) 
_____________________________________________________________ 
 
Child care arrangements 
(Ulungiselelo malunga nenkathalelo yomntwana) 
 
D.24.Who looks after the child during the day? 
(Ngubani ogcina umntwana emini) 
1= attends school 
(Uhamba isikolo) 
2= attends day care centre/crèche 





5= no regular care-taking (Specify):__________________________ 
(Akukho mntu usisigxina – chaza) 
9= Other (specify eg. Neighbour, aunt, etc) ______________________ 
(Enye – umzekelo: umelwane, uAnti) 
D.25.With whom does the child live (go home to at night)? (Uhlala nabani 
umntwana endlini) 










9= Other (specify) (Enye – chaza)___________ 
 
D.26. Does the child sleep over at another caretaker for part of the week eg.  
Weekends?(Ingaba umntwana ukhe alale komnye umntu ogcinayo kwezinye 
intsuku zeveki: umz. Impelaveki)        
 Yes□   No□ 
D.27.  If yes, specify ______________________________________ 













D.28. Does your child ever sleep over with family or friends? 
(Ingaba umntwana wakho ukhe alale kwisizalwane sakho okanye kumhlobo 
wakho)   
1=sometimes (ngamanye amaxesha)  □  
2= always (ngamaxesha onke)  □     
3= never (zange)     □ 
 
D.29. If yes, do you send the medication along with instructions how to give it? 
Yes□  No□ 
 
(Ukuba ewe, ingaba uyanikela nangamayeza kwanemigaqo ekufuneka enikwe ngayo) 
 
D.30. Does the person to whom the child goes, know his/her HIV status?  
 Yes□   No□ 
(Ingaba lomntu umntwana aya kuye uyazi ngesimo somntwana malunga 
nentsholongwane kaGawulayo) 
 
E. Reasons for starting Treatment (Izizathu zokuqalisa unyango) 
 
E.1.  The reason/s why I agreed to start my child on ARV is/are: 
(Iz/sizathu esabangela ndivume ukuqalisa umntwana wam unyango luka gawulayo)         
1=the child was very sick in hospital and the doctors recommended ARVs 
 (Umntwana ebegula kakhulu esibhedlele waze uGqirha wacebisa ukuba 
aqalise unyango) 
2= the child was always sick and the doctors recommended 
(Umntwana ebesoloko egula waze uGqirha wacebisa njalo) 
3= the child was always sick and I asked the doctors for ARVs (Umntwana 
ebesoloko egula ndaze ndacela uGqirha ngamachiza onyango) 
4= the child was not sick but the doctors recommended 
(Umntwana ebengaguli waze uGqirha wacebisa) 
9= Other (specify)______________________________________________ 
(Enye – chaza) 
 
E.2. Is the child on any medication OTHER than ARVs? (include prescription and 
home remedies)        Yes □ No □  
(Ingaba lo mntwana ukunyango OLULOLUNYE ngaphandle kolu lamachiza 
entsholongwane kaGawulayo)    [If no, skip to F.1. ] 
 
E.3. If yes(specify)____________________________________________ 
(Ukuba ewe – chaza) 
E.4. State purpose of other medication (include prescription medication): 
_____________________________________________________________________ 
 
F. Disclosure, Stigma & Discrimination 
(Ukuxelela abantu, ukungamkeleki kwakunye nokuhlekumezwa) 
 (Ukuchazela umntwana)       
F.1. When was the child first diagnosed with HIV infection? [Year]_______ 












F.2. Have you told the child about his/her HIV status?     Yes □  No □ 
(Ingaba umntwana wamxelela ngokuba uphila nale ntsholongwane) 
F.3. What have you told the child about the reason for his/her hospital visits?  
(Umxelele ntoni umntwana malunga nezizathu zotyelelo lwakhe apha esibedlele) 
__________________________________________________________________ 
F.4. What do you think the child knows about HIV? 
(Ucinga ukuba umntwana wazintoni malunga nentsholongwane 
kaGawulayo) 
_____________________________________________________________________ 
F.5. When do you think is the right time and age to talk to the child about HIV?  
(Ucinga ukuba liliphi ixesha elilungileyo nonyaka, wokuthetha nomntwana malunga 
nalentsholongwane) 
____________________________________________________________ 
F.6. Who is the best person to start this discussion with the child?  
(Ngubani oyenamntu olungileyo wokuqalisa lencoko nomntwana) 
____________________________________________________________ 
F.7. How do you think the clinic can assist you with telling your child?  
(Ucinga ukuba ikliniki ingakuncedisa njani ukuxelela umntwana wakho) 
_____________________________________________________________________
_____________________________________________________________________ 
F.8. Who have you told about the child‟s HIV status? 
(Ngubani omxeleleyo malunga nokugula komntwana yile ntsholongwane) 
____________________________________________________________________ 
F.9. Did you receive any „bad reactions from people you‟ve told?  Yes □No □ 
(Ingaba wafumana ukungamkeleki ebantwini owabaxelelayo) 
F.10. If Yes, describe the „bad reaction‟ 
(Ukuba ewe, chaza izinto abazenzayo) 



























G. Support  (Inxaso) 
G.1. Do you attend a support group regularly?  Yes□   No□  [if no, skip to G.4] 
(Ingaba uyalihamba iqela lenxaso rhoto) 
G.2. Where do you attend a support group?[circle appropriate number below] 
(Ulihamba phi) 
1=at the hospital (esibhedlele)   
2= at the clinic where I live (kwikliniki apho ndihlala khona) 
3= at the church (ecaweni) 
4= at an NGO (kwiqumrhu elizimeleyo) 
5= Other (Enye) [specify - chaza]__________________________ 
G.3.  What is your opinion about the support group you attend? 
_____________________________________________________________________
_____________________________________________________________________ 
G.4. What do you think should be discussed or done in a support group meeting 
for caregivers of children on ARVs? 
 1= practical tips on giving medication 
 2= factual information about HIV, AIDS and children 
 3= tips on how to start telling a child about HIV 
 4= stress management and coping skills 
 5= all of the above 
 6= Other, specify ____________________________________________ 
 7= did not answer 
 8= don‟t know 




G.6.  I have family living close by who are supportive and help me.   Yes   No   
G.7.  I have friends living close by who are supportive and help me.   Yes   No   
 
H. ARV Administration 
(Indlela yokuphatha lamachiza kaGawulayo) 
 
H.1. Who else helps you give the child medication when you‟re not available to 
do so?(Ngubani ongom ye onceda ngokunika umntwana amayeza xa ungekho) 
_________________________________________________________________ 
H.2. Where is the medication stored?  (Uwahlalisa phi amayeza) 
_____________________________________________________________________ 
 
I would like you to describe how you fit giving medicines into your daily routine.   
(Ndizakucela undibalisele ukuba ukudibanisa njani ukunika umntwana amayeza 
nakwizinto ekufuneka uzenzile ngemini) 
 
Could you specifically describe the following: 
(Ndicela ichaze malunga noku kulandelayo) 
 
H.3.Explain your weekday morning routine [time you get up, and routine around 












Who is responsible for the morning dose? Ixesha ovuka ngalo, ukuya 
ukunikeni amayeza) 
_____________________________________________________________________ 
H3.1 What time does the child wake up? 
_____________________________________________________________________




H3.3 What you use as a reminder ?     
1= cell phone alarm 
2= TV programme (specify)_____________ 
3= Other, (specify) __________________ 
4=Routine (habit*) 
9=Nothing 
(* you remember when you do the same things everyday.) 
 
H.4. Explain your weekday evening routine.(Chaza izinto ezenza rhoqo ngeveki malanga) 
H4.1 Who is responsible for the evening dose? 
_____________________________________________________________________ 




H4.3 What do you use as a reminder tool?     
1= cell phone alarm 
2= TV programme (specify)_____________ 




H.5. Explain your Saturday morning routine – what happens most Saturdays?  
(Chaza izinto ozenza rhoqo ngomgqibelo kusasa  - kuqhubeka ntoni ngemigqibelo emininzi) 
H5.1Who is responsible for giving the morning dose?  _______________________ 
H5.2 What time does the child wake up?_________________________________ 
H5.3 When is the medication given? (what activity does medication administration follow?) 
_____________________________________________________________________ 
 
H5.4 What do you use as a reminder ?    
1= cellphone alarm 
2= TV programme (specify)_____________ 
3= Other, (specify) __________________ 
4=Routine (habit) 
9=Nothing 
H.6. Explain your Saturday evening routine: what happens most Saturday 
evenings?  













H6.1 Who is responsible for giving the evening dose_________________________ 
 
H6.2 When is the medication given? (what activity does medication administration 
follow?) 
___________________________________________________________ 
H6.3 What do you use as a reminder ?     
1= cellphone alarm 
2= TV programme (specify)_____________ 
3= Other, (specify) __________________ 
4=Routine (habit) 
9=Nothing 
H.7. Explain your Sunday morning routine – what happens most Sunday 
mornings? 
(Chaza izinto ozenza rhoqo ngeCawe kusasa – kuqhubeka ntoni ngeCawe kusasa) 
H7.1 Who is responsible for giving the morning dose?_______________________ 
H7.2 What time does the child wake up?________________________ 
H7.3 When is the medication given? (what activity does medication administration 
follow/? __________________________________________________________________ 
H7.4 What do you use as a reminder?____________________________________ 
H.8. Explain your Sunday evening routine.(Chaza izinto ozenza rhoqo ngeCawe malanga) 
H 8.1Who is responsible for giving the evening dose?   ______________________ 
H8.2 When is the medication given? (what activity does medication administration 
follow? 
_____________________________________________________________________ 
H8.3 What do you use as a reminder ?  ___________________________________ 
1= cellphone alarm 
2= TV programme (specify)_____________ 
3= Other, (specify) __________________ 
4=Routine (habit) 
9=Nothing 
H.9.  When you go out, do you mostly : 
1= give the medicines before leaving home even if it is earlier than scheduled?   
2= take medicines with 
3= give when you return home even if it is later than scheduled 
4= skip the dose if you return home too late 
5= Other, specify: ______________________ 













H.10. Which of the ARVs does the child take easily [with no fuss]? 
(Ngawaphi amachiza kula entsholongwane kaGawulayo umntwana awathatha lula –engenangxaki) 
 







1.    
2.    
3.    
4.    
 
H.11. What do you do when the child does not want to take the ARVs? 
[Note to Interviewer: Prompt for techniques to make medicine palatable or „luxury 
bribes, coat mouth with peanut butter‟ etc.] 
 (Wenza ntoni xa umntwana engafuni ukuthabatha/ ukusela lamachiza) 
_____________________________________________________________________
_________________________________________________________________ 
I.  Knowledge, Attitude and Practice regarding Treatment 
 
I.1 Answer the following questions by choosing one of the following responses: 





I.1 I think it is (always/sometimes/never) good to give my 
child a break  from ARV treatment  
(Ndicinga ingaluncedo ukuba ndinike umntwana wam 
ikhefu ekuthabatheni olunyango lwalamachiza) 
 
I.2. I (always/sometimes/never) take my child to a 
traditional healer  
(Ndiyamsa umntwana wam nako Siyazi) 
 
I.3. I (always/sometimes/never) give all the medicines 
exactly at the same time each day (Monday to Sunday) 
(Ndiyamnika amayeza ngexesha elifanayo qho ngemini - 














I.2 State whether you agree or disagree with the following statements? 
(Chaza ukuba uyavumelana okanye awuvumelani noku kulandelayo) 




I.4.  Each ARV medicine/tablet I give my child works in 
the same way therefore I do not have to give all at the 
same time it is okay to leave out one sometimes. 
(Iyeza/ Ipilisi nganye endiyinika umntwana isebenza 
ngendlela enye ngako oko akufanelekanga ukuba 
ndimnike rhoqo, kulungile ukushiya noba inye nagmanye 
amaxeshe) 
    
I.5. I know all the names and doses of the ARVs 
prescribed to my child [name and dosing] 
(Ndiyawazi onke amagama kwakunye namachiza 






    
I.6.Once the child starts getting better one can stop the 
treatment 
(Xa umntwana eqalisa ukubangcno angaluyeka 
olunyango) 
    
I.7.After a while of taking the treatment the child can be 
cured of HIV 
(Emva kwethuba umntwana ekolunyango uyaphila kule 
ntshalongwane iphela) 
 
    
I..8. My child has experienced no side-effects to the 
medication thus far 
(Umntwana wam zange afumane ziphumo zosecaleni 
ukuzokuthi gha ngoku) 
    
I.9. My child will have to take this medicine for the rest 
of his/her life 
(Umntwana wam kufuneka ethathe lamayeza ubomi 
bakhe bonke) 
    
I.10. I am worried about whether my child will grow up 
to complete school. 
(Andikho sexhaleni malunga nokuba umntwana wam 
uzakukhula agqibe isikolo) 
    
I.11. I believe the benefits of taking the ARVs far 
outweigh the risks 
    
 
Note to Interviewer:  Do Not Prompt for answers below! 
 
I.3.  What do you think will happen if you miss 1 dose in a week? 
1= Nothing 
2= Child will get sick 
3= Medicine will stop working 
4= the viral load will go up 
5= Other (specify)____________________________ 













I.4. What do you think will happen if you miss more than 3 doses in a week? 
1= Nothing 
2= Child will get sick 
3= Medicine will stop working 
4= the viral load will go up 
5= Other (specify)____________________________ 
9= don‟t know 
 
General Comments: 
Thank you for giving your time to complete this questionnaire, before you leave, is 
















Appendix 11:  Caregiver depression screening (CES_D) 
 
Enrolment No:_______________    Date of Interview:_________________ 
Interviewer: _________________  Score:   /___/ 
Study Visit No: _______(B ; 2wk; 1,3,6mth) 
 
This questionnaire lists feelings and behaviour that you may have experienced during  
the past week.  Please tell me how often you have felt this way during this past week. 
(Le mibuzo icalucalula indlela oziva ngayo, nendlela zokuziphatha onokuthi kanti 
uthe wazifumana kwiveki egqithileyo. Nceda undixelele ukuba uzive ngoluhlobo 
kangakanani kwiveki egqithileyo) 
 
Circle on number on each line: 
 
1= Rarely or none of the time (less than 1 day) 
(kunqabile okanye tu kweli xesha) 
2= Some or a little of the time (1-2 days) 
(Ngamanye or ixesha elincinci) 
3= Occasionally or a moderate amount of time (3-4 days) 
(Ngamaxesha athile okanye ixeshana nje) 
4= Most or all of the time (5-7 days) 
(Amaxesha amaninzi okanye ixesha lonke) 
 
During the past week: 
1. I was bothered by things that usually don‟t bother me.  
(Bendikhathazwa zizinto ebezingadli ukundikhathaza) 
1  2 3 4 
2. I did not feel like eating; my appetite was poor. 
(Akhange ndibenamdla wokutya: umdla wam ebemncinci) 
1 2 3 4 
3. I felt that I could not shake off the blues even with help from my 
family or friends. 
(Ndizive ingathi andinakuvele nje ndiyeke ukutyhafa nokuba 
ndincedwa zizizalwane okanye abahlobo) 
1 2 3 4 
4. I felt that I was just as good as other people. 
(Ndizive ukuba ndilungile njengabanye abantu) 
1 2 3 4 
5. I had trouble keeping my mind on what I was doing. 
(Bendinengxaki yokubeka ingqondo yam kwinto endiyenzayo) 
1 2 3 4 
6. I felt depressed. 
(Bendiziva ndidakumbile) 
1 2 3 4 
7. I felt that everything I did was an effort. 
(Bendiziva okokuba yonke into endiyenzayo ibazinzame) 
1 2 3 4 
8. I felt hopeful about the future. 
(Ndiziva ndinethemba malunga nekamva) 
1 2 3 4 
9. I thought my life had been a failure 
(Bendicinga ukuba ubomi bam abuphumelelanga) 
1 2 3 4 
10. I felt fearful. 
(Ndizive ndisoyika) 
1 2 3 4 
11. My sleep was restless. 
(Bendiphuthelwa – kungekho kuphumla ebusuku) 
1 2 3 4 
12. I was happy. 
(Ndando nwabile) 












13. I talked less than usual. 
(Ndithetha kancinci kunesiqhelo) 
1 2 3 4 
14. I felt lonely. 
(Ndinomva ndedwa) 
1 2 3 4 
15. People were unfriendly. 
(Abantu bebenganabuhlobo) 
1 2 3 4 
16. I enjoyed life. 
(Ndibuvuyele ubomi bam) 
1 2 3 4 
17. I had crying spells. 
(Bendisuka nje ndikhale) 
1 2 3 4 
18. I felt sad. 
(Bendiziva ndilusizi) 
1 2 3 4 
19. I felt that people dislike me. 
(Bendiziva ingathi abantu abandifuni) 
1 2 3 4 
20. I could not get “going”. 
(Bendiziva umzimba wam uphantsi- ndingakwazi nokuqalisa na nto) 





















Appendix 12:  MOS Social Support Survey 
 
 
Enrolment No:_______________    Date of Interview:_________________ 
Interviewer: _________________  Score:   /___/ 
Study Visit:  ____________ 
 
 
We would like to ask you some questions about the practical and emotional support 
that is available to you. 
(Singathanda ukubuza imibuzo malunga nokwenzekayo kwakunye nenxaso 
yokuzwelana nawe )othi uyifumane) 
 
1.  About how many close friends and close relatives do you have (people you feel at 
ease with and can talk to about what is on your mind)? 
(Malunga nokuba bangaphi abahlobo kwkunye nezizalwane ezisondeleleyo onazo) 
[Abantu ochinga ukuba balulutho kwaye unagthetha nabo malunga nokucingayo] 
 
Write in number of close friends and close relatives     
(Bhala inani labahlobo abasondeleleyo kwakunye nezizalwane 
ezisondeleyo) 
 
People sometimes look to others for companionship, assistance or other types of 
support. I will ask you about specific situations and you will tell me how often each of 
the various kinds of support is available to you if you need it and whether or not you 
are satisfied with the different kinds of support you receive. [You may use the scale in 
front of you.] 
 
(Abantu ngamanye amaxesha bajonga abanye abantu njengabangane, abancedi, 
okanye njengolunye uhlobo lwenxaso. Ndizakubuza malunga nemeko ezithile uze 
undixelele ukuba lixesha elingakanani kulamancedo akhankanyiweyo othi ulifumane 















Note to Interviewer:   Circle one number on each line 
1= None of the time [Akukho nalinye ixesha] 
2=A little of the time [Ixesha elincinci] 
3=Some of the time [Amaxesha athile] 
4=Most of the time [Amaxesha amaninzi] 
5=All of the time [Amaxesha onke] 
 
1. Someone to help you if you were confined to bed  
(Umntu wokunceda ukuba ngaba ububambekile ebhedini) 
1 2 3 4 5 …       
2. Someone you can count on to listen to you when you need to talk. 
(Umntu onokuxhomekeka kuye onokumamela kuwe xa ufuna ukuthetha) 
1 2 3 4 5 … 
3. Someone to give you good advice about a crisis. 
(Umntu onokunika ingcebiso ezintle malunga nengxaki) 
1 2 3 4 5 … 
4. Someone to take you to the doctor if you needed it. 
(Umntu onokuthi akuse kwagqirha ukuba ngaba uyafuna) 
1 2 3 4 5 … 
5. Someone who shows you love and affection. 
(Umntu obonakalisa uthando nenkathalelo) 
1 2 3 4 5 … 
6. Someone to have a good time with. 
(Umntu othi ubenexesha elimnandi naye) 
1 2 3 4 5 … 
7. Someone to give you information to help you understand a situation. 
(Umntu onokunika izimvo zokuzinceda ukuba uqonde malunga nemeko 
ethile) 
1 2 3 4 5 … 
8. Someone to confide in or talk to about yourself or your problems. 
(Umntu onokuthi umhlebele okanye nincokole malunaga nawe kunye 
nengxaki yakho) 
1 2 3 4 5 … 
9. Someone who hugs you. 
(Umntu okuwongayo) 
1 2 3 4 5 … 
10. Someone to get together with for relaxation. 
(Umntu ohlala naye xa upholile) 
1 2 3 4 5 … 
11. Someone to prepare your meals if you were unable to do it yourself. 
(Umntu okwaziyo ukulungiselela isidlo xa wena ungakwazi ukwenza 
njalo) 
1 2 3 4 5 … 
12. Someone whose advice you really want. 
(Umntu ofuna ezona ingcebiso zakhe) 
1 2 3 4 5 … 
13. Someone to do things with to help you get your mind off things. 
(Umntu owenza izinto naye ukunceda ingcinga zakho okokuba zisuke 
ezintweni) 
1 2 3 4 5 … 
14. Someone to help with daily chores if you were sick. 
(Umntu okunceda malunga nezinto zangemihla ukuba ubugula) 
1 2 3 4 5 … 
15. Someone to share your most private worries and fears with. 
(Umntu owabelana naye nemfihlelo zakho kwakunye noloyiko) 
1 2 3 4 5 … 
16. Someone to turn to for suggestions about how to deal with a personal 
problem. 
(Umntu onokubhenela kuye ngengcebiso malunga nokusombulula ingxaki 
yakho) 
1 2 3 4 5 … 
17. Someone to do something enjoyable with. 
(Umntu uwenza into eyonwabisayo naye) 
1 2 3 4 5 … 
18. Someone who understands your problems. 
(Umntu oyiqondayo ingxaki yakho) 
1 2 3 4 5 … 
19. Someone to love and make you feel wanted. 
(Umntu okuthandayo nokwenza uzive usafuneka) 
1 2 3 4 5 … 
20. Someone to help take care of your children when you can‟t. 
(Umntu onokunceda ukukhathaleleni abantwana xa ungakwazi) 











































































Appendix 14:  Boxplots  
 










































Baseline by other drugs
Boxplots of Logged Baseline Viral Loads
 













































Viral load by other drugs













Appendix 15: Regression Models correlates of adherence 
 
Backwards Stepwise regression analysis with (pr 0.1) 
 
Variables entered into model: 
sw logistic adherence  agemo recentsick dayslasthosp Otherdrugs since housedensity Stage Reltochild 
PMTCT  GiverAge Educ Employment Planmore Anyother Counsel Access PostSchool Housing 







Variables entered into model: 
sw logistic adherence  agemo recentsick dayslasthosp Otherdrugs since housedensity Stage Reltochild 
PMTCT  GiverAge Educ Employment Planmore Anyother Counsel Access PostSchool Housing 






















Variables entered into model 
sw logistic adherence  agemo recentsick  monthlasthosp Otherdrugs  IDduration 
housedensity Stage Reltochild PMTCT  GiverAge Educ Employment Planmore 
Anyother Counsel Access PostSchool Housing Gender HealthProb IDattend 






Variables entered into model 
. sw logistic adherence  agemo recentsick  monthlasthosp Otherdrugs  IDduration 
housedensity Stage Reltochild PMTCT  GiverAge Educ Employment Planmore 
Anyother Counsel Access PostSchool Housing Gender HealthProb IDattend 

















Variables entered into model 
sw logistic adherence  agemo recentsick  monthlasthosp Otherdrugs  IDduration 
housedensity Stage Reltochild PMTCT  GiverAge Educ Employment Planmore 
Anyother Counsel Access PostSchool Housing Gender HealthProb IDattend 
CurrentTB, pr(0.1) 
 
(Excluding depression, sigle, fldwh~hz fldw~waz fldw~haz „maritalstatus and grants)  
 
 
 
